

(12) STANDARD PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. **AU 2003282337 B2**

- (54) Title
Neuroprotective iron chelators and pharmaceutical compositions comprising them
- (51) International Patent Classification(s)
A61K 45/06 (2006.01) **C07D 295/205** (2006.01)
A61K 31/47 (2006.01) **C07K 7/22** (2006.01)
C07D 213/69 (2006.01) **C07K 7/23** (2006.01)
C07D 215/26 (2006.01) **C07K 14/575** (2006.01)
C07D 295/15 (2006.01) **C07K 14/70** (2006.01)
- (21) Application No: **2003282337** (22) Date of Filing: **2003.11.07**
- (87) WIPO No: **WO04/041151**
- (30) Priority Data
- | | | |
|-------------------|-------------------|--------------|
| (31) Number | (32) Date | (33) Country |
| 60/424,313 | 2002.11.07 | US |
| 60/504,126 | 2003.09.22 | US |
- (43) Publication Date: **2004.06.07**
(43) Publication Journal Date: **2004.07.01**
(44) Accepted Journal Date: **2009.07.16**
- (71) Applicant(s)
Yeda Research and Development Co. Ltd.;Technion Research and Development Foundation Ltd.
- (72) Inventor(s)
Fridkin, Matitiyahu;Youdim, Moussa B. H.;Warshawsky, Rivka;Zheng, Hailin;Warshawsky, Abraham
- (74) Agent / Attorney
FB Rice & Co, Level 23 44 Market Street, Sydney, NSW, 2000
- (56) Related Art
WO 2000/074664 A2

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
21 May 2004 (21.05.2004)

PCT

(10) International Publication Number
WO 2004/041151 A3

(51) International Patent Classification⁷: **A61K 31/47**,
31/4709, 31/495, C07D 215/12

WARSHAWSKY, Rivka [IL/IL]; 3 Baal Hatorim, 68133
Jaffa (IL).

(21) International Application Number:
PCT/IL2003/000932

(74) **Agent: BEN-AMI, Paulina**; Ben-Ami & Associates, P.O.
Box 94, 76100 Rehovot (IL).

(22) International Filing Date:
7 November 2003 (07.11.2003)

(81) **Designated States (national)**: AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR,
CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN,
MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU,
SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) **Priority Data**:
60/424,313 7 November 2002 (07.11.2002) US
60/504,126 22 September 2003 (22.09.2003) US

(84) **Designated States (regional)**: ARIPO patent (BW, GH,
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE,
SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) **Applicants (for all designated States except US)**:
**TECHNION RESEARCH AND DEVELOPMENT
FOUNDATION LTD.** [IL/IL]; Gutwirth Science Park,
Technion City, 32000 Haifa (IL). **YEDA RESEARCH
AND DEVELOPMENT CO. LTD.** [IL/IL]; Weizmann
Institute of Science, P.O. Box 95, 76100 Rehovot (IL).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

(72) **Inventor: WARSHAWSKY, Abraham** (deceased).

(72) **Inventors; and**

(88) **Date of publication of the international search report**:
28 October 2004

(75) **Inventors/Applicants (for US only)**: **YOUDIM, Moussa,
B., H.** [IL/IL]; 18 Hankin St., 32763 Haifa (IL). **FRIDKIN,
Matitياهو** [IL/IL]; 23 Miller Street, 76284 Rehovot (IL).
ZHENG, Hailin [CN/IL]; Organic Chemistry Weizmann
Institute of Science, P.O. Box 96, 76100 Rehovot (IL).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) **Title: NEUROPROTECTIVE IRON CHELATORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM**

(57) **Abstract**: Novel iron chelators exhibiting neuroprotective and good transport properties are useful in iron chelation therapy for treatment of a disease, disorder or condition associated with iron overload and oxidative stress, eg. a neurodegenerative or cerebrovascular disease or disorder, a neoplastic disease, hemochromatosis, thalassemia, a cardiovascular disease, diabetes, a inflammatory disorder, anthracycline cardiotoxicity, a viral infection, a protozoal infection, a yeast infection, retarding ageing, and prevention and/or treatment of skin ageing and skin protection against sunlight and/or UV light. The iron chelator function is provided by a 8-hydroxyquinoline, a hydroxypyridinone or a hydroxamate moiety, the neuroprotective function is imparted to the compound e.g. by a neuroprotective peptide, and a combined antiapoptotic and neuroprotective function by a propargyl group.



WO 2004/041151 A3

NEUROPROTECTIVE IRON CHELATORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM

5

FIELD OF THE INVENTION

The present invention relates to amphiphilic metal chelators that have specificity for iron and are useful for treatment of diseases, disorders and conditions by iron chelation therapy. In one aspect, the iron chelators are designed to provide
10 desired cell membrane, particularly blood-brain-barrier (BBB), transport properties in lipophilic media. In another aspect, these chelators are part of multifunctional compounds possessing an iron chelator function and a residue that imparts a neuroprotective function and/or a residue that imparts both antiapoptotic and neuroprotective functions. The invention further relates to pharmaceutical
15 compositions and methods for treatment and/or prevention of diseases, disorders and conditions associated with iron overload and oxidative stress, in particular neurodegenerative diseases, conditions and disorders such as Parkinson's disease, Alzheimer's disease, stroke, amyotrophic lateral sclerosis (ALS), multiple sclerosis, Friedreich's ataxia, Hallervorden-Spatz disease, epilepsy and neurotrauma.

20

BACKGROUND OF THE INVENTION

Iron is known to enhance the production of the highly reactive and toxic hydroxyl radical, thus stimulating oxidative damage. Iron has been associated with a number of diseases, disorders and conditions because humans have no physiologic
25 means of eliminating excess iron.

Hereditary hemochromatosis, a condition in which the body accumulates excess amounts of iron, is one of the most common genetic diseases in humans. In

the United States, as many as one million people have evidence of hemochromatosis, and up to one in every ten people may carry the gene for the disorder. Hemochromatosis is characterized by lifelong excessive absorption of iron from the diet, with iron accumulating in body organs, eventually causing inflammation and damage. Serious and even fatal health effects can result, including
5 cirrhosis of the liver, liver cancer, heart abnormalities (leading to heart failure), diabetes, impotence, and arthritis.

Clinical thalassemia (major and minor) are hereditary disorders characterized by defective production of hemoglobin, which leads to decreased production and
10 increased destruction of red blood cells. With severe thalassemia, regular blood transfusions and folate supplementation are given, resulting in iron overload. Since iron is usually not ingested in large amounts, the body holds onto what it receives and has no way of ridding itself of any excess. Iron overload is therefore the leading cause of death among thalassemia patients in industrialized nations.

15 Patients with β -thalassemia major (TM) or refractory anemia (as in myelodysplastic syndrome) who receive frequent or regular red-cell transfusions, coupled with increased iron absorption due to ineffective erythropoiesis, develop iron overload rapidly. The toxicity of iron begins when its load exceeds the tissue or blood binding capacity to join a mobile intracellular or free nontransferrin-bound
20 pool in the blood, the unbound iron accelerates hydroxyl radical formation resulting in peroxidative damage to cells. In the absence of chelation therapy, chronically transfused patients inevitably undergo progressive deterioration in pancreatic, hepatic and cardiac function, and usually succumb to life-threatening arrhythmias or intractable heart failure as a result of iron overload. This usually happens in the
25 second decade of life in poorly or unchelated patients with thalassemia major.

Deferoxamine (DFO), a naturally occurring siderophore, chelating iron in a labile intracellular pool that is itself rapidly renewed from the storage pool, was introduced in early 1960s. The minimal absorption of DFO from the gastrointestinal tract and its short half-life in the blood necessitate a slow prolonged parenteral

administration of the drug to achieve net negative iron balance as the prime goal of an effective chelation therapy. The expense and inconvenience of DFO has led to a search for an orally-active iron chelator, and deferiprone (L1) has been used in the last years for oral treatment of thalassemia major patients, but the risk of agranulocytosis mandates a careful evaluation of the use of this drug. Other orally active iron chelators have reached clinical trials in the past decade but their use in iron chelation therapy need more investigation. The identification of suitable, preferably orally, effective iron chelators for the treatment of iron overload diseases, disorders and conditions still remains an unsolved problem.

Neurodegenerative diseases, such as Parkinson's disease (PD) and Alzheimer's disease (AD), are neurodegenerative syndromes for which at present no cure is available. Both diseases are the most widespread neurodegenerative disorders. They affect approximately 0.5% and 4-8 %, respectively, of the population over the age of 50 years, thereby, considering the still growing number of the elderly, forming an increasing economic burden for society. Therefore, development of an effective drug for preventing (neuroprotective) and treating neurodegenerative diseases is essential for the whole society.

Numerous studies including *in vivo*, *in vitro* and relevant animal models have shown a linkage between free radical production and neurodegenerative diseases and disorders, such as Parkinson's diseases, Alzheimer's disease and stroke as well as ALS, multiple sclerosis, Friedreich's ataxia, Hallervorden-Spatz disease, epilepsy and neurotrauma.

For this reason, 8-hydroxyquinolines and hydroxypyridinones have been proposed for iron binding as antioxidant-type drugs. Since iron accumulation in neurodegenerative diseases is a common feature, the inventors have shown previously that it has a pivotal role in the process of neurodegeneration (Youdim, 1988). We (Gassen and Youdim, 1999) and others (Cuajungco et al., 2000; Sayre et al., 2000) have suggested on several occasions the development of iron chelators as therapeutic agents for Alzheimer's disease and Parkinson's disease.

In Parkinson's disease, the brain defensive mechanisms against the formation of oxygen free radicals are defective. In the substantia nigra of parkinsonian brains there are reductions in activities of antioxidant enzymes. Moreover, iron concentrations are significantly elevated in parkinsonian substantia nigra pars compacta and within the melanized dopamine neurons. Latest studies have also shown that significant accumulations of iron in white matter tracts and nuclei throughout the brain precede the onset of neurodegeneration and movement disorder symptoms. Indeed the accumulation of iron at the site of neurodegeneration is one of the mysteries of neurodegenerative diseases because iron does not cross the BBB. Where the iron comes from and why it accumulates is not known.

The etiology of Alzheimer's disease (AD) and the mechanism of cholinergic neuron degeneration remain elusive. Nevertheless, the chemical pathology of AD shows many similarities to Parkinson's disease: the involvement of increased iron, release of cytochrome C, increased alpha-synuclein aggregation, oxidative stress, loss of tissue reduced glutathione (GSH), an essential factor for removal of hydrogen peroxide, reduction in mitochondrial complex I activity, increased lipid peroxidation, and loss of calcium-binding protein 28-kDa calbindin, to mention a few. These similarities also include the progressive nature of the disease, proliferation of reactive microglia around and on top of the dying neurons, the onset of oxidative stress and inflammatory processes.

Oxygen free radicals have been shown to be associated with protein denaturation, enzyme inactivation, and DNA damage, resulting in lipid peroxidation of cell membranes, and finally the cell death in neurodegenerative diseases. One of the profound aspects of neurodegenerative diseases is the accumulation and deposition of significant amount of iron at the neurodegenerative sites. In AD, iron accumulates within the microglia and within the neurons and in plaques and tangles. Current reports have provided evidence that the pathogenesis of AD is linked to the characteristic neocortical beta-amyloid deposition, which may be mediated by abnormal interaction with metals such as iron. Indeed, iron is thought to cause

aggregation of not only beta-amyloid protein but also of alpha-synuclein, promoting a greater neurotoxicity. This has led to the notion that chelatable free iron may have a pivotal role in the induction of the oxidative stress and the inflammatory process leading to apoptosis of neurons. Iron and radical oxygen species activate the proinflammatory transcription factor, NF κ B, which is thought to be responsible for promotion of the cytotoxic proinflammatory cytokines IL-1, IL-6 and TNF-alpha, which increase in AD brains is one feature of AD pathology. This is considered logical since iron, as a transition metal, participates in Fenton chemistry with hydrogen peroxide to generate the most reactive of all radical oxygen species, reactive hydroxyl radical. This radical has been implicated in the pathology of cell death and mechanism of action of numerous toxins and neurotoxins (6-hydroxydopamine, MPTP, kainite, streptocozin model of AD). Furthermore, such toxins mimic many of the pathologies of neurodegenerative diseases (AD, Parkinson's disease and Huntington's Chorea), one feature of which is the accumulation of iron, but not of other metals, at the site of neurodegeneration.

Iron alone or iron decompartmentalized from its binding site by a neurotoxin, e.g. the dopaminergic neurotoxin 6-hydroxydopamine (6-OHDA), may induce oxidative stress and neurodegeneration, as evidenced in previous studies of the inventors in which intranigral administration of iron-induced "Parkinsonism" in rats and the iron chelator desferrioxamine protected the rats against 6-OHDA-induced lesions of nigrostriatal dopamine neurons (Ben-Shachar et al., 1991). It has thus been suggested that treatment or retardation of the process of dopaminergic neurodegeneration in the substantia nigra may be affected by iron chelators capable of crossing the blood brain barrier in a fashion similar to the copper chelator D-penicillamine used in the treatment of Wilson's disease. This therapeutic approach for the treatment of Parkinson's disease can be applied to other metal-associated neurological disorders such as tardive dyskinesia, Alzheimer's and Hallervorden-Spatz diseases.

Stroke is the third leading cause of death in the Western world today, exceeded only by heart diseases and cancer. The overall prevalence of the disease is 0.5-0.8% of the population. Stroke is characterized by a sudden appearance of neurological disorders such as paralysis of limbs, speech and memory disorders, sight and hearing defects, etc., which result from a cerebrovascular damage.

Haemorrhage and ischemia are the two major causes of stroke. The impairment of normal blood supply to the brain is associated with a rapid damage to normal cell metabolism including impaired respiration and energy metabolism lactacidosis, impaired cellular calcium homeostasis release of excitatory neurotransmitters, elevated oxidative stress, formation of free radicals, etc. Ultimately these events lead to cerebral cell death and neurological disfunction.

Treatment of stroke is primarily surgical. Much effort is being invested in less aggressive therapeutical intervention in the search for drugs which are capable of restoring normal blood perfusion in the damaged area as well as drugs which are designed to overcome the above listed damaging events associated with cellular damage.

Oxidative stress and free radical formation play a major role in tissue injury and cell death. These processes are catalyzed by transient metal ions, mainly iron and copper. In the case of stroke, since vascular damage is involved, iron is available for the free radical formation, a process that could be prevented by iron chelators. Indeed, with lazaroides (21-amino steroids), known free radical scavengers, a significant improvement of local and global ischemia damages induced in animals has been achieved.

Iron chelators and radical scavengers have been shown to have potent neuroprotective activity in animal models of neurodegeneration. However, the major problem with such compounds is that they do not cross the BBB. The prototype iron chelator Desferal (desferrioxamine) was first shown by us to be a highly potent neuroprotective agent in animal models of Parkinson's disease (Ben-

Schachar et al., 1991). However, Desferal does not cross the BBB and has to be injected centrally. Desferal also protects against streptozocin model of diabetes.

Free radicals in living organism are believed to be produced by the reaction of transition metal ions (especially copper and iron) with poorly reactive species such as H_2O_2 , $[O_2^{\cdot-}]$, thiols, lipid peroxides. Antioxidant metal chelators, by binding free metal ions (especially copper and iron) or metal ions from active centers of enzymes of the defense system, can influence the oxidant/antioxidant balance *in vivo*, and hence, may affect the process of dopaminergic and cholinergic neurodegeneration and have great therapeutic potential against neurodegenerative diseases.

Iron accumulation in aging and the resulting oxidative stress has been suggested to be a potential causal factor in aging and age-related neurodegenerative disorders (Butterfield et al., 2001). There is increasing evidence that reactive oxygen species play a pivotal role in the process of ageing and the skin, as the outermost barrier of the body, is exposed to various exogenous sources of oxidative stress, in particular UV-irradiation. These are believed to be responsible for the extrinsic type of skin ageing, termed photo-ageing. (Podda et al., 2001). Iron chelators have thus been suggested to favor successful ageing in general, and when applied topically, successful skin ageing (Polla et al., 2003).

Iron is a factor in skin photodamage, not only in ageing, apparently by way of its participation in oxygen radical production. Certain topical iron chelators were found to be photoprotective (Bisset and McBride, 1996; Kitazawa et al., 1999). UVA radiation-induced oxidative damage to lipids and proteins in skin fibroblasts was shown to be dependent on iron and singlet oxygen (Vile and Tyrrel, 1995). Iron chelators can thus be used in cosmetic and non-cosmetic formulations, optionally with sunscreen compositions, to provide protection against UV radiation exposure.

Other diseases, disorders or conditions associated with iron overload include: (i) viral infections, including HIV infection and AIDS – oxidative stress and iron have been described to be important in the activation of HIV-1 and iron chelation,

in combination with antivirals, might add to improve the treatment of viral, particularly HIV disease (van Asbeck et al., 2001); (ii) protozoal, e.g. malaria, infections; (iii) yeast, e.g. *Candida albicans*, infections; (iv) cancer – several iron chelators have been shown to exhibit anti-tumor activity and may be used for cancer therapy either alone or in combination with other anti-cancer therapies (Buss et al., 2003); (v) iron chelators may prevent cardiotoxicity induced by anthracycline neoplastic drugs (Hershko et al., 1996); (vi) inflammatory disorders – iron and oxidative stress have been shown to be associated with inflammatory joint diseases such as rheumatoid arthritis (Andrews et al., 1987; Hewitt et al., 1989; Ostrakhovitch et al., 2001); (vii) diabetes – iron chelators have been shown to delay diabetes in diabetic model rats (Roza et al., 1994); (viii) iron chelators have been described to be potential candidates for treatment of cardiovascular diseases, e.g. to prevent the damage associated with free radical generation in reperfusion injury (Hershko, 1994; Flaherty et al., 1991); (ix) iron chelators may be useful ex-vivo for preservation of organs intended for transplantation such as heart, lung or kidney (Hershko, 1994).

One of the main problems in the use of chelating agents as antioxidant-type drugs is the limited transport of these ligands or their metal complexes through cell membranes or other biological barriers.

Drugs with the brain as the site of action should, in general, be able to cross the blood brain barrier (BBB) in order to attain maximal *in vivo* biological activity. The efficacy of the best established iron-chelating drug, Desferal, in the neurodegenerative diseases, is limited by its ineffective transport property and high cerebro- and oculotoxicity.

8-Hydroxyquinoline is a strong chelating agent for iron, and contains two aromatic rings, which can scavenge free radicals by themselves. In our previous PCT Publication No. WO 00/74664, various iron chelators have been disclosed and their action in Parkinson's disease prevention has been shown. The lead compound, 5-[4-(2-hydroxyethyl)piperazin-1-ylmethyl]-8-hydroxyquinoline (herein referred to

as VK-28), was able to cross the BBB and was shown to be active against 6-hydroxydopamine (6-OHDA) in an animal model of Parkinson's disease.

It would be very desirable to provide novel iron chelators that exhibit also neuroprotective activity and/or good transport properties through cell membranes
5 including the blood brain barrier.

SUMMARY OF THE INVENTION

The present invention relates to amphiphilic metal chelators that have specificity for iron and exhibit neuroprotective and/or good transport transport
10 properties in lipophilic media.

In one aspect, the invention provides a compound comprising an iron chelator function and a residue selected from the group consisting of a residue that imparts a neuroprotective function to the compound, a residue that imparts combined antiapoptotic and neuroprotective functions to the compound, or both,
15 and pharmaceutically acceptable salts thereof.

The iron chelator function is provided preferably by a 8-hydroxyquinoline residue, a hydroxamate residue, or a pyridinone residue, the neuroprotective function may be provided by a cysteine or alanine residue or by the residue of a neuroprotective peptide, a neuroprotective analog or a neuroprotective fragment
20 thereof, and the combined antiapoptotic and neuroprotective functions is preferably provided by a propargyl group.

In another aspect, the invention provides compounds of the formulas I to IV as defined hereinafter in the description and in the claims, and pharmaceutically acceptable salts thereof.

25 The compounds of the present invention are useful for treatment and/or prevention of diseases, disorders and conditions associated with iron overload and oxidative stress such as, but not limited to, neurodegenerative and cerebrovascular diseases and disorders, neoplastic diseases, hemochromatosis, thalassemia,

cardiovascular diseases, diabetes, inflammatory disorders, anthracycline cardiotoxicity, viral, protozoal and yeast infections, for retarding ageing, and for prevention and/or treatment of skin ageing and/or skin damage associated with skin ageing and/or exposure to sunlight and/or UV light.

5 In a further aspect, the present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of the invention.

In yet another aspect, the present invention provides a cosmetic composition comprising a compound of the invention.

10 In still a further aspect, the present invention provides the use of a compound of the invention for the preparation of a pharmaceutical composition for iron chelation therapy.

In still another aspect, the present invention provides a method for iron chelation therapy which comprises administering to an individual in need thereof an effective amount of a compound of the invention or of a pharmaceutically acceptable salt thereof.

15 Any discussion of documents, acts, materials, devices, articles or the like which has been included in the present specification is solely for the purpose of providing a context for the present invention. It is not to be taken as an admission that any or all of these matters form part of the prior art base or were common general knowledge in the field relevant to the present invention as it existed before the priority date of each claim of this application.

20 Throughout this specification the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.

BRIEF DESCRIPTION OF THE FIGURES

The formulas of the compounds defined by the adopted designation used in the description of the specification and in the claims appear in the Appendices I to VI at the end of the description, just before the claims.

5 **Figs. 1A-1C** are graphs showing iron chelation (in solution) by the chelators of the invention HLM7, HLM8, HLM9, HLA16, HLA20 (Fig. 1A), HLA16, HLA20, M9, M10 (Fig. 1B), and M7, M11, M12 (Fig. 1C), and the known iron chelators deferiprone (L1) and VK-28, using iron precomplexed calcein (Fe-CAL) solutions.

10 **FIGS. 2A-2D** show iron permeation into K562 cells of the chelators of the invention HLM7, HLM8, HLM9, HLA16, HLA20 (Fig. 2A), HLA16, HLA20, M9, M10 (Fig. 2B), and M7, M11, M12 (Fig. 2C), HLM9, HLA16, HLA20 (Fig. 2D),

and the known iron chelators deferiprone (L1), VK-28, desferrioxamine B (DFO), and salicylaldehyde isonicotinoyl hydrazone (SIH).

Fig. 3 shows neuroprotective effect of the chelators of the invention HLM7, HLM8, HLM9, HLA16, M7, HLA20 and of apomorphine (Apo) on differentiated neuronal P19 cells treated with 6-OH-dopamine.

Figs. 4A-4B show protection by of PC12 cells against serum deprivation-induced apoptosis by the chelators of the invention M32 (Fig. 4A) and HLA20 (Fig. 4B), in comparison to the known chelators Rasagiline and VK-28.

Figs. 5A-5D are graphs showing the *in vitro* inhibitory action of HLA20 and M32 (Fig. 5A), M30 and M31 (Fig. 5B), VK-28, and propargylamine (P) against rat brain MAO-B, and of M31 (Fig. 5C), M32 and HLA20 (Fig. 5D), VK-28, and propargylamine (P) against rat brain MAO-B and MAO-A.

Fig. 6 shows inhibition of lipid peroxidation by the chelators of the invention HLM7, HLM8, HLM9, HLA16 and HLA20 in the presence of 5.0 μM Fe_2SO_4 /50 μM ascorbic acid. The results are the mean $\pm$ SEM, $n=3$, $p<0.05$.

DETAILED DESCRIPTION OF THE INVENTION


In one broad aspect, the present invention provides a compound comprising an iron chelator function and a residue selected from the group consisting of a residue that imparts a neuroprotective function to the compound, a residue that imparts combined antiapoptotic and neuroprotective functions to the compound, or both.

In one most preferred embodiment, the residue imparting combined antiapoptotic and neuroprotective functions is a propargyl moiety, described recently as playing a crucial role in the antiapoptotic and neuroprotective effects of the anti-Parkinson drug rasagiline [N-propargyl-(1R)-aminoindan] (Yogev-Falach et al., 2003).

The iron chelator function in the compounds of the invention is provided by a residue selected from the group consisting of a 8-hydroxyquinoline residue, a hydroxamate residue, and a pyridinone residue.

In one preferred embodiment, the iron chelator function is provided by a 8-hydroxyquinoline group to which the residue imparting the neuroprotective function and/or combined antiapoptotic and neuroprotective functions may be linked through the 5, 6 or 7 position of the quinoline ring. In a more preferred embodiment, the iron-chelating group is the 8-hydroxy-5-quinolinyl group of the formula below and, most preferably, it is a 8-hydroxy-5-quinolinylmethylene group.

In another preferred embodiment, the iron chelator function is provided by or a 3-hydroxypyridin-4-one or 1-hydroxypyridin-2-one of the formulas below:



In the formulas above, R represents the group carrying the neuroprotective function and/or combined neuroprotective and antiapoptotic functions that may be linked at position 5, 6 or 7 of the quinoline ring, at position 1, 2, 5 or 6 of the 3-hydroxy-4-pyridinone ring that may be further substituted by a lower alkyl, preferably, methyl group, and at position 4 or 5 of the 1-hydroxy-2-pyridinone ring. In one preferred embodiment, the iron-chelating function is provided by a 2-methyl-3-hydroxy-4-pyridinone group substituted at position 1 by the desired further functions.

The proposed N-hydroxypyridin-2-ones and 3-hydroxypyridin-4-ones are a suitable type of candidate iron chelators for three reasons: (1) hydroxypyridinones are the most promising oral iron chelators considering both their properties and the results of biological trials - one hydroxypyridinone, deferiprone (CP20 or L1), is an

orally iron chelating agent which is used worldwide in thalassaemia, cancer, leukaemia, haemodialysis and other patients (Kontoghiorghes, 2001); (2) some hydroxypyridinones, for example CP20, CP24, CP94, have been proved to be able to cross the BBB (Crivori et al., 2000); and (3) there are many structural similarities
5 between hydroxypyridinones with catechol, an iron chelator group in the DOPA structure.

In another embodiment, the iron-chelating function is provided by a hydroxamate group. Hydroxamates are known as iron chelators. For decades, desferrioxamine B (Desferal) has been the therapeutic iron chelator of choice for
10 iron-overload treatment, despite numerous problems associated with its use.

In one embodiment of the invention, the residue imparting a neuroprotective function to the compound of the invention is selected from the group consisting of a neuroprotective peptide, a neuroprotective analog and a neuroprotective fragment thereof.


15 The neuroprotective peptide that can be used in the compounds of the invention may be, without being limited to, vasoactive intestinal peptide (VIP), gonadotropin-releasing hormone (GnRH), Substance P and enkephalin.

In one preferred embodiment, the neuroprotective function is provided by the residue of VIP, GnRH, Substance P or enkephalin or a fragment thereof in which
20 one amino acid residue is replaced by a L- or D-cysteine residue, to which the iron-chelating residue is linked via the -S- atom of the L- or D-Cys residue.

In one embodiment of the invention, the neuroprotective peptide is vasoactive intestinal peptide (VIP), a basic 28 amino acid peptide, originally isolated from the gastrointestinal system, that has been shown to protect neurons in
25 the central nervous system from a variety of neurotoxic substances including the envelop protein from HIV, tetrodotoxin, and the beta amyloid peptide. The beta amyloid peptide is a major component of the cerebral amyloid plaque in Alzheimer disease and has been shown to be neurotoxic and associated with Alzheimer disease onset and progression. VIP itself presents a limitation for clinical use as a possible



neuroprotectant since it does not cross the BBB. Lipophilic derivatives of VIP, such as stearyl-VIP, do cross the BBB. However, for more efficient penetration and as well as from economical aspects, it is desirable to have much smaller molecules mimicking the parent peptide (VIP) activity while possessing better penetration through biological barriers. In the laboratory of one of the present inventors it was found that a 4-amino acids lipidic derivative of VIP (stearyl-Lys-Lys-Tyr-Leu-NH₂ – SEQ ID NO:1) surpasses the activity of the parent peptide (VIP), through binding and activation of its receptor, and provides a lead compound for drug design against neurodegenerative diseases (Gozes et al., 1999).

Thus, in one embodiment of the invention, the neuroprotective function is imparted by a VIP fragment of the SEQ ID NO: 2:



wherein Z is H or a hydrophobic group such as stearyl (St) or Fmoc.

In one embodiment, the iron chelator is a 8-hydroxyquinolinylmethyl group and the compound has the formula:



R = Stearyl, Fmoc, etc.

In this model, the peptide Lys-Lys-Tyr-Leu-NH₂ (SEQ ID NO:1) is the core active site for neuroprotective effect. The aromatic phenolic moiety of Tyr is substituted by an iron chelator 8-hydroxyquinoline, which serves as an antioxidative active core. The hydrophobic group R may be used to adjust the lipophilicity of the whole molecule so as to control the transport properties through the BBB.

Examples of compounds containing the above formula containing a 8-hydroxy-5-quinolinylmethyl residue (HQ) are the compounds herein designated StKKC(HQ)L (M6) and Fmoc-KKC(HQ)L (M7) in Appendix II. The

corresponding compounds herein designated StKKC(HQ-Pr)L (M6A) and Fmoc-KKC(HQ-Pr)L (M7A) in Appendix I have in addition a propargylamino (Pr) group linked to the -CH₂ group at the 5-position of the quinoline ring.

5 Examples of further compounds of the invention comprising a VIP fragment analog of SEQ ID NO: 2 are the hydroxamates herein designated M6B and M7B in Appendix V that comprise also an aminopropargyl group.

Gonadotropin-releasing hormone (GnRH) is a neurohormone produced in the hypothalamic neurosecretory cells that controls release of the gonadotropins luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the anterior
10 pituitary. The peptide was later found to function in the brain as a neurotransmitter and/or neuromodulator and to have good transport properties (GnRH is able to cross the BBB). Several GnRH analogs are now either in clinical trials or in clinical use for contraception and for the treatment of various hormone-dependent diseases including prostate and breast cancers. The combination of GnRH analogs with an
15 iron chelator, e.g. hydroxamate, pyridinone or 8-hydroxyquinoline as an antioxidative core, is envisaged specially as protective agents in the treatment of neurodegenerative diseases.

GnRH is a decapeptide of the sequence below (the 5-oxo proline at the amino terminal is sometimes presented as pyroglutamic acid - pGlu):

20 5-oxo-Pro-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH₂ (SEQ ID NO:3)

Two analogs of GnRH were prepared in which the amino acid residue at position 5 (Tyr) or 6 (Gly) was replaced by L-Cys or D-Cys, respectively. These modifications are not expected to significantly affect the bioactivity of GnRH. Moreover these changes may generate superagonists. The free SH group of this
25 analogs at the cysteine (5 or 6) position makes these compounds good candidates for specific chemical modifications. This change, *ie*, at position 6, also serves to improve the stability of the analog to proteolysis.

The resulting GnRG analogs have the sequences identified by SEQ ID NO:4 and SEQ ID NO:5, as follows:

5-oxo-Pro-His-Trp-Ser-Cys-Gly-Leu-Arg-Pro-Gly-NH₂ (SEQ ID NO:4)

5-oxo-Pro-His-Trp-Ser-Tyr-D-Cys-Leu-Arg-Pro-Gly-NH₂ (SEQ ID NO:5)

To the S atom of the L-Cys or D-Cys residue the iron chelator function is attached. For example, the resulting compounds with a 8-hydroxy-5-quinolinylmethyl residue (HQ) are the compounds herein designated L-Cys⁵(HQ)GnRH (M8) and D-Cys⁶(HQ)GnRH (M22) in Appendix II. The corresponding compounds herein designated L-Cys⁵(HQ-Pr)GnRH (M8) and D-Cys⁶(HQ-Pr)GnRH (M22) in Appendix I have in addition a propargylamino (Pr) group linked to the -CH₂ group at the 5-position of the quinoline ring.

10 Examples of further compounds of the invention comprising a GnRH analog of SEQ ID NO:4 or SEQ ID NO:5 are the hydroxamates herein designated M8B and M22B in Appendix V that comprise also a propargylamino group.

According to the invention, similar Cys-containing GnRH analogs can be prepared starting from analogs of GnRH such as, but not limited to, leuprolide, 15 nafarelin, goserelin, histrelin, and D-Lys⁶GnRH, and then attaching them to a HQ, pyridinone or hydroxamate residue and, optionally, to a propargylamino residue.

Substance P (SP) is a peptide neurotransmitter widely distributed in the peripheral and central nervous systems of vertebrates. SP is involved in modulating neuronal nicotinic acetylcholine receptors (nAChRs) in the sympathetic nervous system. Substance P analogs may be useful as drugs in control of neurodegenerative 20 diseases.

Substance P is a undecapeptide of the sequence:

Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH₂ (SEQ ID NO:6)

Two analogs of Substance P were prepared in which the amino acid residue 25 at position 7 (Phe) or 8 (Phe) was replaced by Cys, resulting in the peptides of the sequences:

Arg-Pro-Lys-Pro-Gln-Gln-Cys-Phe-Gly-Leu-Met-NH₂ (SEQ ID NO:7)

Arg-Pro-Lys-Pro-Gln-Gln-Phe-Cys-Gly-Leu-Met-NH₂ (SEQ ID NO:8)

To the S atom of the Cys residue the iron chelator function is attached. For example, the resulting compounds with a 8-hydroxy-5-quinolinylmethyl residue (HQ) are the compounds herein designated Cys⁷(HQ)Substance-P (M27) and Cys⁸(HQ) Substance-P (M28) in Appendix II. The corresponding compounds herein
 5 designated Cys⁷(HQ-Pr)Substance-P (M27A) and Cys⁸(HQ-Pr) Substance-P (M28A) in Appendix I have in addition a propargylamino group (Pr) linked to the -CH₂ group at the 5-position of the quinoline ring.

Examples of further compounds of the invention comprising a Substance-P analog of SEQ ID NO:7 or SEQ ID NO:8 are the hydroxamates herein designated
 10 M27B and M28B in Appendix V that comprise also a propargylamino group.

Met⁵-enkephalin and Leu⁵-enkephalin are two naturally occurring pentapeptides belonging to the endorphin class, of the sequences, respectively:

Tyr-Gly-Gly-Phe-Met (SEQ ID NO:9)

Tyr-Gly-Gly-Phe-Leu (SEQ ID NO:10).

15 Two analogs of each of Met⁵-enkephalin (SEQ ID NO:9) and Leu⁵-enkephalin (SEQ ID NO:10) have been prepared in which either the Phe residue at position 4 or the Tyr residue at position 1 was replaced by a Cys residue, as follows:

Tyr-Gly-Gly-Cys-Met (SEQ ID NO:11)

Cys-Gly-Gly-Phe-Met (SEQ ID NO:12)

20 Tyr-Gly-Gly-Cys-Leu (SEQ ID NO:13)

Cys-Gly-Gly-Phe-Leu (SEQ ID NO:14)

To the S atom of the Cys residue the iron chelator function is attached. For example, the resulting compounds with a 8-hydroxy-5-quinolinylmethyl residue (HQ) are the compounds herein designated YGGC(HQ)L (M18) for SEQ ID NO:
 25 13, YGGC(HQ)M (M19) for SEQ ID NO: 11, C(HQ)GGFL (M20) for SEQ ID NO: 14, and C(HQ)GGFM (M21) for SEQ ID NO: 12, in Appendix II. The corresponding compounds herein designated YGGC(HQ-Pr)L (M18A), YGGC(HQ-Pr)M (M19A), C(HQ-Pr)GGFL (M20A), and C(HQ-Pr)GGFM

(M21A) in Appendix I have in addition a propargylamino (Pr) group linked to the -CH₂ group at the 5-position of the quinoline ring.

Examples of further compounds of the invention comprising an enkephalin analog of SEQ ID NO:11-14 are the hydroxamates herein designated M18BA,
5 M19B, M20B and M21B in Appendix V that comprise also a propargylamino group.

In another embodiment of the invention, the residue imparting a neuroprotective function to the compound of the invention is selected from the group consisting of a L or D cysteine or alanine residue.

10 When the neuroprotective function is L- or D-cysteine, the iron chelator function is attached to the S atom of the Cys residue. For example, the resulting compounds with a 8-hydroxy-5-quinolinylmethyl residue (HQ) are the compounds herein designated D-HQ-CysOH (M11) and L-HQ-CysOH (M12) in Appendix II, and the corresponding compounds herein designated D-(HQ-Pr)-CysOH (M11a)
15 and L-(HQ-Pr)-CysOH (M12a) in Appendix III. Examples of further compounds of the invention comprising a cysteine residue are the hydropyridinone derivatives herein designated M11b and M12b in Appendix VI that contain a propargylamino group.

Examples of compounds of the invention wherein the neuroprotective
20 function is L- or D-alanine are the compounds with a 8-hydroxy-5-quinolinyll residue (HQ) herein designated D-HQ-Ala (M9), L-HQ-Ala (M10), the internal salt HQAla (HLM8), and the ethyl ester HQAlaEt (HLM9) in Appendix IV, and the corresponding compounds herein designated D-(HQ-Pr)-Ala (M9a), L-(HQ-Pr)-Ala (M10a), in Appendix III. A further example is the hydroxypyridinone derivative
25 herein designated M9b in Appendix VI.

Parkinson's disease is associated with decreased dopaminergic function in the brain, and many of the symptoms of the disease can be alleviated by oral administration of L-DOPA (L-dihydroxyphenylalanine). L-DOPA is converted to dopamine by DOPA decarboxylase in the brain. Based on retrosynthesis analysis of


the lead compound DOPA, which contains iron chelating group (catechol) and an amino acid (alanine), the iron-chelator-peptide and iron chelator-amino acid derivatives described above may be useful drug candidates as antioxidant-type drugs constituting another class of antiparkinsonism, and also potentially other neurodegenerative diseases and other disorders in which iron chelators are useful.

As mentioned before, drugs with the brain as the site of action should, in general, be able to cross the blood brain barrier (BBB) in order to attain maximal *in vivo* biological activity. When the intention is to bring to the brain iron chelators to bind and remove iron that accumulates in the brain in some neurodegenerative diseases, one of the possible solutions is to design iron-chelating molecules with specific groups, responsible for amphiphilic behavior. Such amphiphilic groups possess lipophilic and hydrophilic centers. The size and structure of both centers control the overall lipophilicity of the whole molecule, and hence its transport properties.

The present invention further provides amphiphilic metal chelators that have specificity for iron and are designed to provide desired blood brain barrier (BBB) transport properties in lipophilic media.



In one embodiment, the invention relates to compounds comprising an iron chelating residue that crosses the BBB wherein said iron chelating residue is a 8-hydroxy-5-quinolinylmethyl group linked to an aliphatic chain via a linker selected from the group consisting of an ethylenediamine moiety or a piperazine or 1,3,5-perhydrotriazine ring as shown below, but excluding the compound 5-[4-(2-hydroxyethyl)piperazin-1-ylmethyl]-8-hydroxy-quinoline.

According to this embodiment, the 8-hydroxyquinoline part of the molecule serves both as iron-specific chelator and radical-scavenger and R is an aliphatic




chain of different lengths, but is not a 2-hydroxyethyl group when the linker is a piperazine ring. By changing R, we can adjust the size and lipophilicity of the whole molecule, thus controlling the transport properties through the BBB. In a preferred embodiment, the linker is a piperazine ring.

The above iron chelators when the linker is piperazine may be prepared by reacting piperazine with di(t-butyl)dicarbonate (Boc_2O), followed by reaction of the Boc-protected piperazine with a halide R-X (R is a propargyl containing group, X is hal), removal of the Boc group with TFA, and reaction with 8-hydroxy-5-chloromethylquinoline, as described in the scheme below:



The lipid solubility of the whole molecule, which is a key factor in controlling the transport property of a drug through the BBB, can be adjusted by changing n. The aliphatic chain may also contain a heteroatom selected from O, S and N. Examples of such compounds according to the invention are the compounds herein designated HLA16a, HLA20 and M17 in Appendix III. Also envisaged by the invention is Compound HLA16 in Appendix IV, that has no propargyl group.

The present invention encompasses compounds of the formulas I to IV:




wherein

15 R_1 is a residue of an analog of a neuroprotective peptide or a fragment thereof containing a cysteine residue that is linked to the C atom via the -S- atom of the Cys residue, and wherein the amino terminal of the peptide is optionally substituted by a hydrophobic group such as Fmoc or stearyl;

R_2 is H or -NH-X;

20 R_3 is a group selected from the group consisting of



(ii) -CR₅R₆R₇; (iii) -N(CH₃)-X; (iv) -N(R₈)-CH(CH₂SH)COOC₂H₅;

25 (v) -N(R₈)-CH₂-COOCH₂C₆H₅; and (vi) -S-CH₂-CH(COOH)-NHR₈';

R_4 is selected from the group consisting of (i) X; (ii) COOC₂H₅;

(iii) $(\text{CH}_2)_2\text{-O-}$ R_8 ; and (iv) $\text{-COO-}(\text{CH}_2)_2\text{-NH-}$ R_8 ;

R_5 is H, $\text{C}_1\text{-C}_4$ lower alkyl, preferably CH_3 , or COOC_2H_5 ;

R_6 is H, COOH , COO^- or COOC_2H_5 ;

R_7 is selected from the group consisting of (i) -NH- R_8 ; (ii) -NH_3^+ ;

5 (iii) -NH-COCH_3 ; (iv) -NH-NH- R_8 ;



and (v) $\text{-NH-NH-CO-CH}(\text{CH}_2\text{OH})\text{-NH-}$ R_8 ;

R_8 is H or X, and R'_8 is H, X, or Fmoc;


R_9 is selected from the group consisting of (i) H; (ii) $\text{-CO-CH}_2\text{-}$ R_1 ;

(iii) $\text{-CH}_2\text{-COOCH}_2\text{C}_6\text{H}_5$; (iv) $\text{-CH}(\text{CH}_2\text{SH})\text{COOC}_2\text{H}_5$; (v)

10



15



n is an integer from 1 to 6;

R_{11} is a group selected from the group consisting of

20

(i) $\text{-S-CH}_2\text{-CH}(\text{COOH})\text{-NH-X}$;

(ii) $\text{-N(X)-CH}_2\text{COO-CH}_2\text{-C}_6\text{H}_5$;

(iii) $\text{-N(CH}_3\text{)-X}$;


(iv) $\text{-N(X)-CH}(\text{CH}_2\text{SH})\text{COOC}_2\text{H}_5$;

(v) $\text{-CH}_2\text{-NH-NH-CO-CH}(\text{CH}_2\text{OH})\text{-NH-X}$;

25

(vi) $\text{-C(CH}_3\text{)(COOH)-NH-NH-X}$;

(vii) $\text{-CH}(\text{COOH})\text{-NH-X}$;



R_{12} is X , C_1 - C_4 lower alkyl, preferably methyl, COOC_2H_5 , or $-(\text{CH}_2)_2-\text{OH}$;


R_{13} is X , $-(\text{CH}_2)_2-\text{OX}$, or $-\text{COO}-(\text{CH}_2)_2-\text{NH}-\text{X}$; and

5 X is a propargyl group,

but excluding the compound 5-[4-(2-hydroxyethyl)piperazin-1-ylmethyl]-8-hydroxy-quinoline.

In one preferred embodiment, the compound of the invention is a compound of the formula I above

10



15 R_1 is a residue of an analog of a neuroprotective peptide or a fragment thereof containing a cysteine residue that is linked to the C atom via the -S- atom of the Cys residue, and wherein the amino terminal of the peptide is optionally substituted by a hydrophobic group such as Fmoc or stearyl;

R_2 is H or $-\text{NH}-\text{X}$; and


20 X is a propargyl group.

R_1 is preferably the residue of an analog of VIP, GnRH, Substance P or enkephalin or a fragment thereof in which one amino acid residue is replaced by a cysteine residue, more preferably the VIP fragment analogs of SEQ ID NO:2 that may bear a stearyl or a Fmoc group at the amino terminal, the GnRH analogs of
25 SEQ ID NO:4 and SEQ ID NO:5, the Substance P analogs of SEQ ID NO:7 and SEQ ID NO:8, and the enkephalin analogs SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, and SEQ ID NO:14.


In preferred embodiments, the compounds of formula I are the compounds wherein R_2 is H and R_1 is selected from the group consisting of the residue of a VIP fragment analog of SEQ ID NO:2 bearing a stearyl (M6, Appendix II) or a Fmoc group (M7, Appendix II) at the amino terminal, the residue of a GnRH analog of SEQ ID NO:4 (M8, Appendix II) or SEQ ID NO:5 (M22, Appendix II), the residue of a Substance P analog of SEQ ID NO:7 (M27, Appendix II) or SEQ ID NO:8 (M28, Appendix II), and the residue of an enkephalin analog of SEQ ID NO:11 (M19, Appendix II), SEQ ID NO:12 (M21, Appendix II), SEQ ID NO:13 (M18, Appendix II), and SEQ ID NO:14 (M20, Appendix II).

In more preferred embodiments, the compounds of formula I are the compounds wherein R_2 is a propargylamino group and R_1 is selected from the group consisting of the residue of a VIP fragment analog of SEQ ID NO:2 bearing a stearyl (M6A, Appendix I) or a Fmoc group (M7A, Appendix I) at the amino terminal, the residue of a GnRH analog of SEQ ID NO:4 (M8A) or SEQ ID NO:5 (M22A, Appendix I), the residue of a Substance P analog of SEQ ID NO:7 (M27A, Appendix I) or SEQ ID NO:8 (M28A, Appendix I), and the residue of an enkephalin analog of SEQ ID NO:11 (M19A, Appendix I), SEQ ID NO:12 (M21A, Appendix I), SEQ ID NO:13 (M18A, Appendix I), and SEQ ID NO:14 (M20A, Appendix I).

In another preferred embodiment of the invention, there is provided a compound of formula II:



R_3 is a group selected from the group consisting of



- 5 (ii) $-\text{CR}_5\text{R}_6\text{R}_7$; (iii) $-\text{N}(\text{CH}_3)-\text{X}$; (iv) $-\text{N}(\text{R}_8)-\text{CH}(\text{CH}_2\text{SH})\text{COOC}_2\text{H}_5$;
 (v) $-\text{N}(\text{R}_8)-\text{CH}_2-\text{COOCH}_2\text{C}_6\text{H}_5$; and (vi) $-\text{S}-\text{CH}_2-\text{CH}(\text{COOH})-\text{NHR}_8'$;

R_4 is selected from the group consisting of (i) X ; (ii) COOC_2H_5 ;

(iii) $(\text{CH}_2)_2-\text{O}-\text{R}_8$; and (iv) $-\text{COO}-(\text{CH}_2)_2-\text{NH}-\text{R}_8$;

R_5 is H , CH_3 or COOC_2H_5 ;

- 10 R_6 is H , COOH , COO^- or COOC_2H_5 ;

R_7 is selected from the group consisting of (i) $-\text{NH}-\text{R}_8$; (ii) $-\text{NH}_3^+$;

(iii) $-\text{NH}-\text{COCH}_3$; (iv) $-\text{NH}-\text{NH}-\text{R}_8$;

and (v) $-\text{NH}-\text{NH}-\text{CO}-\text{CH}(\text{CH}_2\text{OH})-\text{NH}-\text{R}_8$;

R_8 is H or X , and R'_8 is H , X , or Fmoc ; and

- 15 X is a propargyl group,

but excluding the compound 5-[4-(2-hydroxyethyl)piperazin-1-ylmethyl]-8-hydroxy-quinoline.

In a more preferred embodiment, in the compound of formula II, R_3 is a piperazine ring to which an aliphatic chain R_4 is linked to the nitrogen atom at the 4-position, but excluding the compound wherein R_4 is $-(\text{CH}_2)_2-\text{OH}$. This compound, 5-[4-(2-hydroxyethyl)piperazin-1-ylmethyl]-8-hydroxy-quinoline, is herein identified in Appendix IV as VK-28, and is known from WO 00/74664. In one preferred embodiment, the 8-hydroxy-5-quinolinylmethylpiperazine compounds of the invention do not contain a propargyl group (R_4 is $-\text{COOC}_2\text{H}_5$ or R_8 is H), as represented by the compound herein designated HLA16 (Appendix IV).
 20 In another preferred embodiment, the 8-hydroxy-5-quinolinylmethylpiperazine compounds of the invention contain a propargyl group (R_8 is X), as represented by the compounds herein designated HLA16a, HLA20, and M17 (Appendix III).


In another more preferred embodiment, in the compound of formula II, R_3 is $-S-CH_2-CH(COOH)-NHR_8'$, wherein R_8' is H, namely, R_3 is the residue of L-Cys or D-Cys, as represented by the compounds herein designated D-HQ-CysOH (M11, Appendix II) and L-HQ-CysOH (M12, Appendix II), or R_8' is propargyl, as
5 represented by the compounds herein designated D-(HQ-Pr)-CysOH (M11a, Appendix III) and L-(HQ-Pr)-CysOH (M12a, Appendix III), or R_8' is Fmoc, as represented by the compounds herein designated M11B and m12B (Appendix IV).

In another more preferred embodiment, in the compound of formula II, R_3 is a group $-CR_5R_6R_7$, wherein R_5 is H, R_6 is COOH, and R_7 is $-NH-R_8$, wherein R_8 is
10 H, namely, R_3 is the residue of L-Ala or D-Ala, as represented by the compounds herein designated D-HQ-Ala (M9, Appendix IV) and L-HQ-Ala (M10, Appendix IV); or R_8 is propargyl, as represented by the compounds herein designated D-(HQ-Pr)-Ala (M9a, Appendix III) and L-(HQ-Pr)-Ala (M10a, Appendix III); or R_5 is H, R_6 is COO^- and R_7 is $-NH_3^+$, as represented by the compound herein designated HQ-
15 Ala (HLM8, Appendix IV); or R_5 is H, R_6 is $COOC_2H_5$ and R_7 is $-NH_2$, as represented by the compound herein designated HQ-AlaEt (HLM9, Appendix IV); or R_5 and R_6 are both $COOC_2H_5$, and R_7 is $-NH-COCH_3$, as represented by the compound herein designated HLM7 (Appendix IV); or R_5 is H, R_6 is $COOC_2H_5$ and R_7 is $-NH$ -propargyl, as represented by the compound herein designated M31
20 (Appendix III).

In another more preferred embodiment, in the compound of formula II, R_3 is a group $-NR_8-CH(CH_2SH)COOC_2H_5$, wherein R_8 is H or propargyl, as represented by the compounds herein designated M32 (Appendix IV) and M33 (Appendix III), respectively.

25 In another more preferred embodiment, in the compound of formula II, R_3 is a group $-N(CH_3)$ -propargyl, as represented by the compound herein designated M30 (Appendix III).

In still another preferred embodiment of the invention, there is provided a compound of formula III:




5

wherein


R_9 is selected from the group consisting of (i) H; (ii) $-CO-CH_2-R_1$;

(iii) $-CH_2-COOC_2H_5$; (iv) $-CH(CH_2SH)COOC_2H_5$; (v)

10




(vii)



15

R_{10} is X; $-CH_2-CH(SH)COOC_2H_5$; or



n is an integer from 1 to 6, preferably 1 or 2;

R_{12} is X, C_1-C_4 lower alkyl, preferably methyl, $COOC_2H_5$, or $-(CH_2)_2-OH$;

and X is a propargyl group.

20


In one preferred embodiment, R_9 is $-CO-CH_2-R_1$, wherein R_1 is the residue of an analog of a neuroprotective peptide or a fragment thereof containing a Cys residue. In more preferred embodiments, the compounds of formula III are the hydroxamates containing a propargylamino group and a R_1 selected from the group consisting of the residue of a VIP fragment analog of SEQ ID NO:2 bearing a stearyl (M6B, Appendix V) or a Fmoc group (M7B, Appendix V) at the amino terminal, the residue of a GnRH analog of SEQ ID NO:4 (M8B, Appendix V) or

25

SEQ ID NO:5 (M22B, Appendix V), the residue of a Substance P analog of SEQ ID NO:7 (M27B, Appendix V) or SEQ ID NO:8 (M28B, Appendix V), and the residue of an enkephalin analog of SEQ ID NO:11 (M19B, Appendix V), SEQ ID NO:12 (M21B, Appendix V), SEQ ID NO:13 (M18B, Appendix V), and SEQ ID NO:14 (M20B, Appendix V).

In other preferred embodiments, R_9 , R_{10} and R_{12} are as defined above as exemplified by the compounds herein designated M35, M36, M37, M38, M39, M40, M41, M42, M43, M44, M45 and M46 (Appendix V).

In yet another preferred embodiment, there is provided a compound of formula IV:



wherein

R_{11} is selected from the group consisting of

- (i) $-S-CH_2-CH(COOH)-NH-X$;
- (ii) $-N(X)-CH_2COO-CH_2-C_6H_5$;
- (iii) $-N(CH_3)-X$;
- (iv) $-N(X)-CH(CH_2SH)COOC_2H_5$;
- (v) $-CH_2-NH-NH-CO-CH(CH_2OH)-NH-X$;
- (vi) $-C(CH_3)(COOH)-NH-NH-X$;
- (vii) $-CH(COOH)-NH-X$;
- (viii) $-CH(COOC_2H_5)-NH-X$; and (ix) $-N<C_6H_{10}>N-R_{13}$

R_{13} is X , $-(CH_2)_2-OX$, or $-COO-(CH_2)_2-NH-X$; and

X is a propargyl group.


In preferred embodiments, the pyridinone derivatives are exemplified by the compounds herein designated M9b, M11b, M12b, M13b, M15b, HLA16b, M17a, HLA20a, M30a, M31a, M33a, and M34b, whose formulas are depicted in Appendix VI herein. Other derivatives of pyridinones may be used wherein the Me group is replaced by a different alkyl, e.g. ethyl, or the ring may contain a further alkyl group, optionally substituted.

The following Schemes A-D depict examples of methods that can be used for the preparation of compounds of the formulas I, II, III and IV. All of the starting materials are prepared by procedures described in these schemes, by procedures well known to one of ordinary skill in organic chemistry or can be obtained commercially. All of the final compounds of the present invention are prepared by procedures described in these schemes or by procedures analogous thereto, which would be well known to one of ordinary skill in organic chemistry. All the modified peptides were prepared automatically or manually by solid-phase peptide synthesis using Fmoc chemistry following the company's protocols.

The compounds of formula I can be prepared by the method as shown in Scheme A, or by the methods given in the examples or by analogous methods.

As shown in Scheme A below, 8-hydroxyquinoline (A1) is treated with hydrochloric acid and formaldehyde to give 5-chloromethyl-8-hydroxyquinoline (A2). The chloro group of A2 is substituted with propargylamine to afford 5-(1-propargylamino)methyl-8-hydroxyquinoline (A3). Bromination of A3 employing N-bromosuccinimide (NBS) provides the bromide A4 which is then treated, for example, with the modified peptide [D-Cys⁶]GnRH to give the target compound A5, which is the compound M22A in Appendix I.

Scheme A




5

The compounds of formula II can be prepared by the method as shown in Scheme B, or by the methods given in the examples or by analogous methods.

As shown in Scheme B below, substitution of the chloro group in 5-chloromethyl-8-hydroxyquinoline A2 (prepared as described in Scheme A) with cysteine provides the intermediate B1. Alkylation of the intermediate B1 with propargyl bromide produces the target compound B2, which is the compound M11a or M12a in Appendix III.


Scheme B



In another synthetic route according to Scheme B, the OH group of 5-chloromethyl-8-hydroxyquinoline A2 is first protected as its acetyl derivative B3. Condensation of compound B3 with diethyl acetamidomalonate proceeds smoothly in ethanol, with sodium ethoxide as the base, and gives the expected condensation derivative B4. Decarboxylation of compound B4 affords the amino acid derivative B5. Esterification of B5 in the presence of thionyl chloride and ethanol produces the ethyl ester derivative B6. Compound B6 is hydrolyzed using α -chymotripsin as a catalyst to give a mixture of the L-amino acid derivative B8 (α -chymotripsin is L-specific and hydrolyzes only the L-form) and the D-amino acid ester derivative B7, which can be separated by HPLC. Treatment of the L-amino acid B8 or D-amino acid (obtained from the ester B7) with propargyl bromide provides the desired compound B9, which is the compound M9a or M31 in Appendix III.

For production of the compounds of formula III, the method shown in Scheme C or analogous methods or the methods given in the examples may be used.


Scheme C




Hydroxamates (C2) can either be purchased from commercial sources or prepared by procedures well known to one of ordinary skill in organic chemistry. Alkylation of a hydroxamate (C2) with propargyl bromide (C1) in the presence of the appropriate base such as diisopropylethylamine provides a compound C3. Reaction of compound C3 with chloroacetyl chloride at about 0 °C in the presence of nitrogen, gives the N-chloroacetyl derivative (C4). Treatment of C4, for example, with the modified peptide [D-Cys⁶]GnRH, followed by deprotection of the hydroxamate, affords the target compound C6, which is the compound M22B in Appendix V.

The compounds of formula IV can be manufactured by the method as shown in Scheme D, or by the methods given in the examples or by analogous methods.

Scheme D





The starting material 1-chloroethyl-2-methyl-3-hydroxypyridinone (D1) can be prepared by known procedures. Treatment of D1 with cysteine results in the formation of the sulfide D2, that is then alkylated with propargylamine to give the desired compound D4, which is the compound designated M11b in Appendix VI.

In another synthetic route according to Scheme D, the compound D1 is directly reacted with propargylpiperazine D7 to give the desired chelator compound D4, which is the compound designated HLA20a in Appendix VI.

Propargylpiperazine (D7) is prepared by reaction of N-Boc-piperazine (D5) with propargylamine giving the compound D6, followed by removal of the protecting Boc group using trifluoroacetic acid.

Also contemplated by the present invention are pharmaceutically acceptable salts of the compounds of formula I, both salts formed by any carboxy groups present in the molecule and a base as well as acid addition and/or base salts.

Pharmaceutically acceptable salts are formed with metals or amines, such as alkali and alkaline earth metals or organic amines. Examples of metals used as cations are sodium, potassium, magnesium, calcium, and the like. Examples of suitable amines are N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, N-methylglucamine, and procaine (see, for example, Berge S. M., et al., "Pharmaceutical Salts," (1977) J. of Pharmaceutical Science, 66:1-19). The salts can also be pharmaceutically acceptable quaternary salts such as a quaternary salt of the formula $-NRR'R'' + Z'$ wherein R, R' and R'' each is independently hydrogen, alkyl or benzyl and Z is a counterion, including chloride, bromide, iodide, O-alkyl, toluenesulfonate, methylsulfonate, sulfonate, phosphate, or carboxylate.

Pharmaceutically acceptable acid addition salts of the compounds include salts derived from inorganic acids such as hydrochloric, nitric, phosphoric, sulfuric, hydrobromic, hydriodic, phosphorous, and the like, as well as salts derived from organic acids such as aliphatic mono- and dicarboxylic acids, phenyl-substituted
5 alkanolic acids, hydroxy alkanolic acids, alkanedioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, etc. Such salts thus include sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, nitrate, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, propionate, caprylate, isobutyrate, oxalate, malonate, succinate, suberate,
10 sebacate, fumarate, maleate, mandelate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, phthalate, benzenesulfonate, toluenesulfonate, phenylacetate, citrate, lactate, maleate, tartrate, methanesulfonate, and the like. Also contemplated are salts of amino acids such as arginate and the like and gluconate or galacturonate (see, for example, Berge S. M., et al., "Pharmaceutical Salts," (1977) J. of
15 Pharmaceutical Science, 66:1-19).

The acid addition salts of said basic compounds are prepared by contacting the free base form with a sufficient amount of the desired acid to produce the salt in the conventional manner. The free base form may be regenerated by contacting the salt form with a base and isolating the free base in the conventional manner. The
20 free base forms differ from their respective salt forms somewhat in certain physical properties such as solubility in polar solvents, but otherwise the salts are equivalent to their respective free base for purposes of the present invention.

The base addition salts of said acidic compounds are prepared by contacting the free acid form with a sufficient amount of the desired base to produce the salt in the conventional manner. The free acid form may be regenerated by contacting the
25 salt form with an acid and isolating the free acid in the conventional manner. The free acid forms differ from their respective salt forms somewhat in certain physical properties such as solubility in polar solvents, but otherwise the salts are equivalent to their respective free acid for purposes of the present invention.

The compounds of the invention are specific iron chelators that are suitable to bind unbound iron within the cells. Iron that is not bound to transferrin is the toxic form of iron. The iron chelators of the invention have good transport properties and cross cell membranes thus chelating the unbound iron in excess
5 within the cells. It is expected that their complexes with iron will leave the cells freely and will be rapidly excreted. It is further expected that the compounds, or at least a major part of the compounds, will be able to cross the BBB and thus will be suitable candidates for treatment of neurodegenerative diseases, disorders and conditions.

10 In another aspect, the present invention relates to pharmaceutical compositions comprising a compound of the invention or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier.

In a further aspect, the present invention provides the use of a compound of the invention or of a pharmaceutically acceptable salt thereof as neuroprotective
15 iron chelator for the preparation of a pharmaceutical composition for iron chelation therapy.

The pharmaceutical composition are intended for use in iron chelation therapy for treatment of diseases, disorders and conditions associated with iron overload and oxidative stress.

20 The pharmaceutical composition of the invention is for treatment and/or prevention of diseases, disorders and conditions associated with iron overload and oxidative stress such as, but not limited to, neurodegenerative and cerebrovascular diseases and disorders, neoplastic diseases, hemochromatosis, thalassemia, cardiovascular diseases, diabetes, inflammatory disorders, anthracycline
25 cardiotoxicity, viral, protozoal and yeast infections, and for retarding ageing, and prevention and/or treatment of skin ageing and skin protection against sunlight and/or UV light.

In one preferred embodiment, the pharmaceutical compositions are for use for iron chelation and neuroprotection in the prevention and/or treatment of

neurodegenerative and cerebrovascular diseases, conditions and disorders such as Parkinson's disease, Alzheimer's disease, stroke, amyotrophic lateral sclerosis (ALS), multiple sclerosis, Friedreich's ataxia, Hallervorden-Spatz disease, epilepsy and neurotrauma. In one preferred embodiment, the pharmaceutical composition is
5 for treatment of Parkinson's disease. In another preferred embodiment, the pharmaceutical composition is for treatment of Alzheimer's disease. In a further preferred embodiment, the pharmaceutical composition is for treatment of a cerebrovascular disorder, particularly stroke.

The "prevention" aspect of the use of the iron chelators of the invention in
10 diseases such as Parkinson's disease and Alzheimer's disease involves the prevention of further neurodegeneration and the further progress of the disease.

In still another preferred embodiment, the pharmaceutical compositions are for inhibition of cell proliferation in the treatment of neoplastic diseases, all types of cancer being encompassed by the invention. The iron chelator of the invention can
15 be used alone or in combination with one or more cytotoxic anticancer drugs.

In another preferred embodiment, the pharmaceutical compositions are for prevention and/or treatment of iron overload in hemochromatosis and thalassemia.

In yet another preferred embodiment, the pharmaceutical compositions are for prevention and/or treatment of cardiovascular diseases, e.g. to prevent the
20 damage associated with free radical generation in reperfusion injury.

In yet another preferred embodiment, the pharmaceutical compositions are for prevention and/or treatment of diabetes.

In yet another preferred embodiment, the pharmaceutical compositions are for prevention and/or treatment of inflammatory disorders. In one preferred
25 embodiment, the inflammatory disorder is a joint inflammatory disorder, particularly rheumatoid arthritis. In another preferred embodiment, the inflammatory disorder is inflammatory bowel disease (IBD). In a further preferred embodiment, the inflammatory disorder is psoriasis.

In yet another preferred embodiment, the pharmaceutical compositions are for prevention and/or treatment of anthracycline cardiotoxicity, in case of cancer patients being treated with anthracycline neoplastic drugs.

5 In yet another preferred embodiment, the pharmaceutical compositions are for prevention and/or treatment of viral, protozoal and yeast infections. In one preferred embodiment, the viral infection is a retroviral infection, e.g, HIV-1, and the compound is used in the treatment of AIDS, optionally in combination with antiviral agents. In another preferred embodiment, the protozoal infection is malaria caused by *Plasmodium falciparum*. In a further preferred embodiment, the yeast
10 infection is a *Candida albicans* infection.

In yet another preferred embodiment, the pharmaceutical compositions are for retarding ageing and/or improving the ageing process by prevention of ageing-related diseases, disorders or conditions such as neurodegenerative diseases, disorders or conditions.

15 In yet another preferred embodiment, the pharmaceutical compositions are for prevention and/or treatment of skin ageing and/or skin damage associated with ageing and/or exposure to sunlight and/or UV light.

In yet another preferred embodiment, the present invention provides a cosmetic composition for topical application for prevention and/or treatment of skin
20 ageing and/or skin damage associated with ageing and/or exposure to sunlight and/or UV light. The cosmetic composition may be in the form of a lotion or cream and may be administered with other agents for skin treatment.

In another embodiment, the iron chelators are for use ex-vivo for preservation of organs intended for transplantation such as heart, lung or kidney

25 In still another aspect, the present invention provides a method for iron chelation therapy which comprises administering to an individual in need thereof an effective amount of a compound of the invention or of a pharmaceutically acceptable salt thereof.

In one embodiment, the present invention provides a method for the prevention and/treatment of a neurodegenerative disease, condition or disorder, which comprises administering to an individual in need thereof an effective amount of a compound of the invention or of a pharmaceutically acceptable salt thereof.

5 In yet another embodiment, the present invention provides a method for the prevention and/or treatment of cancer, which comprises administering to an individual in need thereof an effective amount of a compound of the invention or of a pharmaceutically acceptable salt thereof. In one preferred embodiment, the iron chelator of the invention is administered before, concurrently or after administration
10 of one or more chemotherapeutic agents.

In another embodiment, the present invention provides a method for the prevention and/or treatment of iron overload in hemochromatosis or thalassemia patients, which comprises administering to said patient an effective amount of a compound of the invention or of a pharmaceutically acceptable salt thereof.

15 In yet another preferred embodiment, the present invention provides a method for prevention and/or treatment of cardiovascular diseases, e.g. to prevent the damage associated with free radical generation in reperfusion injury, which comprises administering to an individual in need thereof an effective amount of a compound of the invention or of a pharmaceutically acceptable salt thereof.

20 In yet another preferred embodiment, the present invention provides a method for prevention and/or treatment of diabetes, which comprises administering to an individual in need thereof an effective amount of a compound of the invention or of a pharmaceutically acceptable salt thereof.

In yet another preferred embodiment, the present invention provides a
25 method for prevention and/or treatment of inflammatory disorders, which comprises administering to an individual in need thereof an effective amount of a compound of the invention or of a pharmaceutically acceptable salt thereof. In one preferred embodiment, the inflammatory disorder is a joint inflammatory disorder, particularly rheumatoid arthritis. In another preferred embodiment, the

inflammatory disorder is inflammatory bowel disease (IBD). In a further preferred embodiment, the inflammatory disorder is psoriasis.

In yet another preferred embodiment, the present invention provides a method for prevention and/or treatment of anthracycline cardiotoxicity, which
5 comprises administering to an individual undergoing treatment with anthracycline neoplastic drugs an effective amount of a compound of the invention or of a pharmaceutically acceptable salt thereof.

In yet another preferred embodiment, the present invention provides a method for prevention and/or treatment of a viral, protozoal or yeast infection which
10 comprises administering to an individual in need thereof an effective amount of a compound of the invention or of a pharmaceutically acceptable salt thereof. In one preferred embodiment, the viral infection is a retroviral infection, e.g, HIV-1, and the compound is used in the treatment of AIDS, optionally in combination with antiviral agents. In another preferred embodiment, the protozoal infection is malaria
15 caused by *Plasmodium falciparum*. In a further preferred embodiment, the yeast infection is a *Candida albicans* infection.

In yet another preferred embodiment, the present invention provides a method for retarding ageing and/or improving the ageing process by prevention of ageing-related diseases, disorders or conditions which comprises administering to
20 an individual in need thereof an effective amount of a compound of the invention or of a pharmaceutically acceptable salt thereof. The individual in need may be a healthy individual or an individual suffering from an age-related disease such as a neurodegenerative disease, disorder or condition.

In yet another preferred embodiment, the present invention provides a
25 method for prevention and/or treatment of skin ageing and/or skin damage associated with ageing and/or exposure to sunlight and/or UV light, which comprises administering to an individual in need thereof an effective amount of a compound of the invention or of a pharmaceutically acceptable salt thereof. The

compound is most preferably administered topically in a pharmaceutical or cosmetic formulation.

The present invention also provides the use of the compound 5-[4-(2-hydroxyethyl)piperazin-1-ylmethyl]-8-hydroxyquinoline (herein identified as VK-28, Appendix IV) for the preparation of a pharmaceutical composition for treatment and/or prevention of a disease, disorder or condition associated with iron overload and oxidative stress selected from a neoplastic disease, hemochromatosis, thalassemia, a cardiovascular disease, diabetes, a inflammatory disorder, anthracycline cardiotoxicity, a viral infection, a protozoal infection, a yeast infection, retarding ageing, and prevention and/or treatment of skin ageing and skin protection against sunlight and/or UV light.

The present invention further provides a method for iron chelation therapy which comprises administering to an individual in need thereof an effective amount the compound 5-[4-(2-hydroxyethyl)piperazin-1-ylmethyl]-8-hydroxyquinoline (herein identified as VK-28, Appendix IV) for treatment and/or prevention of a disease, disorder or condition associated with iron overload and oxidative stress, excluding the prevention and/or treatment of a neurodegenerative disease, condition or disorder.

The present invention still further provides the use of the compound 5-[4-(2-hydroxyethyl)piperazin-1-ylmethyl]-8-hydroxyquinoline (herein identified as VK-28, Appendix IV) for the preparation of a cosmetic composition for topical application for prevention and/or treatment of skin ageing and/or skin damage associated with ageing and/or exposure to sunlight and/or UV light.

The present invention yet further provides the use of the compound 5-[4-(2-hydroxyethyl)piperazin-1-ylmethyl]-8-hydroxyquinoline (herein identified as VK-28, Appendix IV) ex-vivo for preservation of organs intended for transplantation such as heart, lung or kidney.

For preparing the pharmaceutical compositions of the present invention, methods well-known in the art can be used. Inert pharmaceutically acceptable

carriers can be used that are either solid or liquid. Solid form preparations include powders, tablets, dispersible granules, capsules, cachets and suppositories.

A solid carrier can be one or more substances which may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, or tablet
5 disintegrating agents; it can also be an encapsulating material.

Liquid pharmaceutical compositions include solutions, suspensions, and emulsions. As an example, water or water-propylene glycol solutions for parenteral injection may be mentioned. Liquid preparations can also be formulated in solution in aqueous polyethylene glycol solution. Aqueous solutions for oral use can be
10 prepared by dissolving the active component in water and adding suitable colorants, flavoring agents, stabilizers, and thickening agents as desired. Aqueous suspensions for oral use can be made by dispersing the finely divided active component in water with viscous material, i.e., natural or synthetic gums, resins, methyl cellulose, sodium carboxymethyl cellulose, and other well-known suspending agents.

15 Preferably, the pharmaceutical composition is in unit dosage form. In such form, the preparation is subdivided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, for example, packeted tablets, capsules, and powders in vial or ampoules. The unit dosage form can also be a
20 capsule, cachet, or tablet itself or it can be the appropriate number of any of these packaged forms.

In therapeutic use for the treatment of Parkinson's disease, the compounds utilized in the pharmaceutical method of this invention may be administered to the patient at dosage levels of from 1 mg/Kg to 20 mg/Kg per day.

25 In therapeutic use for the treatment of stroke one or more dosages of from about 100 mg/Kg to about 500 mg/Kg of body weight may be administered to the patient as soon as possible after the event.

The dosage, however, may be varied depending upon the requirements of the patient, the severity of the condition being treated, and the compound being

employed. Determination of optimum dosages for a particular situation is within the skill of the art.

The following examples illustrate particular methods for preparing compounds in accordance with this invention. These examples are intended as an
5 illustration, and not as a limitation, of the scope of the invention.

EXAMPLES

The following examples describe the synthesis of the compounds of the invention (Chemical Section) and their biological activity (Biological Section).

10

I. CHEMICAL SECTION

(i) Appendices I - VII

The structural formulas of the compounds of the invention are depicted in
15 Appendices I to VI herein. Appendix VII contains the formulas of some intermediate compounds. For better identification of the compounds in the following examples, when possible, the compound designations used herein and the respective Appendix are given within brackets near the compound's name. When
suitable, the designation given in the Schemes A-D above are used for starting
20 compounds or intermediates.

The contents of the Appendices are as follows:

Appendix I – Compounds M6A, M7A, M8A, M18A, M19A, M20A, M21A, M22A, M27A, M28A.

Appendix II – Compounds M6, M7, M8, M11, M12, M18, M19, M20, M21, M22
25 M27, M28.

Appendix III – Compounds HLA16a, HLA20, M9a, M10a, M11a, M12a, M13a, M15a, M17, M30, M31, M33, M34.

Appendix IV – Compounds VK-28 (known), HLA16, HLM7, HLM8, HLM9, M9, M10, M11B, M12B, M13, M15, M32.

Appendix V – Compounds M6B, M7B, M8B, M18B, M19B, M20B, M21B, M22B, M27B, M28B, M35, M36, M36a, M37-46.

5 **Appendix VI** – Compounds M9b, M11b, M12b, M13b, M15b, HLA16b, M17a, HLA20a, M30a, M31a, M33a, M34b.

Appendix VII – Intermediates H1, H2, H3, H4, H5, H6.

(ii) General

10 Starting materials for chemical synthesis were obtained from the following companies: Aldrich (USA), E. Merck(Germany), Fluka, (Switzerland).

Proton NMR spectra were measured on a Bruker WH-270, a Bruker DPX-250, or a Bruker AMX-400 NMR spectrometer. Flash column chromatography separations were performed on silica gel Merck 60 (230-400 mesh ASTM). UV/VIS
15 spectra were measured on a Hewlett-Packard 8450A diode array spectrophotometer. TLC was performed on E. Merck Kieselgel 60 F254 plates. Staining of TLC plates was done by: (i) basic aqueous 1% KMnO₄; (ii) 0.3% ninhydrin in EtOH_{abs}. Tetrahydrofuran was distilled over LiAlH₄ and passed through an Al₂O₃ column. Mass spectra (DI, EI-MS) were measured on a VG-platform-II electrospray single
20 quadrupole mass spectrometry (Micro Mass, UK).

EXAMPLES

Example 1. Synthesis of D-N-propargyl-3-(8-hydroxyquinolin-5-yl)alanine (M9a, Appendix III) and L-N-propargyl- 3-(8-hydroxyquinolin-5-yl)alanine (M10a, Appendix III) .
25

These enantiomers of Formula II herein were prepared by the method depicted in Scheme B above, by the following steps:

(i) Synthesis of 5-chloromethyl-8-hydroxyquinolinoline (A2).

A mixture of 14.6g (0.1 mole) of 8-hydroxyquinolinoline, 16 ml of 32% hydrochloric acid, and 16 ml (0.1 ml) of 37% formaldehyde at 0 °C was treated with hydrogen chloride gas for 6 h. The solution was allowed to stand at room temperature for 2 h without stirring. The yellow solid was collected on a filter and dried to give crude 5-chloromethyl-8-hydroxyquinoline hydrochloride (A2): 2.16 g; ^1H NMR (250 MHz, CDCl_3): 5.32 (s, 2H), 7.53 (m, 1H), 7.85 (m, 1H), 8.12 (m, 1H), 9.12 (m, 1H), 9.28 (m, 1H).

(ii) Synthesis of 8-(5-chloromethyl)quinolyl acetate (B3).

To a stirred solution of crude A2 obtained in step (i) above (230 mg, 1 mmole) in dry DMF (5 ml) at 0 °C, pyridine (0.3 ml, 2.5 mmol) and acetyl chloride (0.6 ml, 8 mmole) were slowly added simultaneously under N_2 . The reaction mixture was stirred at 0 °C for 1 h and at room temperature for 1 h. After cooling to 0 °C, 10 ml of water were added, and the resulting mixture was stirred at 0 °C, for 20 min. The mixture was then extracted with chloroform (3x20 ml). The combined organic layer was washed with saturated NaHCO_3 (2x20 ml), brine (2x20 ml) and dried over Na_2SO_4 . Evaporation afforded the compound (B3) (crude) (180 mg, 75 %) as a light brown solid. m.p.=119-120 °C, R_f 0.75 (CHCl_3 : MeOH : NH_3 9 : 1 : 0.25). ^1H NMR (250 MHz, CDCl_3): 2.25 (s, 3H), 4.98 (s, 2H), 7.40 (d, $J=7.7$ Hz, 1H), 7.55 (m, 2H), 8.47 (dd, $J=8.6, 1.6$ Hz, 1H), 8.96 (dd, $J=4.2, 1.5$ Hz, 1H).

(iii) Synthesis of diethyl 8-hydroxyquinolin-5-yl-methyl-acetamidomalonate (HLM7, Appendix IV)

To a solution of acetamidomalonate (183 mg, 0.842 mmol) and metallic sodium (34 mg, 0.842 mmole) in ethanol (50 ml), 8-(5-chloromethyl)quinolyl acetate (B3) (180mg, 765 mmole) in CHCl_3 (5 ml) was added. The mixture was stirred for 5 h under reflux, cooled, and evaporated in vacuum. Water (20 ml) was added to the residue and the mixture was extracted with CHCl_3 : EtOAc (3x20 ml, 1

: 1). The organic layer was washed with brine (2x20 ml) and dried over Na₂SO₄. Evaporation afforded the title compound (HLM7): (170 mg, 59 %) as a light brown solid (crude) m.p.=153-154 °C, R_f 0.25 (CHCl₃ : MeOH : NH₃ 9 : 1: 0.25). ¹H NMR (250 MHz, CDCl₃): 1.30 (dd, J=7.1, 7.1 Hz, 6H), 1.86 (s, 3H), 4.03 (s, 2H),
5 4.27 (m, 4H), 6.46 (s, 1NH), 7.10 (dd, J=16.6, 7.9 Hz, 2H), 7.42 (dd, J=8.7, 4.2 Hz, 1H), 8.76 (dd, J=4.2, 1.1 Hz, 1H).

(iv) Synthesis of DL-3-(8-hydroxyquinolin-5-yl)alanine (HLM8, Appendix IV).

Diethyl (8-hydroxyquinolin-5-yl-methyl)-acetamidomalonate (HLM7)
10 obtained in (iii) above (8.9 g, 21.9 mmol) was dissolved in 6 N HCl (150 ml), and the resultant mixture was refluxed for 10 h. The reaction mixture was evaporated to dryness; solvent was removed in vacuum. The residue was redissolved in H₂O and filtered. The pH of the solution was adjusted to between 5-5.5 with 10% NaOH. A yellow precipitate was collected by filtration, washed with water thoroughly, and
15 re-crystallized from water (pH = 5.5) and then washed with acetone to give the title compound (HLM8) (3.8 g, yield 65%), 100% purity, checked by HPLC [(C₁₈; solvent A= water, 0.1% v/v TFA; solvent B= MeCN : water = 3 : 1, 0.1% v/v TFA; t_R = 18.2 min (linear gradient 0-80% B over 55 min)]. m.p. = 194 °C, (decompose). ¹H NMR (250 MHz, D₂O) 3.42 (m, 1H), 3.58 (m, 1H), 3.93 (dd, J=7.2, 7.2 Hz, 1H),
20 7.22 (d, J=8.0Hz, 1H), 7.50 (d, J=8.1 Hz, 1H), 7.94 (dd, J=8.7, 5.4 Hz, 1H), 8.84 (d, J=5.1 Hz, 1H), 9.06 (d, J=8.7 Hz, 1H); ¹³C NMR (100 MHz, DMSO) 32.14, 53.11, 111.03, 121.27, 127.46., 129.76, 133.35, 138.13, 147.46, 152.55, 170.30. Mass spectrometry: calculated for C₁₂H₁₂N₂O₃ m/z [M +H]⁺ = 233.24, found [M +H]⁺ = 233.25.

25

(v) Synthesis of DL-3-(8-hydroxyquinolin-5-yl)alanine ethyl ester (HLM9, Appendix IV).

To a stirred slurry of DL-3-(8-hydroxyquinolin-5-yl)alanine (HLM8) (2.19 g, 7.04 mmol) in absolute ethanol (26 ml) at 0 °C, with protection from atmospheric


moisture by CaCl₂ tube in N₂, thionyl chloride was added dropwise (1.1 ml, 14.1 mmol). The reaction mixture was stirred at 0 °C for 30 minutes and at room temperature for 30 minutes, and then refluxed overnight. The solution was evaporated to dryness *in vacuum*. The residue was dissolved in absolute ethanol and reevaporated to dryness. To ensure completeness of the esterification, the whole operation was repeated. The ester HLM9 (yellow solid, 1.67g, 92% yield), which was shown by HPLC to contain about 1% of free amino acid, was further purified by FC (CH₂Cl₂ : MeOH : AcOH 9 : 1.5 : 1.5). ¹H NMR (250 MHz, D₂O) 0.94 (dd, J=7.2, 7.2 Hz, 3H), 3.63 (m, 2H), 4.01 (m, 2H), 4.34 (dd, J=7.7, 7.5 Hz, 1H), 7.31 (d, J=8.0 Hz, 1H), 7.56 (d, J=8.2 Hz, 1H), 8.01 (dd, J=8.7, 5.4 Hz, 1H), 8.93 (d, J=5.4 Hz, 1H), 9.08 (d, J=8.7 Hz, 1H).

(vi) Synthesis of L-3-(8-hydroxyquinolin-5-yl)alanine (M10, Appendix IV) and D-3-(8-hydroxy-quinolin-5-yl)alanine ethyl ester (B7, Scheme B)

DL-3-(8-hydroxy-quinolin-5-yl)alanine ethyl ester (HLM9) (89.2 mg) obtained in 1(v) above was dissolved in 5 ml water, the pH of the solution was adjusted to about 6.4 with 0.2M NaOH, α-chymotrypsin (0.9 mg) was added, and the mixture was incubated at room temperature for 6 h, the pH being kept constant by addition of 0.2 M NaOH. After the digestion, the mixture was lyophilized to dryness and separated by semi-preparative HPLC [(C₁₈; solvent A= water, 0.1% v/v TFA; solvent B = MeCN : water = 3: 1, 0.1% v/v TFA; t_R = 18.0 min (linear gradient 0-80% B over 55 min)]. Since α-chymotrypsin is specific for the L-form, L-3-(8-hydroxyquinolin-5-yl)alanine (M10) was obtained: 27.6 mg, 35%, 100% purity, [α]_D²⁰ = + 13.5. (D-3-(8-hydroxy-quinolin-5-yl)alanine ethyl ester (B7) was recovered: 39.2 mg, 88% recovery). ¹H NMR (250 MHz, D₂O) 3.49 (m, 1H), 3.65 (m, 1H), 3.95 (m, 1H), 7.34 (m, 1H), 7.57 (m, 1H), 8.0 (m, 1H), 8.91 (m, 1H), 9.14 (m, 1H). Mass spectrometry: calculated for C₁₂H₁₂N₂O₃ m/z [M +H]⁺ = 233.24 , found [M +H]⁺ = 233.26.

(vii) Synthesis of D-3-(8-hydroxyquinolin-5-yl)alanine (M9, Appendix IV)

For hydrolysis of the ethyl ester, 33.4 mg D-3-(8-hydroxyquinolin-5-yl)alanine ethyl ester (B7) recovered in step 1(vi) was dissolved in 11 ml 0.2 M NaOH, and the solution was stirred at room temperature for 6 h. The water was removed by lyophilization, and the product was purified by semi-preparative HPLC [(C₁₈; solvent A= water, 0.1% v/v TFA; solvent B = MeCN : water = 3: 1, 0.1% v/v TFA; t_R = 18.4 min (linear gradient 0-80% B over 55 min)] to give the title compound M9: 26.8 mg, 89%, 99.1% purity. $[\alpha]_D^{20} = -10.3$. ¹H NMR (250 MHz, D₂O) 3.40 (s, 1H), 3.55 (s, 1H), 3.91 (s, 1H), 7.15 (s, 1H), 7.45 (s, 1H), 7.91 (s, 1H), 8.80 (s, 1H), 9.02 (s, 1H). Mass spectrometry: calculated for C₁₂H₁₂N₂O₃ m/z [M + H]⁺ = 233.24, found [M + H]⁺ = 233.26.

(viii) Synthesis of D-N-propargyl-3-(8-hydroxyquinolin-5-yl)alanine (M9a, Appendix III).

A mixture of NaHCO₃ (17 mg, 0.2 mmol) and compound M9 (23.2 mg, 0.1 mmol) from step (vii) above was dissolved in 5 ml DMSO, and the solution was stirred at room temperature for 2 h. To the solution, propargyl bromide (11.9 mg, 0.1 mmol) was slowly added, and the solution was stirred at room temperature for 24 h. The solvent was removed by vacuum, and the crude product was purified by semi-preparative HPLC [(C₁₈; solvent A= water, 0.1% v/v TFA; solvent B = MeCN : water = 3: 1, 0.1% v/v TFA; t_R = 22.4 min (linear gradient 0-80% B over 55 min)] to give the title compound M9a: 19 mg, 70% yield. $[\alpha]_D^{20} = -12.3$. ¹H NMR (250


20

25

MHz, CDCl₃), 2.21 (m, 1H), 3.28 (d, J=2.44Hz, 2H), 3.82 (s, 2H), 7.08 (m, 1H), 7.33 (d, J=10.59, 1H), 7.46 (dd, J=8.55, 4.18Hz, 1H), 8.67 (dd, J=8.56, 1.55Hz, 1H), 8.78 (dd, J=4.18, 1.51Hz, 1H). Mass spectrometry: calculated for C₁₅H₁₄N₂O₃ m/z [M + H]⁺ = 271.28, found [M + H]⁺ = 271.30.

5

(ix) *Synthesis of L-N-propargyl- 3-(8-hydroxyquinolin-5-yl)alanine (M10a, Appendix III).*



10

M10**M10a**

The title compound was synthesized using the procedure of step (viii) above. 78% yield. $[\alpha]_D^{20} = +15.3$. ¹H NMR (250 MHz, CDCl₃), 2.25 (m, 1H), 3.26 (d, J=2.44Hz, 2H), 3.80 (s, 2H), 7.08 (m, 1H), 7.33 (d, J=10.59, 1H), 7.46 (dd, J=8.55, 4.18Hz, 1H), 8.64 (dd, J=8.53, 1.55Hz, 1H), 8.78 (dd, J=4.18, 1.51Hz, 1H); Mass spectrometry: calculated for C₁₅H₁₄N₂O₃ m/z [M + H]⁺ = 271.28, found [M + H]⁺ = 271.30.

15

Example 2. Synthesis of 5-(4-propargylpiperazin-1-ylmethyl)-8-hydroxyquinoline (HLA20, Appendix III).

20

The title compound was prepared by reaction of 5-chloromethyl-8-hydroxyquinolinoline (A2) with N-propargyl piperazine as follows:

(i) *Synthesis of tert-butyl 1-piperazinecarboxylate (D5, Scheme D).*

A solution of di(tert-butyl) dicarbonate (2.93 g, 12.77 mmole) in MeOH (25ml) was slowly added to a stirring solution of piperazine (2.00 g, 23.22 mmole)

25

in MeOH (50 ml) at 0°C. The mixture was then stirred for 2 days at room temperature, and the solvent was removed in vacuum. The crude solid was redissolved in Et₂O (100 ml) with warming, and a white precipitate was filtered off. The product was extracted from the mother liquor with 1 M citric acid solution (3x50 ml), and the aqueous layer was washed with Et₂OAc (3x50 ml), basified with Na₂CO₃ (pH 11), and extracted with Et₂OAc (3x50 ml). The organic layer was dried over Na₂SO₄ and evaporated *in vacuum* to give tert-butyl 1-piperazinecarboxylate (D5) as a waxy white solid (crude, 1.57 g, 66%), mp=53-45 °C. H¹ NMR (250 MHz, CDCl₃) 1.42 (s, 9H), 1.89 (s, 1NH), 2.78 (m, 4H), 3.36 (m, 4H).

(ii) Synthesis of tert-butyl 4-propargylpiperazine-1-carboxylate (D6, Scheme D).

Propargyl bromide (356.9 mg, 3 mmol) was slowly added to a mixture of tert-butyl 1-piperazinecarboxylate obtained in step 2(i) above (558.8 mg, 3 mmole) and diisopropylethylamine (407.1 mg, 3.15 mmol) in CHCl₃ (25 ml) at 0 °C. The mixture was stirred for 24 h at room temperature. 50 ml of CHCl₃ was then added and the solution was washed with 5% NaHCO₃ (3x50 ml), brine (2x50 ml), and then dried over Na₂SO₄. The solution was filtered and evaporated to dryness. The residue was crystallized from a mixture of benzene-hexane (1:1) to give tert-butyl 4-propargylpiperazine-1-carboxylate (D6) (crude 337 mg, 86%). H¹ NMR (250 MHz, CDCl₃): 1.42 (s, 9H), 2.22(s, 1H), 2.46 (s, 4H), 3.26 (s, 2H), 3.41 (s, 4H).

(iii) Synthesis of N-propargylpiperazine (D7, Scheme D)

tert-Butyl 4-propargylpiperazine-1-carboxylate of step 2(ii) above (570 mg, 2.545 mmol) was dissolved in trifluoroacetic acid (10 ml) and water (2.5 ml). The mixture was then stirred at room temperature overnight. The solution was evaporated to dryness in vacuum. The residue was dissolved in water (10 ml) and then basified with Na₂CO₃ (pH 11), and extracted with Et₂OAc (3x50 ml). The organic layer was washed with brine (2x50 ml) and dried over Na₂SO₄ overnight. Evaporation in *vacuum* gave N- propargylpiperazine (D7) as white solid. (crude,

193 mg, 62% yield). ^1H NMR (250 MHz, CDCl_3) 1.64 (s, 1H), 2.26 (m, 1H), 2.55 (dd, $J=4.73, 4.50$ Hz, 4H), 2.93 (dd, $J=4.96, 4.84$ Hz, 4H), 3.29 (d, $J=2.44$ Hz, 2H).

(iv) *Synthesis of 5-(4-propargylpiperazin-1-ylmethyl)-8-hydroxyquinoline (HLA20, Appendix III)*

To a mixture of 5-chloromethyl-8-hydroxyquinoline hydrochloride (A2) (323 mg, 1.407 mmol) and diisopropylethylamine (0.26 ml, 1.477 mmol, 1.05 eq) in 6 ml CHCl_3 at 0 °C, N-propargylpiperazine obtained in step 2(iii) above was added (173 mg, 1.407 mmol, 1 eq). The mixture was stirred for 24 h at room temperature. 10 ml of CHCl_3 was then added and the solution was washed with 5% NaHCO_3 (3x50 ml), brine (2x50 ml), and then dried over Na_2SO_4 . The crude product was purified by FC to give the title compound (HLA20) as a white solid. (337 mg, 86% yield). ^1H NMR (250 MHz, CDCl_3) 2.23 (m, 1H), 2.54 (s, 8H), 3.28 (d, $J=2.44$ Hz, 2H), 3.80 (s, 2H), 7.08 (m, 1H), 7.36 (d, $J=10.59$, 1H), 7.46 (dd, $J=8.55, 4.18$ Hz, 1H), 8.67 (dd, $J=8.56, 1.55$ Hz, 1H), 8.78 (dd, $J=4.18, 1.51$ Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) 46.77, 51.98, 52.87, 60.55, 73.05, 78.92, 108.60, 121.40, 124.58, 127.87, 128.87, 134.10, 138.68, 147.50, 151.78.

Example 3. *Synthesis of 5-(4-propargylaminoethoxycarbonyl-piperazin-1-ylmethyl)-8-hydroxyquinoline (HLA16a, Appendix III).*


(i) *Synthesis of ethyl 4-(8-hydroxyquinolin-5-ylmethyl)-1-piperazine carboxylate (HLA16, Appendix IV)*

To a mixture of 5-chloromethyl-8-hydroxyquinoline hydrochloride (A2) (2.36 g, 10.2 mmol) and diisopropylethylamine (3.6 ml, 20.4 mmol, 2 eq) in 50 ml CHCl_3 at 0 °C, ethyl 1-piperazinecarboxylate (1.5 ml, 10.2 mmol, 1 eq) was added. The mixture was stirred for 24 h at room temperature, and then 100 ml of CHCl_3 was added and the solution was washed with 5% NaHCO_3 (3x50 ml), brine (2x50 ml), and then dried over Na_2SO_4 . The solution was filtered and evaporated to

dryness. The residue was crystallized from a mixture of benzene-hexane (1:1) to yield the title compound HLA16 as white solid. (1.38 g, 42% yield, m.p. = 92-93 °C). ^1H NMR (250 MHz, CDCl_3), 1.25 (dd, $J=7.1, 7.1\text{Hz}$ 3H), 2.42 (s, 4H), 3.43 (s, 4H), 3.81 (s, 2H), 4.14 (dd, $J=14.21, 7.12\text{ Hz}$, 2H), 7.08 (d, $J=7.72\text{ Hz}$, 1H), 7.31 (m, 1H), 7.47 (dd, $J=8.52, 4.20\text{ Hz}$, 1H), 8.66 (dd, $J=8.56, 1.58\text{Hz}$, 1H), 8.79 (dd, $J=4.18, 1.54\text{ Hz}$, 1H).

(ii) In an alternative method, the title compound HLA16a is prepared by reaction of 5-chloromethyl-8-hydroxyquinoline with N-propargylaminoethoxycarbonyl-piperazine as follows:


(iii) *Synthesis of N-propargylaminoethoxycarbonylpiperazine (H1, Appendix VII)*



2-chloroethyl chloroformate (429 mg, 3 mmol) was added slowly to a mixture of *tert*-butyl 1-piperazinecarboxylate obtained as step (ii) in Example 2 (559 mg, 3 mmol) and diisopropylethylamine (407 mg, 3.15 mmol) in CHCl_3 (25 ml) at 0 °C. The mixture was stirred for 2 h at room temperature. CHCl_3 (50 ml) was then added and the solution was washed with 5% NaHCO_3 (3x50 ml), brine (2x50 ml), and then dried over Na_2SO_4 . The solution was filtered and evaporated to dryness. The residue was dissolved in CH_2Cl_2 (25 ml) at room temperature, and propargylamine (0.205 ml, 165 mg, 3 mmol) was added. After 24 h of stirring at room temperature, the solvent was removed by vacuum, and to the residue was

added 20 ml of a solution of TFA:H₂O:TES:thioanisole (85:5:5:5). The mixture was then stirred at room temperature for 2 h. The solution was evaporated to dryness in vacuum. The resulted residue was dissolved in water (10 ml) and then basified with Na₂CO₃ (pH 11), and extracted with Et₂OAc (3x50 ml). The organic layer was washed with brine (2x50 ml) and dried over Na₂SO₄ overnight. Evaporation in vacuum gave the title compound H1: (251 mg, 40% total yield). H¹ NMR (250 MHz, CDCl₃ + D₂O) 2.26 (m, 1H), 3.11 (s 2H), 3.29 (dd, J=10.21, 7.45 Hz, 2H), 4.29 (d, J=11.23, 7.12 Hz, 2H), 2.55 (dd, J=4.73, 4.50 Hz, 4H), 2.93 (dd, J=4.96, 4.84 Hz, 4H). Mass spectrometry: calculated for C₁₀H₁₇N₃O₂ m/z [M + H]⁺ = 212.26, found [M + H]⁺ = 212.22.

(iib) Synthesis of 5-(4-propargylaminoethoxycarbonyl-piperazin-1-ylmethyl)-8-hydroxyquinoline (HLA16a, Appendix III).



To a mixture of 5-chloromethyl-8-hydroxyquinoline hydrochloride (A2) (194 mg, 1 mmol) and diisopropylethylamine (0.348 ml, 2 mmol, 2 eq) in 5 ml CHCl₃ at room temperature, was added H1 (221 mg, 1 mmol, 1 eq). The mixture was stirred for 24 h at room temperature. 10 ml of CHCl₃ was then added and the solution was washed with 5% NaHCO₃ (3x10 ml), brine (2x10 ml), and then dried over Na₂SO₄. The solution was filtered and evaporated to dryness. The residue was crystallized from a mixture of toluene-hexane (1:1) to yield the title compound HLA16a as white solid. (184 mg, 50% yield). H¹ NMR (250 MHz, CDCl₃ + D₂O) 2.23 (m, 1H), 3.30 (s 2H), 3.29 (dd, J=10.21, 7.45 Hz, 2H), 4.29 (d, J=11.23, 7.12 Hz, 2H), 2.55 (dd, J=4.73, 4.50 Hz, 4H), 2.93 (dd, J=4.96, 4.84 Hz, 4H), 3.78 (s, 2H), 7.08 (d, J = 7.72 Hz, 1H), 7.31 (m, 1H), 7.47 (dd, J=8.52, 4.20 Hz, 1H), 8.66

(dd, $J=8.56, 1.58$ Hz, 1H), 8.79 (dd, $J=4.18, 1.54$ Hz, 1H). Mass spectrometry: calculated for $C_{20}H_{24}N_4O_3$ m/z $[M + H]^+ = 369.43$, found $[M + H]^+ = 369.28$.

Example 4. Synthesis of N-propargyl S-(8-hydroxyquinolin-5-ylmethyl)-L-cysteine (M12a, Appendix III) and N-propargyl S-(8-hydroxyquinolin-5-ylmethyl)-D-cysteine (M11a, Appendix III)

The title compounds were prepared according to the first route depicted in Scheme B hereinabove.

(i) Synthesis of S-(8-hydroxyquinolin-5-ylmethyl)-L-cysteine (M12, Appendix II).

L-cysteine hydrochloride hydrate (37 mg, 0.31 mmol) was dissolved in DMSO (3 ml). To the solution powdered KOH (36 mg, 0.34 mmol) was added, and the mixture was stirred for 30 min at room temperature. Then, powdered 5-chloromethyl-8-hydroxyquinoline hydrochloride (A2) (65 mg, 0.34 mmol) was added. The suspension was stirred at room temperature 12 h, 2 N HCl was added and the pH was adjusted to 5. The precipitate was washed with water and acetone. The crude product was further purified by semi-preparative HPLC to yield compound M12: 53mg (61%). HPLC (t_R): 38.1 min (linear gradient: 50% B for the first 4 min, increased linearly to 100% B for 60 min) $[\alpha]_D^{20} = +20.5^\circ$ ($c = 1.0$, H_2O); ^1H NMR (250 MHz, D_2O) 2.89 (d, $J=5.6$ Hz, 2H), 3.95 (dd, $J=5.1, 5.0$ Hz, 1H), 4.18 (s, 2H), 7.25 (d, $J=8.0$ Hz, 1H), 7.57 (d, $J=8.0$ Hz, 1H), 7.96 (dd, $J=8.7, 5.5$ Hz, 1H), 8.88 (d, $J=5.4$ Hz, 1H), 9.22 (d, $J=8.7$ Hz, 1H); IR (KBr) cm^{-1} : 3438 (broad), 3081, 1685, 1637, 1560; Mass spectrometry: calculated for $C_{12}H_{12}N_2O_3$ m/z $[M + H]^+ = 279.33$, found $[M + H]^+ = 279.13$.

25


(ii) Synthesis of S-(8-hydroxyquinolin-5-ylmethyl)-D-cysteine (M11, Appendix II)

Compound M11 was prepared as method described in 4(i) above for M12, but using D-cysteine instead of L-cysteine as starting material. ^1H NMR (250 MHz, D_2O) 2.85 (d, $J=5.5$ Hz, 2H), 3.83 (t, $J=5.4$, 1H), 4.05 (s, 2H), 7.06 (d, $J=8.0$ Hz,

1H), 7.42 (d, J=8.0 Hz, 1H), 7.86 (dd, J=8.7, 5.4 Hz, 1H), 8.77 (d, J=5.3 Hz, 1H), 9.06 (d, J=8.7 Hz, 1H). IR (KBr) cm^{-1} : 3410 (broad), 3050, 2926, 1701, 1685, 1550. Mass spectrometry: calculated for $\text{C}_{12}\text{H}_{12}\text{N}_2\text{O}_3$ m/z $[\text{M} + \text{H}]^+ = 279.33$, found $[\text{M} + \text{H}]^+ = 279.26$; $[\alpha]_{\text{D}}^{20} = -15.3^\circ$ ($c = 1.0$, H_2O).

5

(iii) *Synthesis of N-propargyl S-(8-hydroxyquinolin-5-ylmethyl)-L-cysteine (M12a, Appendix III)*




10

M12**M12a**

To a stirred mixture of NaHCO_3 (34 mg, 0.4 mmol) and compound M12 (54 mg, 0.2 mmol) in 5 ml DMSO, propargyl bromide (24 mg, 0.2 mmol) was slowly added, and the solution was stirred at room temperature for 24 h. The solvent was removed by vacuum, and the crude product was crystallized (pH 5.5) and then further purified by semi-preparative HPLC [(C₁₈; solvent A= water, 0.1% v/v TFA; solvent B = CH_3CN : water = 3: 1, 0.1% v/v TFA; $t_{\text{R}} = 24.4$ min (linear gradient 0-80% B over 55 min)] to give the title compound M12a: 37 mg, 60% yield. $[\alpha]_{\text{D}}^{20} = -16.3$. ($c = 1.0$, 0.1 N HCl). Mass spectrometry: calculated for $\text{C}_{16}\text{H}_{16}\text{N}_2\text{O}_3\text{S}$ m/z $[\text{M} + \text{H}]^+ = 317.38$, found $[\text{M} + \text{H}]^+ = 317.30$. ^1H NMR (250 MHz, $\text{CHCl}_3 + \text{D}_2\text{O}$) 2.34 (m, 1H), 2.89 (d, J=5.6 Hz, 2H), 3.37 (s, 2H), 3.91 (dd, J=5.1, 5.0 Hz, 1H), 4.13 (s, 2H), 7.25 (d, J=8.0 Hz, 1H), 7.57 (d, J=8.0 Hz, 1H), 7.96 (dd, J=8.7, 5.5 Hz, 1H), 8.88 (d, J=5.4 Hz, 1H), 9.22 (d, J=8.7 Hz, 1H); IR (KBr) cm^{-1} : 3428 (broad), 3091, 1695, 1637, 1568.

25

(iv) *Synthesis of N-propargyl S-(8-hydroxyquinolin-5-ylmethyl)-D-cysteine (M11a, Appendix III)*



5

The title compound M11a was prepared according to the procedure for M12a, but using M11 instead of M12 as the starting material. Yield 70%. $[\alpha]_D^{20} = -18.3$. ($c = 1.0$, 0.1 N HCl). Mass spectrometry: calculated for $C_{16}H_{16}N_2O_3S$ m/z $[M + H]^+ = 317.38$, found $[M + H]^+ = 317.31$. ^1H NMR (250 MHz, $CHCl_3 + D_2O$) 2.39 (m, 1H), 2.85 (d, $J = 5.6$ Hz, 2H), 3.27 (s, 2H), 3.91 (dd, $J = 5.1, 5.0$ Hz, 1H), 4.13 (s, 2H), 7.25 (d, $J = 8.0$ Hz, 1H), 7.57 (d, $J = 8.0$ Hz, 1H), 7.96 (dd, $J = 8.7, 5.5$ Hz, 1H), 8.88 (d, $J = 5.4$ Hz, 1H), 9.22 (d, $J = 8.7$ Hz, 1H); IR (KBr) cm^{-1} : 3422 (broad), 3090, 1691, 1639, 1565.

15 **Example 5. Synthesis of N-propargyl S-(8-hydroxyquinolin-5-ylmethyl)-L-cysteine (M12a, Appendix III) and N-propargyl S-(8-hydroxyquinolin-5-ylmethyl)-D-cysteine (M11a, Appendix III) - Method B.**

The title compounds can be prepared by another method consisting in preparation of the N-9-fluorenylmethoxycarbonyl (N-Fmoc) derivatives of the compounds M11 and M12, removing the protecting Fmoc group and reacting with propargyl bromide.

(i) *Synthesis of N-9-Fmoc-S-(8-hydroxyquinolin-5-ylmethyl)-L-cysteine (M11B, Appendix IV)*

25 The crude compound M11 obtained in Example 4(i) (27.5 mg, 0.1 mmol) was dissolved in 10% $NaCO_3$ (12 ml). The solution was stirred and the pH was

adjusted to approximately 8 using small portions of 10% NaCO₃. To the solution, (9-Fluorenylmethyl)succinimidyl carbonate (36.6 mg, 0.11mmol, 1.1 equiv) in dioxane (2 ml) was added dropwise. The reaction mixture was stirred at room temperature for 12 h. The dioxane was evaporated under reduced pressure at room temperature, and the aqueous phase was extracted with Et₂O (3x30 ml). The aqueous phase was acidified to pH 2-3 with 10% KHSO₄ and extracted with EtOAc (3x30 ml). The combined EtOAc portions were dried over NaSO₄ and concentrated under reduced pressure. The residue was further purified by semi-preparative HPLC to yield the title compound: 26 mg (50%) HPLC (t_R): 38.1 min (linear gradient: 50% B for the first 4 min, increased linearly to 100% B 60 min) ¹H NMR (250 MHz, CD₃OD) 2.71 (dd, J=14.1, 9.1 Hz, 1H), 2.95 (dd, J=14.2, 4.5 Hz, 1H), 4.07 (t, J=7.1 Hz, 1H), 4.23 (m, 5H), 7.19 (m, 5H), 7.54 (m, 3H), 7.68 (m, 3H), 8.78 (d, J=4.9 Hz, 1H), 9.13 (d, J=8.6 Hz, 1H); IR (KBr) cm⁻¹: 3398, 3063, 2950, 1702, 1598, 1555; Mass spectrometry: calculated for C₂₈H₂₄N₂O₅S m/z [M +H]⁺=501.57, found [M +H]⁺ = 501.51; [α]_D²⁰ = -18.3 ° (c = 1.0, 9:1 MeOH/1.0 aqueous HCl).

(ii) Synthesis of N-9-Fmoc-(8-hydroxyquinolin-5-ylmethyl)-D-cysteine (M12B, Appendix IV)

Compound M12B was prepared by the method for synthesizing compound M11B as described in step 5(i) above, using the appropriate starting materials. ¹H NMR (250 MHz, CD₃OD) 2.71 (dd, J=14.2, 9.1 Hz, 1H), 2.96 (dd, J=14.2, 4.4 Hz, 1H), 4.08 (t, J=7.0 Hz, 1H), 4.21 (m, 5H), 7.19 (m, 5H), 7.55 (m, 3H), 7.72 (m, 3H), 8.79 (d, J=4.9 Hz, 1H), 9.14 (d, J=8.2 Hz, 1H); IR (KBr) cm⁻¹: 3397, 3065, 2952, 1701, 1598, 1554; Mass spectrometry: calculated for C₂₈H₂₄N₂O₅S m/z [M +H]⁺=501.57, found [M +H]⁺ = 501.51; [α]_D²⁰ = +17.1 ° (c = 1.0, 9:1 MeOH/1.0 aqueous HCl)

(iii) Synthesis of N-propargyl S-(8-hydroxyquinolin-5-ylmethyl)-L-cysteine (M12a, Appendix III)


The title compound is obtained by removal of the Fmoc group from the compound M12B and reaction thereof with propargyl bromide.

(iv) *Synthesis of N-propargyl S-(8-hydroxyquinolin-5-ylmethyl)-D-cysteine*
 5 (M11a, Appendix III).

The title compound is obtained by removal of the Fmoc group from the compound M11B and reaction thereof with propargyl bromide.

Example 6. Synthesis of N-(4-propargylpiperazin-1-ylethyl)-2-methyl-3-
 10 **hydroxy-4-pyridinone (HLA20a, Appendix VI)**

The title compound was prepared as described in Scheme D by reaction of N-(2-chloroethyl)-2-methyl-3-hydroxy-4-pyridinone (H2, Appendix VII) (prepared as described in Bijaya L.Rai, Lotfollah Dekhordi, Hicham Khodr, Yi Jin, Zudong Liu, and Robert C.Hider *J.Med.Chem.* **1998**, *41*,3347-3359) with N-
 15 propargylpiperazine (obtained as in step (iii) in Example 2):



20

To a mixture of H2 (375 mg, 2 mmol) and diisopropylethylamine (0.352 ml, 2 mmol, 1 eq) in 6 ml CHCl₃ at 0 °C, N-propargylpiperazine (245 mg, 2 mmol, 1 eq) was added. The mixture was then stirred for 24 h at room temperature. CHCl₃ (10 ml) was added and the solution was washed with 5% NaHCO₃ (3x50 ml), brine
 25 (2x50 ml), and then dried over Na₂SO₄. The crude product was purified by FC to give the title compound HLA20a: 337 mg, 60% yield. ¹H NMR (250 MHz, CDCl₃+D₂O), 2.23 (m, 1H), 3.28 (d, J=2.44Hz, 2H), 2.54 (s, 8H), 3.42 (dd, J=3.44,


1.5Hz 2H), 3.70 (dd, J=3.44, 1.5Hz 2H), 7.18 (m, 1H), 7.78 (d, J=7.59, 1H), 2.60 (s 3H) Mass spectrometry: calculated for $C_{15}H_{21}N_3O_2$ m/z $[M + H]^+ = 276.35$, found $[M + H]^+ = 276.30$.

5 **Example 7. Synthesis of N-(N-methyl-propargylaminoethyl)-2-methyl-3-hydroxy-4-pyridinone (M30a, Appendix VI)**

The title compound was prepared as described in Scheme D by reaction of H2 and N-methyl-propargylamine as starting compound instead of N-propargylpiperazine:


10

15



A solution of N-methyl-propargylamine hydrochloride (212 mg, 2mmole) in
 20 CH_2Cl_2 (2 ml) was slowly added to a stirred solution of H2 (375 mg, 2 mmol) and diisopropylethylamine (0.352 ml, 2 mmol, 1 eq) in 6 ml CH_2Cl_2 at 0 °C. The mixture was then stirred overnight at room temperature, and the solvent was removed in vacuum. The crude solid was redissolved in 10 ml of $CHCl_3$, then washed with 5% $NaHCO_3$ (3x30 ml), brine (2x20 ml). The organic layer was dried
 25 over Na_2SO_4 and evaporated *in vacuum* to give the title compound M30a. H^1 NMR (250 MHz, $CDCl_3+D_2O$), 2.23 (m, 1H), 3.28 (d, J=2.44Hz, 2H), 2.33 (s 3H), 3.41 (dd, J=3.44, 1.5Hz 2H), 3.78 (dd, J=3.44, 1.5 Hz 2H), 7.08 (m, 1H), 7.78 (d, J=7.59, 1H), 2.60 (s, 3H). Mass spectrometry: calculated for $C_{12}H_{16}N_2O_2$ m/z $[M + H]^+ = 221.27$, found $[M + H]^+ = 221.30$.

Example 8. Synthesis of N-(4-propargylaminoethoxycarbonyl-piperazin-1-ylmethyl)-2-methyl-3-hydroxy-4-pyridinone (HLA16b, Appendix VI).




The title compound HLA16b was synthesized according to the procedure for M30a in Example 7, but using *N*-propargylaminoethoxycarbonylpiperazine (H1) instead of *N*-methylpropargylamine as the starting material. Yield 64%. ^1H NMR (250 MHz, $\text{CDCl}_3 + \text{D}_2\text{O}$) 2.27 (m, 1H), 3.11 (s 2H), 3.29 (dd, $J=10.21, 7.45$ Hz, 2H), 4.29 (d, $J=11.23, 7.12$ Hz, 2H), 2.55 (dd, $J=4.73, 4.50$ Hz, 4H), 2.93 (dd, $J=4.96, 4.84$ Hz, 4H), 3.45 (dd, $J=3.44, 1.5$ Hz, 2H), 3.81 (dd, $J=3.44, 1.5$ Hz, 2H), 7.18 (m, 1H), 7.78 (d, $J=7.59$, 1H), 2.56 (s 3H). Mass spectrometry: calculated for $\text{C}_{17}\text{H}_{24}\text{N}_4\text{O}_4$ m/z $[\text{M} + \text{H}]^+ = 349.40$, found $[\text{M} + \text{H}]^+ = 349.51$.

Example 9. Synthesis of N-propargyl-S-(2-methyl-3-hydroxy-4-pyridinon-1-ylethyl)-L-cysteine (M12b, Appendix VI) and N-propargyl-S-(2-methyl-3-hydroxy-4-pyridinon-1-ylethyl)-D-cysteine (M11b, Appendix VI).


25 The title compounds were prepared according to the first route depicted in Scheme D hereinabove by reaction of D1 with cysteine, and further reaction of the obtained D2 with propargyl bromide, as follows:

(i) *Synthesis of S-(2-methyl-3-hydroxy-4-pyridinon-1-ylethyl)-L-cysteine (L-H3, Appendix VII)*




5 L-cysteine hydrochloride hydrate (37 mg, 0.31 mmol) was dissolved in DMSO (3 ml). To the solution, powdered KOH (36 mg, 0.34 mmol) was added and the mixture was stirred for 30 min at room temperature. Then, H2 (64 mg, 0.34 mmol) in DMSO was added. After 24 hours of stirring at room temperature, 2 N HCl was added to the reaction mixture and the pH was adjusted to 5.5. The
10 precipitate was washed with water and acetone. The crude product was further purified by semi-preparative HPLC to yield the title compound L-H3: 64 mg (70%). HPLC (t_R): 32.1 min (linear gradient: 50% B for the first 4 min, increased linearly to 100% B 60 min) $[\alpha]_D^{20} = -20.5^\circ$ ($c = 1.0$, H_2O). H^1 NMR (250 MHz, $CDCl_3+D_2O$), 3.90 (m, 1H), 2.92 (d, 5.0 Hz, 2H), 3.07 (m, 2H), 3.78 (m, 2H), 7.10
15 (d, $J=7.0$ Hz, 1H), 7.90 (d, $J=8.1$ Hz, 1H), 2.50 (s, 3H). Mass spectrometry: calculated for $C_{14}H_{18}N_2O_4$ S m/z $[M+H]^+ = 273.32$, found $[M+H]^+ = 273.22$.

(ii) *Synthesis of N-propargyl-S-(2-methyl-3-hydroxy-4-pyridinon-1-ylethyl)-L-cysteine (M12b, Appendix VI)*




A mixture of NaHCO₃ (34 mg, 0.4 mmol) and L-H3 (75 mg, 0.34 mmol) was dissolved in 5 ml DMSO, and the solution was stirred at room temperature for 2 h. To the solution propargyl bromide (24 mg, 0.2 mmol) was slowly added, and the solution was stirred at room temperature for 24 h. The solvent was removed by *vacuum*, and the crude product was crystallized in water (pH 5.5) and further purified by semi-preparative HPLC [(C₁₈; solvent A= water, 0.1% v/v TFA; solvent B = CH₃CN: water = 3: 1, 0.1% v/v TFA; t_R = 20.4 min (linear gradient 0-80% B over 55 min)] to give the title compound M12b: 37 mg, 60% yield. [α]_D²⁰ = -16.3. ¹H NMR (250 MHz, CHCl₃+D₂O) 2.39 (m, 1H), 3.35 (d, J=5.6 Hz, 2H), 4.01(m, 1H), 2.92 (d, 5.0 Hz, 2H), 3.07 (m, 2H), 3.78 (m, 2H), 7.20 (d, J=7.0Hz, 1H), 8.01 (d, J=8.1 Hz, 1H), 2.60 (s, 3H). Mass spectrometry: calculated for C₁₄H₁₈N₂O₄ S m/z [M +H]⁺ = 311.37, found [M +H]⁺ = 311.40.

(iii) *Synthesis of S-(2-methyl-3-hydroxy-4-pyridinon-1-ylethyl)-D-cysteine (D-H3, Appendix VII)*



The title compound was prepared according to the procedure for L-H3, but using D-cysteine instead of L-cysteine as the starting material. Yield 71%. HPLC (t_R): 32.1 min (linear gradient: 50% B for the first 4 min, increased linearly to 100% B 60 min) [α]_D²⁰ = +19.5° (c = 1.0, H₂O). ¹H NMR (250 MHz, CDCl₃+D₂O), 3.89 (m, 1H), 2.91 (d, 5.0 Hz, 2H), 3.07 (m, 2H), 3.78 (m, 2H), 7.10 (d, J=7.0Hz, 1H), 7.90 (d, J=8.1 Hz, 1H), 2.50 (s, 3H). Mass spectrometry: calculated for C₁₄H₁₈N₂O₄ S m/z [M +H]⁺ = 273.32, found [M +H]⁺ = 273.40


(iv) *Synthesis of N-propargyl S-(2-methyl-3-hydroxy-4-pyridinon-1-ylethyl)-D-cysteine. (M11b, Appendix VI)*



The title compound M11b was synthesized according to the procedure for M12b, but using S-(2-methyl-3-hydroxy-4-pyridinon-1-ylethyl)-D-cysteine (D-H3) instead of S-(2-methyl-3-hydroxy-4-pyridinon-1-ylethyl)-L-cysteine as the starting compound. Yield 70%, $[\alpha]_D^{20} = +17.3$. ^1H NMR (250 MHz, $\text{CHCl}_3 + \text{D}_2\text{O}$): 2.30 (m, 1H), 3.40 (d, $J=5.6$ Hz, 2H), 4.01 (m, 1H), 2.98 (d, 5.0 Hz, 2H), 3.07 (m, 2H), 3.78 (m, 2H), 7.20 (d, $J=7.0$ Hz, 1H), 7.89 (d, $J=8.1$ Hz, 1H), 2.58 (s, 3H). Mass spectrometry: calculated for $\text{C}_{14}\text{H}_{18}\text{N}_2\text{O}_4$ S m/z $[\text{M} + \text{H}]^+ = 311.37$, found $[\text{M} + \text{H}]^+ =$

15 311.30.

Example 10. Synthesis of N-propargylglycine hydroxamate (M37, Appendix V)




Propargyl bromide (356.9 mg, 3 mmol) was slowly added to a mixture of glycine hydroxamate (270 mg, 3 mmol) and diisopropylethylamine (407.1 mg, 3.15

mmol) in CHCl_3 (20 ml) at 0 °C. The mixture was stirred for 24 h at room temperature, and CHCl_3 (50 ml) was added. The solution was washed with 5% NaHCO_3 (3x50 ml), brine (2x50 ml), and then dried over Na_2SO_4 . The solution was filtered and evaporated to dryness to give the title compound M37: 192 mg, 50% yield. ^1H NMR (250 MHz, $\text{CHCl}_3+\text{D}_2\text{O}$) 2.33 (m, 1H), 3.33 (d, $J=5.6$ Hz, 2H), 3.13 (s 2H). Mass spectrometry: calculated for $\text{C}_5\text{H}_8\text{N}_2\text{O}_2\text{S}$ m/z $[\text{M} + \text{H}]^+ = 129.13$, found $[\text{M} + \text{H}]^+ = 129.20$.

Example 11. Synthesis of N-(4-methylpiperazin-1-ylmethylcarbonyl),N-propargyl glycine hydroxamate (M38, Appendix V)


The title compound was prepared by reaction of N-t-butoxy 2-(N-chloroacetyl,N-propargyl)amino-acetamide (H4, Appendix VII) with N-methyl piperazine. Compound H4 was obtained by reaction of N-t-butoxy 2-amino-acetamide with chloroacetyl chloride and propargyl bromide, as follows:

(i) Synthesis of N-t-butoxy 2-(N-chloroacetyl-N-propargyl)amino-acetamide (H4)



Propargyl bromide (356.9 mg, 3 mmol) was slowly added to a mixture of 2-amino-N-t-butoxy-acetamide (438.6 mg, 3 mmol) and diisopropylethylamine (407.1 mg, 3.15 mmol) in CHCl_3 (20 ml) at 0 °C. The mixture was stirred for 24 h at room temperature, and CHCl_3 (50 ml) was added. The solution was washed with 5% NaHCO_3 (3x50 ml), brine (2x50 ml), and then dried over Na_2SO_4 . The solution was filtered and evaporated to dryness. The residue was dissolved in diisopropylethylamine (258 mg, 2 mmol) in CH_2Cl_2 (25 ml) at room temperature, and chloroacetyl chloride (0.239 mL, 339 mg, 3 mmol) was slowly added at 0 °C over 30 min. After 2 h of stirring at room temperature, the solvent was removed by vacuum. The resulted residue was dissolved in Et_2OAc (60 ml) and washed with saturated NaHCO_3 (2x50 ml), brine (2x50 ml) and dried over Na_2SO_4 overnight. Evaporation in *vacuum* gave the title compound H4: 390 mg, 50 % yield. ^1H NMR (250 MHz, CHCl_3) 2.23 (m, 1H), 3.31 (d, $J=5.6$ Hz, 2H), 3.13 (s 2H), 4.85 (s 2H), 1.38 (s, 9H). Mass spectrometry: calculated for $\text{C}_{11}\text{H}_{17}\text{ClN}_2\text{O}_3$ m/z $[\text{M} + \text{H}]^+ = 261.72$, found $[\text{M} + \text{H}]^+ = 261.61$.


(ii) *Synthesis of N-(4-methylpiperazin-1-ylmethylcarbonyl)-N-propargyl glycine hydroxamate (M38, Appendix V)*



N-methylpiperazine (100 mg, 1 mmol, 1 eq) was added to a stirred solution of chloroform (5 ml), diisopropylethylamine (0.348 ml, 2 mmol, 2 eq) and H4 obtained in step (i) above (261 mg, 1 mmol) at room temperature. After being stirred for 24 h at room temperature, 10 ml of CHCl_3 was then added and the solution was washed with 5% NaHCO_3 (3x10 ml), brine (2x10 ml), and then dried over Na_2SO_4 .

The solution was filtered and evaporated to dryness. The residue was dissolved in a solution of TFA:H₂O:TES:thioanisole (85:5:5:5) (5 ml), and stirred for 1 h at room temperature. After removal of the solvent under *vacuum*, the residue was dissolved in EtOAc (50 ml), washed with saturated NaHCO₃ (3x20 ml), brine (2x10 ml), and then dried over Na₂SO₄. Evaporation in *vacuum* gave the title compound M38: 160 mg, 60% yield. ¹H NMR (250 MHz, CHCl₃+D₂O) 2.30 (m, 1H), 3.31 (d, J=5.6 Hz, 2H), 3.13 (s 2H), 2.83 (s, 3H), 2.44 (s, 8H), 3.87 (s, 2H) Mass spectrometry: calculated for C₁₂H₂₀N₄O₃ m/z [M +H]⁺=269.31, found [M +H]⁺ = 269.40.

Example 12. Synthesis of N-[4-(2-hydroxyethyl)piperazin-1-ylmethylcarbonyl], N-propargylglycine hydroxamate (M39, Appendix V)




15

The title compound M39 was synthesized according to the procedure for M38 in Example 11 above, but using 4-(2-hydroxyethyl)piperazine instead of *N*-methylpiperazine as the starting material. Yield 72%. Mass spectrometry: calculated for C₁₃H₂₂N₄O₄ m/z [M +H]⁺=299.34, found [M +H]⁺ = 299.40. ¹H NMR (250 MHz, CHCl₃+D₂O): 2.25 (m, 1H), 3.31 (d, J=5.6 Hz, 2H), 3.13 (s 2H), 4.01 (dd, J=5.6, 1.5 Hz, 2H), 3.56 (dd, J=6.6, 1.5 Hz, 2H), 2.44 (s, 8H), 3.87 (s, 2H).

20

Example 13. Synthesis of N-[4-ethoxycarbonylpiperazin-1-ylmethylcarbonyl], N-propargylglycine hydroxamate (M40, Appendix V)

25



The title compound M40 was prepared as described in Example 11 above,
 5 but using 4-ethoxycarbonylpiperazine instead of *N*-methylpiperazine as the starting material. Yield 78%. Mass spectrometry: calculated for $C_{14}H_{22}N_4O_5$ m/z $[M + H]^+ = 327.35$, found $[M + H]^+ = 327.28$. ^1H NMR (250 MHz $CDCl_3 + D_2O$): 1.28 (dd, $J = 7.1, 7.1$ Hz, 3H), 3.81 (s, 2H), 2.44 (s, 4H), 3.43 (s, 4H), 4.01 (dd, $J = 14.21, 7.12$ Hz, 2H), 2.33 (m, 1H), 3.33 (d, $J = 5.6$ Hz, 2H), 3.13 (s, 2H).

10

Example 14. General Peptide Synthesis

The peptides used in the preparation of the compounds of the invention of formula I such as those depicted in Appendix I, are prepared by the general method as described below.

15 Unless otherwise stated, all chemicals and reagents were of analytical grade. Trifluoroacetic acid (TFA) for high performance liquid chromatography (HPLC) was obtained from Merck (Darmstadt, Germany). *N*-9-fluorenylmethoxycarbonyl (Fmoc)-protected amino acid derivatives and Rink amide resins were purchased from Novabiochem (Laufelfingen, Switzerland).

20 The peptides were prepared manually by solid-phase peptide synthesis using Fmoc chemistry following the company's protocols. *N*- α -Fmoc-amino acid derivatives were used in the synthesis. *N*-Methyl morpholine (NMM) and benzotriazol-1-yloxy-tris-pyrrolidino-phosphonium hexafluorophosphate (PyBOP) and, when necessary, a combination of 1,3-dicyclohexylcarbodiimide (DCC) and 1-hydroxybenzotriazole (HOBt), were utilized as coupling agents. *N*-methyl pyrrolidone (NMP) and DMF were used as solvent. Before each coupling, the

25

deprotection of the α -amino group was achieved by reaction with 20% piperidine. All synthesized peptides were deprotected and cleaved from the resin using a solution of TFA: triethylsilane (TES): thioanisole: water (85:5:5:5). The cleavage mixtures were filtered and the peptides were precipitated from the solution with
5 peroxide-free dry ether at 0 °C. Precipitated peptides were washed with cold dry ether, dissolved in water or water/acetonitrile solution, and lyophilized. The crude peptides were subjected to semipreparative HPLC purification, performed on a Waters system composed of two model 510 pumps, model 680 automated gradient controller, and model 441 absorbance detector (Waters, Milford, MA). The column
10 effluents were monitored by UV absorbance at 214/254 nm. HPLC prepacked columns employed (Merck, Darmstadt, Germany) were LichroCART 250-10 mm containing Lichrosorb RP-18 (7 m) for semipreparative purifications and Lichrospher 100 RP-18, 250-4 mm (5 m) for analytical separations. Separations were achieved using gradients of acetonitrile in water containing 0.1% TFA. The
15 solutions containing purified peptides were lyophilized overnight. Molecular weights of all peptides were confirmed by mass spectrometry. Mass spectrometry was performed on a Micromass Platform LCZ4000 (Manchester, UK) utilizing electron spray ionization method. For amino acid composition analysis, peptides were hydrolyzed in 6 N HCl at 100 °C for 24 h under vacuum, and the hydrolyzates
20 were analyzed with a Dionex Automatic Amino Acid Analyzer.

Example 15. Synthesis of VIP analog derivative containing a 8-hydroxyquinoline (HQ) group - Fmoc-KKC(HQ)L-NH₂ (M7, Appendix II).

Vasoactive intestinal peptide (VIP) is a 28-mer peptide known to provide
25 neuroprotection against β -amyloid toxicity in models of Alzheimer's disease. Mapping of the active site of VIP lead to a peptide of four amino acids: Lys-Lys-Tyr-Leu. An analog of this VIP fragment was prepared by replacing the Tyr residue by a Cys residue for linking to a 8-hydroxyquinoline (HQ) residue, thus obtaining the compounds of the invention M7 (Appendix II) and M7A (Appendix I) (see

Example 16 below). Although both compounds M7 and M7A were given the same connotation Fmoc-KKC(HQ)L-NH₂ in Appendices II and I, respectively, it is clear from the structural formula of M7A that it carries a propargylamino group linked to the methylene radical at position 5 of the 8-hydroxyquinolinyl (HQ) radical.

5 To Rink amide resin (71 mg, 33 μ mole) was added 2 ml 20% piperidine in NMP. After 5 minute shaking, the solution was drained and the resin was washed three times with DMF. To the resin was added Fmoc-Leu-OH (47 mg, 132 μ mole, 4 eq) and PyBOP (69 mg, 132 μ mole, 4 eq) in 1 ml DMF, and NMM (29 μ l, 264 μ mol, 8 eq). The resulting mixture was then shaken for 1 h. The liquid was drained
10 and a second coupling was performed with equal amounts of Fmoc-Leu-OH, PyBOP and NMM. The third coupling was performed via DCC/ HOBt activation: Fmoc-Leu-OH (47 mg, 132 μ mole, 4 eq), HOBt (18 mg, 132 μ mol, 4 eq), and DCC (132 μ ml 1N DMF, 132 μ mol, 4 eq) were dissolved in 1 ml DMF. After 1 hour cooling, the precipitated dicyclohexylurea (DCU) was removed and the solution
15 was added to the resin. After shaking overnight and draining the solution, the resin was washed (DMFx3, DCMx3). A negative ninhydrin test indicated the completion of the coupling reaction. Next three coupling cycles with Fmoc-Cys(Mmt)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Lys(Boc)-OH, respectively were carried out according to the procedure above (both PyBOP and DCC). At the completion of all four
20 coupling circles, the resulting resin was treated with a solution of TFA:TES:DCM (dichloromethane) (1:5:94 v/v) to remove the Mmt (4-methoxytrityl) protecting group.


A solution of 5-chloromethyl-8-hydroxyquinoline (32 mg, 165 μ mol, 5 eq) and NMP (17 mg, 20 μ l, 5 eq) in DMF/DCM (1ml) were added to the resin and the
25 mixture was shaken overnight. A negative DTNB (5,5'-dithio-bis-(2-nitrobenzoate) test indicated the completion of the reaction. The resulting HQ-modified peptide was cleaved from the resin using a solution of TFA: H₂O:TES:thioanisole (85:5:5: 5) and precipitated with ether. The crude HQ-modified title peptide M7 was further purified by semi-preparative HPLC, as described above. Yield: 4.8 mg (5.5 μ mol;

16.7%, based on the initial amino acid resin loading). Mass spectrometry: m/z 870.6 (MH⁺) calculated 870.1. Amino acid analysis after hydrolysis with 6 M HCl at 110 °C for 22 h: Leu 1.00, Lys 2.16. Cys could not be detected due to its destruction under the acidic conditions of hydrolysis.

5

Example 16. Synthesis of VIP analog derivative containing a 8-hydroxyquinoline (HQ) group and a propargylamino group - Fmoc-KKC(HQ)L-NH₂ (M7A, Appendix I).

10 (i) *Synthesis of 5-(N-tert-butoxycarbonyl,N-propargyl)aminomethyl-8-t-butoxy-quinoline (H5, Appendix VII)*



H5


15 5-Chloromethyl-8-hydroxyquinoline was protected as 5-chloromethyl-8-t-butoxy-quinoline, and propargylamine was converted into N-(tert-butoxycarbonyl)-propargylamine according to known procedures.

20 N-(tert-Butoxycarbonyl)propargylamine (310 mg, 2 mmol) was added in portions over 30 min to a stirred suspension of NaH (88 mg of 60% dispersion in oil, 2.2 mmol) in DMF (5 ml), under nitrogen. After the H₂ gas evolution had ceased, 5-chloromethyl-8-O-t-butyl-quinoline (600 mg, 2.4 mmol) in DMF (2 ml) was added dropwise below 30 °C (cold-water bath). Stirring was continued for 3 h and the reaction mixture was partitioned between EtOAc (3X30 ml) and H₂O (50 ml). The combined EtOAc solutions were washed with water, dried over Na₂SO₄

and evaporated to a buff solid which was washed with hexane and *vacuum* dried, giving the title compound: 443 mg (60%), ^1H NMR (250 MHz, CHCl_3) 1.31(s, 9H), 1.41(s, 9H), 2.29 (m, 1H), 3.27 (s, 2H), 3.91 (s, 2H), 7.25 (d, $J=8.0\text{Hz}$, 1H), 7.57 (d, $J=8.0\text{ Hz}$, 1H), 7.96 (dd, $J=8.7, 5.5\text{ Hz}$, 1H), 8.88 (d, $J=5.4\text{ Hz}$, 1H), 9.22 (d, $J=8.7$ Hz, 1H); Mass spectrometry: calculated for $\text{C}_{22}\text{H}_{28}\text{N}_2\text{O}_5$ m/z $[\text{M} + \text{H}]^+ = 369.47$,
 5 found $[\text{M} + \text{H}]^+ = 369.54$.

(ii) Synthesis of 5-(propargylaminobromomethyl)-8-hydroxyquinoline (H6, Appendix VII)

10



Compound H5 from step (i) above (368 mg, 1 mmol) and N-bromosuccinimide (231 mg, 1.3 mmol) were dissolved in 5 ml of CCl_4 . To this
 15 solution was added benzoyl peroxide (2.5 mg, 0.01 mmol), and the reaction mixture was heated at reflux for 12 h. After reflux, the solution was cooled to $0\text{ }^\circ\text{C}$, and the solid precipitate was filtered. The filtrate was washed with 1 M aqueous Na_2CO_3 , saturated aqueous NaS_2O_3 , and brine. The organic layer was dried (Na_2SO_4), filtered, and evaporated to dryness in *vacuum*. The residue was dissolved in a
 20 solution of TFA: H_2O :TES:thioanisole (85: 5:5:5) (5 ml). After 1 h, HPLC indicated complete removal of the protecting groups. The solution was evaporated to dryness and the residue was dissolved in water (10 ml) and then basified with Na_2CO_3 (pH 11), and extracted with Et_2OAc (3x50 ml). The organic layer was washed with brine (2x50 ml) and dried over Na_2SO_4 overnight. Evaporation in *vacuum* gave the title

compound H6: 218 mg, 75% yield. ^1H NMR (250 MHz, CHCl_3) 2.23 (m, 1H), 3.27 (s, 2H), 5.10 (s, 1H), 7.25 (d, $J=8.0\text{ Hz}$, 1H), 7.57 (d, $J=8.0\text{ Hz}$, 1H), 7.96 (dd, $J=8.7$, 5.5 Hz, 1H), 8.88 (d, $J=5.4\text{ Hz}$, 1H), 9.22 (d, $J=8.7\text{ Hz}$, 1H); Mass spectrometry: calculated for $\text{C}_{22}\text{H}_{28}\text{N}_2\text{O}_5$ m/z $[\text{M} + \text{H}]^+ = 292.14$, found $[\text{M} + \text{H}]^+ = 292.04$.

5

(iii) Synthesis of VIP analog derivative containing a 8-hydroxyquinoline (HQ) group and a propargylamino group - M7A (Appendix I, Scheme A)

A solution of H6 of step (ii) above (48 mg, 0.165 mmol, 5 eq) and NMP (17 mg, 0.020 ml, 5 eq) in DMF/ CH_2Cl_2 (1ml) was added to the resin (0.033 mmol, 1eq) obtained in Example 15 above and the mixture was shaken overnight. A negative DTNB test indicated the completion of the reaction. The resulting HQ-modified peptide was cleaved from the resin using a solution of TFA: H_2O :TES:thioanisole (85:5:5:5) and precipitated with ether. The crude HQ-modified peptide M7A was further purified by semi-preparative HPLC (t_R): 35.1 min (linear gradient: 50% B for the first 4 min, increased linearly to 100% B 60 min). Yield: 6 mg (5.5 μmol ; 16.7%, based on the initial amino acid resin loading). Mass spectrometry: calculated for $\text{C}_{49}\text{H}_{63}\text{N}_9\text{O}_7\text{S}$ m/z $[\text{M} + \text{H}]^+ = 923.68$, found m/z $[\text{M} + \text{H}]^+ = 923.91$. Amino acid analysis after hydrolysis with 6 M HCl at 110 $^\circ\text{C}$ for 22 h: Leu 1.00, Lys 2.10. Cys could not be detected due to its destruction under the acidic conditions of hydrolysis.

20

Example 17. Synthesis of VIP analog derivative containing a 8-hydroxyquinoline (HQ) group - Stearyl-KKC(HQ)L- NH_2 (M6, Appendix II).

Fmoc-Lys(Boc)-Lys(Boc)-Cys(Mmt)-Leu-[Rink amide resin] 33 μmol was synthesized as described above in Example 15. After removing the Fmoc group, the free N-terminal function was coupled with stearic acid (38 mg, 132 μmol , 4 eq) according to the procedure described above. A negative ninhydrin test indicated the completion of the coupling reaction. The peptide was cleaved from the resin using a solution of TFA: H_2O :TES:thioanisole (85:5:5:5) and precipitated with ether. A

25

solution of 5-chloromethyl-8-hydroxyquinoline (32 mg, 165 μ mol, 5 eq) and NMP (17 mg, 20 μ l, 5 eq) in DMF/CH₂Cl₂. (1 ml) was added to the crude peptide. The mixture was shaken overnight at room temperature. A negative DTNB test indicated the completion of the reaction. Upon completion of the reaction, the solution was
5 drained, and the crude peptide was further purified by semi-preparative HPLC to yield: 4.6 mg (5.0 μ mol; 15.3%, based on the initial amino acid-resin loading). HPLC (t_R): 38.1 min (linear gradient: 50% B for the first 4 min, increased linearly to 100% B 60 min), t_R = 47.5 min for St-KKCLNH₂ at the same conditions. Mass spectrometry: m/z 914.9 (MH⁺), (calculated 914.3). Amino acid analysis after
10 hydrolysis with 6 M HCl at 110 °C for 22 h: Leu 1.00, Lys 2.21. Cys could not be detected due to its destruction under the acidic conditions of hydrolysis.

Example 18. Synthesis of VIP analog derivative containing a 8-hydroxyquinoline (HQ) group and a propargylamino group - Stearyl-KKC(HQ)L-NH₂ (M6A, Appendix I).
15

To the resin (33 μ mol, 1 eq) obtained in Example 17 above was added a solution of 5-(propargylaminobromomethyl)-8-hydroxyquinoline H6 (48 mg, 0.165 mmol, 5 eq) and NMP (17 mg, 0.020 ml, 5 eq) in DMF/CH₂Cl₂ (1ml). The mixture was then shaken overnight. A negative DTNB test indicated the completion of the
20 reaction. The resulting HQ-modified peptide was cleaved from the resin using a solution of TFA:H₂O:TES:thioanisole (85:5:5:5) and precipitated with ether. The crude HQ-modified peptide M6A was further purified by semi-preparative HPLC (t_R): 40.1 min (linear gradient: 50% B for the first 4 min, increased linearly to 100% B 60 min). Yield: 5.8 mg (6 μ mol; 18%, based on the initial amino acid resin
25 loading). Mass spectrometry: calculated for C₅₂H₈₇N₉O₆S m/z [M+H]⁺ = 967.37, found m/z [M+H]⁺ = 967.21. Amino acid analysis after hydrolysis with 6 M HCl at 110 °C for 22 h: Leu 1.00, Lys 2.20. Cys could not be detected due to its destruction under the acidic conditions of hydrolysis.

Example 19. Synthesis of Substance P analog derivative containing a 8-hydroxyquinoline (HQ) group - [Cys⁷(HQ)]-substance P (M27, Appendix II).

[Cys⁷]-Substance P (9.0 mg, 6.9 μ mol) was dissolved in N,N'-dimethylformamide (DMF) (350 μ l), and NMM (7.6 μ l, 69 μ mol, 10 equiv) was added. After being stirred for 1 h at room temperature, 5-chloromethyl-8-hydroxyquinoline hydrochloride (1.5 mg, 7.6 μ mol, 1.1 equiv) in 150 μ l mixed solvent (DMF:DMSO:CH₃CN 3:3:1) was added dropwise. The reaction mixture was stirred overnight at room temperature. The progress of the reaction was monitored by analytical HPLC. When necessary, additional 5-chloromethyl-8-hydroxyquinoline hydrochloride was added for completion of the reaction. Upon completion of the reaction, the crude peptide was precipitated with ice-cold tert-butyl methyl ether/petroleum ether, collected by centrifugation, and then purified by semi-preparative HPLC. t_R = 32.27 min (linear gradient: t B=0% at 1.0 ml/min over 5 min; B=0%-58% at 1.0 ml/min over 45 min), (t_R = 32.28 min for [Cys⁷]-substance P in the same conditions). Amino acid analysis after hydrolysis with 6 M HCl at 110 °C for 22 h: Lys 1.00, Arg 1.09, Glu 2.03, Gly 1.32, Pro 1.93, Leu 1.01, Phe 0.96, Cys 0.92. Cys was detected using S-(8-hydroxyquinolin-5-ylmethyl)-L-cysteine as standard reference. Met could not be detected due to its destruction under the acidic conditions of hydrolysis. Mass spectrometry: calculated for C₆₇H₁₀₁N₁₉O₁₄S₂ m/z [M + H]⁺ = 1461.77, found [M + H]⁺ = 1461.15.

Example 20. Synthesis of Substance P analog derivative containing a 8-hydroxyquinoline (HQ) group - [Cys⁸(HQ)]-substance P (M28, Appendix II).

Compound M28 was synthesized by the method described in Example 19 above for compound M27 using the appropriate starting materials. The crude peptide M28 was further purified by semi-preparative HPLC. t_R = 32.10 min (linear gradient: t B=0% at 1.0 ml/min over 5 min; B=0%-58% at 1.0 ml/min over 45 min), (t_R = 32.89 min for [Cys⁸]-substance P in the same conditions). Mass spectrometry: calculated for C₆₇H₁₀₁N₁₉O₁₄S₂ m/z [M + H]⁺ = 1461.77, found [M + H]⁺ = 1461.17.

Amino acid analysis after hydrolysis with 6 M HCl at 110 °C for 22 h: Lys 1.00, Arg 1.18, Glu 1.96, Gly 1.22, Pro 1.77, Leu 0.92, Phe 0.91, Cys 0.96. Cys was detected using S-(8-hydroxyquinolin-5-ylmethyl)-L-cysteine as standard reference. Met could not be detected due to its destruction under the acidic conditions of hydrolysis.

Example 21. Synthesis of Substance P analog derivative containing a 8-hydroxyquinoline (HQ) group and a propargylamino group - [Cys⁷(HQ)]-Substance P (M27A, Appendix I).

To [Cys⁷]-substance P (9.0 mg, 6.9 μmol, 1eq) in DMF (350 μl) was added NMM (7.6 μl, 69 μmol, 10 equiv). After being stirred for 1 h at room temperature, a solution of 5-(propargylamino-bromomethyl)-8-hydroxyquinoline H6 (2.2 mg, 76 μmol, 1.1 eq) in 150 μl mixed solvent (DMF: DMSO:CH₃CN 3:3:1) was added dropwise. The reaction mixture was stirred overnight at room temperature. The progress of the reaction was monitored by analytical HPLC. When necessary, additional 5-(propargylamino-bromomethyl)-8-hydroxyquinoline was added for completion of the reaction. Upon completion of the reaction, the crude peptide was precipitated with ice-cold tert-butyl methyl ether/petroleum ether, collected by centrifugation, and then purified by semi-preparative HPLC. $t_R = 35.27$ min (linear gradient: $t_B = 0\%$ at 1.0 ml/min over 5 min; $B = 0\% - 58\%$ at 1.0 ml/min over 45 min), ($t_R = 32.28$ min for [Cys⁷]-substance P in the same conditions). Amino acid analysis after hydrolysis with 6 M HCl at 110 °C for 22 h: Lys 1.00, Arg 1.10, Glu 2.01, Gly 1.32, Pro 1.93, Leu 1.03, Phe 0.96, Cys 0.99. Cys was detected using S-(8-hydroxyquinolin-5-yl-(propargylamino-methyl)-L-cysteine as standard reference. Met could not be detected due to its destruction under the acidic conditions of hydrolysis. Mass spectrometry: calculated for C₇₀H₁₀₄N₂₀O₁₄S₂ m/z [M + H]⁺ = 1514.78, found [M + H]⁺ = 1514.25.

Example 22. Synthesis of Substance P analog derivative containing a 8-hydroxyquinoline (HQ) group and a propargylamino group - [Cys⁸(HQ)]-Substance P (M28A, Appendix I).

The title compound M28A was synthesized according to the procedure for M27A in Example 21 above, but using [Cys⁸]-substance P instead of [Cys⁷]-substance P as the starting material. Yield 75%. Amino acid analysis after hydrolysis with 6 M HCl at 110 °C for 22 h: Lys 1.00, Arg 1.08, Glu 2.11, Gly 1.22, Pro 1.93, Leu 1.01, Phe 1.04, Cys 0.99. Cys was detected using S-(8-hydroxyquinolin-5-yl-(propargylaminomethyl)-L-cysteine as standard reference. Met could not be detected due to its destruction under the acidic conditions of hydrolysis. Mass spectrometry: calculated for C₇₀H₁₀₄N₂₀O₁₄S₂ m/z [M + H]⁺ = 1514.78, found [M + H]⁺ = 1514.88.

Example 23. Synthesis of GnRH analog derivative containing a 8-hydroxyquinoline (HQ) group – L-Cys⁵(HQ)]GnRH (M8, Appendix II).

Compound M8 was synthesized according to the method for synthesizing compound M27 described in Example 19 above, using the appropriate starting materials. The crude peptide M8 was further purified by semi-preparative HPLC. t_R = 26.02 min (linear gradient: t B = 0% at 1.0 ml/min over 5 min; B = 0%-75% at 1.0 ml/min over 45 min), (t_R = 27.54 min for [Cys⁵]GnRH under the same conditions). Mass spectrometry: calculated for C₅₉H₇₈N₁₈O₁₃S m/z [M + H]⁺ = 1279.43, found [M + H]⁺ = 1279.86. Amino acid analysis after hydrolysis with 6 M HCl at 110 °C for 22 h: Arg 1.00, Ser 1.09, Glu 0.92, Gly 2.21, His 0.88, Pro 0.89, Leu 0.89, Cys 0.85. Cys was detected using S-(8-hydroxyquinolin-5-ylmethyl)-L-cysteine as standard reference.

Example 24. Synthesis of GnRH analog derivative containing a 8-hydroxyquinoline (HQ) group - D-Cys⁶(HQ)]GnRH (M22, Appendix II).

Compound M22 was synthesized according to the method for synthesizing compound M27 described in Example 19 above, using the appropriate starting materials. Upon completion of the reaction, the crude peptide M22 was precipitated with ice-cold *tert*-butyl methyl ether (3 ml). After centrifugation, the solid was dissolved in DDW and purified by preparative HPLC to yield mg (mmol; %). $t_R=30.82$ min (linear gradient: $t_B=0\%$ at 1.0 ml/min over 5 min; $B=0\%-58\%$ at 1.0 ml/min over 45 min), ($t_R=32.57$ min for [D-Cys⁶]GnRH under the same conditions). Mass spectrometry: calculated for C₆₆H₈₄N₁₈O₁₄S m/z [M + H]⁺ =1386.55, found [M + H]⁺ =1386.71.

10

Example 25. Synthesis of GnRH analog derivative containing a 8-hydroxyquinoline (HQ) group and a propargylamino group – L-Cys⁵(HQ-Pr)]GnRH (M8A, Appendix I).

[Cys⁵]GnRH (7.7 mg, 6.9 μ mol) was dissolved in DMF (350 μ l), and NMM (7.6 μ l, 69 μ mol, 10 equiv) was added. After being stirred for 1 h at room temperature, 5-(propargyl-aminobromomethyl)-8-hydroxyquinoline H6 (2.2 mg, 76 μ mol, 1.1 eq) in 150 μ l mixed solvent (DMF:DMSO:CH₃CN 3:3:1) was added dropwise. The reaction mixture was stirred overnight at room temperature. The progress of the reaction was monitored by analytical HPLC. When necessary, additional H6 was added for completion of the reaction. Upon completion of the reaction, the crude peptide was precipitated with ice-cold *tert*-butyl methyl ether/petroleum ether, collected by centrifugation. The crude peptide M8A was further purified by semi-preparative HPLC. $t_R=30.12$ min (linear gradient: $t_B=0\%$ at 1.0 ml/min over 5 min; $B=0\%-75\%$ at 1.0 ml/min over 45 min), ($t_R=27.54$ min for [Cys⁵]GnRH under the same conditions). Yield: 7.2 mg (5.4 μ mol; 78%). Mass spectrometry: calculated for C₆₂H₈₁N₁₉O₁₃S m/z [M + H]⁺ =1332.46, found [M + H]⁺ =1332.66. Amino acid analysis after hydrolysis with 6 M HCl at 110 °C for 22 h: Arg 1.00, Ser 1.09, Glu 0.99, Gly 2.21, His 0.98, Pro 0.89, Leu 0.89, Cys 0.85. Cys

15

20

25

was detected using S-(8-hydroxyquinolin-5-yl)-(propargylaminomethyl)-L-cysteine as standard reference.

Example 26. Synthesis of GnRH analog derivative containing a 8-hydroxyquinoline (HQ) group and a propargylamino group – D-Cys⁶(HQ-Pr)GnRH (M22A, Appendix I).

The title compound M22A was synthesized according to the procedure for M27A in Example 23 above, but using [D-Cys⁶]GnRH instead of [Cys⁵]GnRH as the starting material. Yield 70%. Mass spectrometry: calculated for C₆₉H₈₇N₂₀O₁₃S
m/z [M + H]⁺ = 1439.56, found [M + H]⁺ = 1439.66. Amino acid analysis after hydrolysis with 6 M HCl at 110 °C for 22 h: Arg 1.00, Ser 1.09, Glu 0.99, Tyr 1.03, Gly 1.11, His 0.98, Pro 0.99, Leu 0.89, Cys 0.85. Cys was detected using S-(8-hydroxyquinolin-5-yl)-(propargylaminomethyl)-L-cysteine as standard reference

Example 27. Synthesis of enkephalin analog derivatives containing a 8-hydroxyquinoline (HQ) group - YGGC(HQ)L (M18), YGGC(HQ)M (M19), C(HQ)GGFL (M20), C(HQ)GGFM (M21) (Appendix II)

(i) General procedure for the synthesis of compounds M18, M19, M20, M21

To a solution of Cys¹Met⁵-enkephalin or Cys¹Leu⁵-enkephalin (25 µmol) in DMF (150 µl) was added NMM (26 µl, 250 µmol). After stirring 1 h at room temperature, 5-chloromethyl-8-hydroxyquinoline hydrochloride (61 mg, 25 µmol) in 250 µl mixed solvent (DMF:DMSO:CH₃CN 3:3:1) was added dropwise. The reaction mixture was stirred overnight at room temperature. The progress of the reaction was monitored by analytical HPLC. When necessary, additional 5-chloromethyl-8-hydroxyquinoline hydrochloride was added for completion of the reaction. Upon completion of the reaction, the crude peptide was precipitated with ice-cold *tert*-butyl methyl ether/petroleum ether, collected by centrifugation, and then purified by semipreparative HPLC (linear gradient: t B=0% at 1.0 ml/min over

5 min; B=0%-58% at 1.0 ml/min over 55 min).

(ii) *[Cys⁴(HQ)]-Leu⁵-enkephalin (M18, Appendix II)* Mass spectrometry: calculated for C₃₂H₄₀N₆O₈S m/z [M + H]⁺ = 669.76, found [M + H]⁺ = 669.62

5

(iii) *[Cys⁴(HQ)]-Met⁵-enkephalin (M19, Appendix II)* HPLC. t_R = 26.43 min (linear gradient: t B=0% at 1.0 ml/min over 5 min; B=0%-58% at 1.0 ml/min over 55 min) (t_R = 23.87 min for [Cys¹]-Leu⁵-enkephalin in the same conditions). Mass spectrometry: calculated for C₃₂H₄₀N₆O₈S m/z [M + H]⁺ = 687.80, found [M + H]⁺ = 687.79.

10

(iv) *[Cys¹(HQ)]-Leu⁵-enkephalin (M20, Appendix II)* HPLC. t_R = 29.56 min (linear gradient: t B=0% at 1.0 ml/min over 5 min; B=0%-58% at 1.0 ml/min over 55 min) (t_R = 27.92 min for [Cys¹]-Leu⁵-enkephalin under the same conditions). Mass spectrometry: calculated for C₃₂H₄₀N₆O₇S m/z [M + H]⁺ = 653.76, found [M + H]⁺ = 653.48

15

(v) *[Cys¹(HQ)]-Met⁵-enkephalin (M21, Appendix II)* Mass spectrometry: calculated for C₃₁H₃₈N₆O₇S₂ m/z [M + H]⁺ = 671.80, found [M + H]⁺ = 671.43.

20

Example 28. Synthesis of enkephalin analog derivatives containing a 8-hydroxyquinoline (HQ) group and a propargylamino group - YGGC(HQ)L (M18A), YGGC(HQ)M (M19A), C(HQ)GGFL (M20A), C(HQ)GGFM (M21A) (Appendix I)

25

(i) *General procedure for the synthesis of compounds M18A, M19A, M20A, M21A (Appendix I, Scheme C)*

The modified enkephalin peptide ([Cys⁴]-Leu⁵-enkephalin, [Cys⁴]-Met⁵-enkephalin, [Cys¹]-Leu⁵-enkephalin, or [Cys¹]-Met⁵-enkephalin) (25 μmol) was

dissolved in DMF (150 μ l), and NMM (26 μ l, 250 μ mol) was added. After 1 h of stirring at room temperature, 5-(propargylaminobromomethyl)-8-hydroxy-quinoline H6 (25 μ mol) in 250 μ l mixed solvent (DMF:DMSO:CH₃CN 3:3:1) was added dropwise. The reaction mixture was stirred overnight at room temperature. The progress of the reaction was monitored by analytical HPLC. When necessary, additional H6 was added for completion of the reaction. Upon completion of the reaction, the crude peptide was precipitated with ice-cold *tert*-butyl methyl ether/petroleum ether, collected by centrifugation, and then purified by semi-preparative HPLC (linear gradient: t B=0% at 1.0 ml/min over 5 min; B=0%-58% at 1.0 ml/min over 55 min).

(ii) **[Cys⁴(propargyl-HQ)]-Leu⁵-enkephalin (M18A, Appendix I)** Yield 70%, HPLC. t_R = 28.43 min (linear gradient: t B=0% at 1.0 ml/min over 5 min; B=0%-58% at 1.0 ml/min over 55 min) (t_R = 25.87 min for [Cys⁴]-Leu⁵-enkephalin in the same conditions) Mass spectrometry: calculated for C₃₅H₄₃N₇O₈S m/z [M + H]⁺ = 722.80, found [M + H]⁺ = 722.62.

(iii) **[Cys⁴(propargyl-HQ)]-Met⁵-enkephalin (M19A, Appendix I)** Yield 60%, HPLC. t_R = 27.83 min (linear gradient: t B=0% at 1.0 ml/min over 5 min; B=0%-58% at 1.0 ml/min over 55 min) (t_R = 23.87 min for [Cys⁴]-Met⁵-enkephalin in the same conditions). Mass spectrometry: calculated for C₃₅H₄₃N₇O₈S m/z [M + H]⁺ = 740.84, found [M + H]⁺ = 740.70.

(iv) **[Cys¹(propargyl-HQ)]-Leu⁵-enkephalin (M20A, Appendix I)** Yield 72%, HPLC. t_R = 30.16 min (linear gradient: t B=0% at 1.0 ml/min over 5 min; B=0%-58% at 1.0 ml/min over 55 min) (t_R = 27.92 min for [Cys¹]-Leu⁵-enkephalin under the same conditions). Mass spectrometry: calculated for C₃₅H₄₃N₇O₇S m/z [M + H]⁺ = 706.80, found [M + H]⁺ = 706.88.

(v) *[Cys¹(propargyl-HQ)]-Met⁵-enkephalin (M21A, Appendix I)* Yield 78%, HPLC. t_R = 27.26 min (linear gradient: t_B = 0% at 1.0 ml/min over 5 min; B = 0% - 58% at 1.0 ml/min over 55 min) (t_R = 25.90 min for [Cys¹]-Leu⁵-enkephalin under the same conditions). Mass spectrometry: calculated for C₃₄H₄₁N₇O₇S₂ m/z [M + H]⁺ = 724.84, found [M + H]⁺ = 724.94.

Example 29. Synthesis of VIP, GnRH, and Substance P analog derivatives containing a propargylamino group and a hydroxamate group - Compounds M6B, M7B, M8B, M22B, M27B, and M28B (n=1) (Appendix V, Scheme C)

(i) General procedure for the synthesis of hydroxamate compounds M6B, M7B, M8B, M22B, M27B, and M28B (n=1) (Appendix V)

The modified peptide (7 μ mol, 1 equiv.) (St-KKCL-NH₂, Fmoc-KKCL-NH₂, [Cys⁵]GnRH, [D-Cys⁶]GnRH, [Cys⁷]-substance P, or [Cys⁸]-substance P synthesized as described above) was dissolved in DMF (350 μ l), and NMM (7.6 μ l, 70 μ mol, 10 equiv) was added. After 1 hour of stirring at room temperature, N-t-butoxy 2-(N-chloroacetyl-N-propargyl)-amino-acetamide (H4) (2 mg, 7.7 μ mol, 1.1 equiv) in 150 μ l DMF was added dropwise. The mixture was stirred overnight at room temperature. The progress of the reaction was monitored by analytical HPLC. When necessary, additional H4 was added for completion of the reaction. Upon completion of the reaction, the solvent was removed under vacuum. To the residue was added a solution (2 mL) of TFA:H₂O:TES:thioanisole (85:5:5:5). The mixture was stirred for 1 h and then precipitated with ice-cold tert-butyl methyl ether/petroleum ether, collected by centrifugation; the crude modified peptide was further purified by semi-preparative HPLC.

(ii) Synthesis of compound M6B (n=1) (Appendix V)

Yield 71%, HPLC (t_R): 25.1 min (linear gradient: 50% B for the first 4 min, increased linearly to 100% B 40 min). Mass spectrometry: calculated for

$C_{46}H_{85}N_9O_8S$ m/z $[M+H]^+ = 925.29$, found m/z $[M+H]^+ = 925.21$. Amino acid analysis after hydrolysis with 6 M HCl at 110 °C for 22 h: Leu 1.00, Lys 2.20. Cys could not be detected due to its destruction under the acidic conditions of hydrolysis.

5

(iii) Synthesis of compound M7B (n=1)(Appendix V)

Yield: 68% HPLC (t_R): 25.1 min (linear gradient: 50% B for the first 4 min, increased linearly to 100% B 50 min. Mass spectrometry: calculated for $C_{43}H_{61}N_9O_9S$ m/z $[M+H]^+ = 881.07$, found m/z $[M+H]^+ = 881.15$. Amino acid analysis after hydrolysis with 6 M HCl at 110 °C for 22 h: Leu 1.00, Lys 2.15. Cys could not be detected due to its destruction under the acidic conditions of hydrolysis.

10

(iv) Synthesis of compound M8B (n=1)(Appendix V)

Yield: 70%. HPLC t_R =29.1 min (linear gradient: t B=0% at 1.0 ml/min over 5 min; B=0%-75% at 1.0 ml/min over 45 min), (t_R =27.54 min for $[Cys^5]GnRH$ under the same conditions). Mass spectrometry: calculated for $C_{56}H_{79}N_{19}O_{15}S$ m/z $[M+H]^+ = 1291.57$, found $[M+H]^+ = 1291.66$. Amino acid analysis after hydrolysis with 6 M HCl at 110 °C for 22 h: Arg 1.00, Ser 1.12, Glu 0.95, Gly 2.16, His 0.98, Pro 0.89, Leu 0.99. Cys could not be detected due to its destruction under the acidic conditions of hydrolysis.

15

20

(v) Synthesis of compounds M22B (n=1)(Appendix V)

Yield 75%. HPLC t_R =25.1 min (linear gradient: t B=0% at 1.0 ml/min over 5 min; B=0%-100% at 1.0 ml/min over 45 min), (t_R =23.54 min for $[D-Cys^6]-GnRH$ under the same conditions). Mass spectrometry: calculated for $C_{63}H_{85}N_{19}O_{16}S$ m/z $[M+H]^+ = 1397.53$, found $[M+H]^+ = 1397.61$. Amino acid analysis after hydrolysis with 6 M HCl at 110 °C for 22 h: Arg 1.00, Ser 1.09, Glu 0.99, Tyr 1.03, Gly 1.11,

25

His 0.98, Pro 0.99, Leu 0.89. Cys could not be detected due to its destruction under the acidic conditions of hydrolysis.

(vi) Synthesis of compound M27B (n=1) (Appendix V)

5 Yield 60%. HPLC. t_R =33.27 min (linear gradient: t B=0% at 1.0 ml/min over 5 min; B=0%-58% at 1.0 ml/min over 45 min), (t_R =32.28 min for [Cys⁷]-substance P in the same conditions). Amino acid analysis after hydrolysis with 6 M HCl at 110 °C for 22 h: Lys 1.00, Arg 1.10, Glu 2.01, Gly 1.32, Pro 1.93, Leu 1.03, Phe 0.96. Cys and Met could not be detected due to its destruction under the acidic
10 conditions of hydrolysis. Mass spectrometry: calculated for C₆₄H₁₀₂N₂₀O₁₆S₂ m/z [M +H]⁺=1472.75, found [M +H]⁺ =1472.55.

(vii). Synthesis of compound M28B (n=1) (Appendix V)

Yield 65%. HPLC. t_R =32.91 min (linear gradient: t B=0% at 1.0 ml/min
15 over 5 min; B=0%-58% at 1.0 ml/min over 45 min), (t_R =31.28 min for [Cys⁸]-substance P in the same conditions). Amino acid analysis after hydrolysis with 6 M HCl at 110 °C for 22 h: Lys 1.00, Arg 1.08, Glu 2.11, Gly 1.22, Pro 1.93, Leu 1.01, Phe 1.04, Cys 0.99. Cys and Met could not be detected due to its destruction under the acidic conditions of hydrolysis. Mass spectrometry: calculated for
20 C₆₃H₁₀₀N₂₀O₁₆S₂ m/z [M +H]⁺=1458.73, found [M +H]⁺ =1458.84.

II BIOLOGICAL SECTION:

25 Methods

(a) Metal binding properties

It is known that 8-hydroxyquinoline is a strong chelator for iron and has a higher selectivity for iron over copper. It is an important precondition for the antioxidative-type drugs because it is the excessive iron stores and iron-mediated

generation of free radicals in the brain that are thought to be associated with neurodegenerative diseases. Therefore, only chelators with a higher selectivity for iron over copper are expected to chelate iron instead of copper and have potential neuroprotective effects. In order to discuss possible correlation between chelating properties of 8-hydroxyquinoline and its derivatives with their anti-oxidative ability, and the correlation between its derivative and the best established iron chelating drug, desferal, with antioxidative properties, a reliable measurement of the stability constants of the newly synthesized compounds is necessary. A spectrophotometric method was used for measurement of the iron-complexes stability constants of the compounds.

(b) Partition coefficients

The partition coefficient (P_{ow}) or the distribution ratio (D_{ow}) between octanol and water are most commonly used measures of the hydrophobicity of compounds. D_{ow} can depend on the concentration of solute, but at reasonably low concentrations. If the solute is in the same form in both phases, D_{ow} becomes constant and is called the partition coefficient P_{ow} . P_{ow} plays an important role in determining the physico-chemical properties and the behaviour of numerous organic compounds in biological systems. P_{ow} is applied to quantitative structure-activity relationship studies, and as a measure of hydrophobicity. All the partition measurements are carried out using a 1-octanol/water shake-flask procedure (Leo, AJ. 1991, "Hydrophobic parameter: measurement and calculation", *Methods Enzymol.* 202:544-91) or simply by the elution time of solute from HPLC column. Thereafter, the transport properties of the iron-complexes are examined in the water/lipid membrane system (liposomes), which mimics biomembranes much better than the octanol/water system (Breuer et al, 1995).

1-Octanol (Riedel-deHaën, synthesis grade (250-270 nm abs. < 0.06) and glass distilled deionized water were used as the partitioning solutions. A Hewlett-Packard 8450A diode array spectrophotometer was used for the quantitative determination of

the tested compounds in the standard solutions and in the partitioned solutions. The aqueous phase stock solutions were shaken with an excess of 1-octanol to presaturate them and were then allowed to stand overnight before use. The 1-octanol stock solutions were also presaturated with 10 mM NaOH and allowed to settle overnight.

5 The experiments were performed in 10-ml stoppered centrifuge tubes. The tubes were inverted gently for 5 min and then, to assure complete phase separation, they were centrifuged for 20 min at 1,000-2,000 g. The aqueous and organic phases were removed separately and analyzed by UV spectrophotometry.

10 (c) *Antioxidative properties*

Free radicals and reactive oxygen species generated in biological systems are thought to be responsible, among other factors, for neurodegenerative diseases. The ability of the compounds to reduce the rate of formation or decrease the overall yield of free radicals and reactive oxygen species in Fenton and Fenton-type reactions is an important precondition for the antioxidative-type drugs. Therefore a reliable measurement of antioxidative properties of the compounds is necessary.

15 When the free radical has a long lifetime, direct electron spin resonance (ESR) spectroscopy may be the convenient way to identify this species. However, for unstable free radicals, like superoxide ($O_2^{\cdot-}$) or hydroxyl radical ($\cdot OH$) other ways must be used. The influence of the compounds on Fenton and Fenton-type reactions is measured by deoxyribose assay and Spin trapping method.

20

The *deoxyribose assay* (Sawahara et al., 1991) is based on the destruction of deoxyribose by hydroxyl radicals, leading to the formation of malondialdehyde (MDA), which reacts on heating with thiobarbituric acid (TBA), at low pH, to give a pink pigment. Visible absorption spectra of this pigment shows very strong and sharp absorbance with maximum at 532 nm.

25

The "spin trapping" method has been developed to detect and identify low concentration of free radicals in reacting systems. This involves the reaction of a free radical $X^{\cdot}$ with a diamagnetic compound to form a more stable radical product,

which is readily observable by EPR (electron paramagnetic resonance) technique. This method consists of using a nitron or nitroso compound to "trap" the initial free radical, as a long-lived nitroxide,

5 ***(d) Mitochondria isolation:***

Male Sprague-Dawley rats (300-350 g) are decapitated and the brains are immediately isolated and cooled in ice-cold isotonic 10 mM Tris-HCl buffer (pH 7.5) containing 0.25 M sucrose, 2 mM EDTA and 2% bovine serum albumin free of fatty acids (isolation buffer), and homogenized with 50 ml glass-teflon homogenizer
10 with a motor (Heidolf, Germany) at 200 rpm in a 1:10 (w/v) ratio isolation buffer. The homogenate is centrifuged at 1000 g for 10 min and the resultant supernatant then centrifuged at 10,000 g for 10 min. The pellet is washed with 10 mM Tris-HCl (pH 7.5), 0.25 M sucrose, and centrifuged again at 10,000 g for 10 min. This step is then repeated three more times. The pellet is resuspended in 10 mM Tris-HCl (pH
15 7.5), 0.25 M sucrose at a final concentration of 50-60 mg protein/ml. The samples are stored at -18°C until use.

(e) Inhibition of lipid peroxidation

The ability of the compounds to inhibit lipid peroxidation as initiated by iron
20 and ascorbate is examined in brain mitochondria preparation employing the malondialdehyde procedure (Gassen et al. 1996; Ben-Shachar et al., 1991).

The experiments are carried out in triplicates. 7.5 µM of mitochondrial preparation (0.25 mg protein) are suspended in 750 µM of 25 mM Tris-HCl (pH 7.4) containing 25pM ascorbic acid. Samples of the drugs to be tested are dissolved
25 in water or ethanol and added to the suspension. The reaction is started by the addition of 2.5 or 5µM FeSO₄ (from a 1 mM stock solution), and incubation for 2 h at room temperature. The reaction is stopped by addition of 750 µl of 20% (w/v) trichloroacetic acid. The samples are centrifuged at 12,000 g for 10 mini. 500 µl of the supernatant is mixed with 500 µl of 0.5% (w/v) thiobarbituric acid and heated t:

95°C for 30 min. The absorption of thiobarbituric acid derivatives is measured photometrically at $\lambda=532$ nm. Blank analysis is based on emission of the mitochondria, or of FeSO₄, or alternatively, addition of the drugs after incubation.

5 **(f) Neuroprotective effects**

Neuroprotective effects of the iron chelators are determined both *in vivo* and *in vitro* systems.

For *in vitro* experiments, rat pheochromocytoma type 12 (PC12) cells and human neuroblastoma SH-SY5Y cells are used to examine the neuroprotective
10 action of the chelators in response to iron and beta-amyloid toxicity. Cell viability is tested in MTT (2,5-diphenyltetrazolium bromide) and LDH (lactate dehydrogenase) tests as well as measuring dopamine and tyrosine hydroxylase by HPLC and release of alpha-amyloid (soluble) by Western, since these cells are used as models of dopamine and cholinergic neurons.

15 The protection *in vivo* is tested in MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) animal model of PD (Parkinson's disease), a very viable and well-established model of neurodegeneration, by measuring striatal dopamine and tyrosine hydroxylase, the markers of dopamine neurons.

20 **(g) PC12 cell culture.**

Rat PC12 cells, originated from rat pheochromocytoma, were grown at 37°C, in a humid 5% CO₂, 95% air environment, in a growth medium containing Dulbecco's modified Eagle's Medium (DMEM, GIBCO, BRL) supplemented with glucose (1 mg/1ml), 5% fetal calf serum, 10% horse serum, and 1% of a mixture of
25 streptomycin/penicillin. On confluence, the culture was removed and the cells were detached by vigorous washing, centrifuged at 200 g for 5 min and resuspended in DMEM with full serum content. 0.5×10^4 cells/well were placed in microtiter plates (96 wells) precoated with collagen ($10 \mu\text{g}/\text{cm}^2$ were allowed to attach for 24 h before treatment).

(h) MTT tests for cell viability.

Twenty-four hours after attachment of the PC12 cells as described in (g), the medium was replaced with DMEM containing 0.1% BSA. The test compounds were added to the cells after 1 h of incubation. After 24 h incubation, the cells were subjected to MTT test as previously described (Gassen et al., 1998). The absorption was determined in a Perkin-Elmer Dual Wavelength Eliza-Reader at $\lambda = 570/650$ nm after automatic subtraction of background readings. The results are expressed as percentage of the untreated control.

Example 30. Iron chelation in solution

Iron binding was determined by the chelator capacity for restoring the fluorescence of iron-quenched calcein (CAL), a dynamic fluorescent metallosensor. The iron-scavenging properties of the chelators were assessed in solution, by mixing iron salts with free CAL.

Iron precomplexed calcein (Fe-CAL) solutions of 1 μ M (in Hepes 20 mM buffered saline, pH 7.4=HBS) were incubated in the presence of the indicated concentrations of different chelators at room temperature and the fluorescence intensity (475nm-> 520 nm) followed with time in a Tecan fluorescence plate reader, using 96-well culture plates (Nunc) at 100 μ l final volume. The time-dependent complexation of iron from Fe-CAL by the chelators was followed by fluorescence dequenching. The results are shown in Figs. 1A-1C. The fluorescence intensity attained after 1h incubation is shown as a function of the chelator concentration.

The corresponding half maximal dequenching level for the corresponding chelator was (in μ M) (rank order from the fastest acting to the slowest):

Fig. 1A: DFO (0.5)(not shown) >> HLA16 (3.5) = HLA20 (3.5) > HLM7 (5.0) > HLM8 (6.0) > HLM9 (7.2) > L1 (8.3).

Fig. 1B: DFO (0.5)(not shown)>> HLA16 (4.4) >VK-28 (5.2) > HLA20 (5.4) > L1 (8.4) > M9 (9.7) > M10 (9.85)

Fig. 1C: DFO (0.5)(not shown)>> VK-28(3.2) > M7 (3.4) > M11 (5.4) > M12 (6) > L1 (6.6).

5 DFO= desferrioxamine B

L1= 1,2-dimethyl-3-hydroxy-pyridin-4-one (deferiprone)

Example 31. Iron permeation of the chelators into K562 cells

10 The iron-scavenging properties of the chelators were assessed in human erythroleukemia K562 cells, by loading with the permeant CAL-AM probe, *in situ* formation of free CAL, and binding of cytosolic labile iron. Calcein-AM readily passes through the cell membrane of viable cells because of the enhanced hydrophobicity as compared to Calcein. When Calcein-AM permeates into the cytoplasm, it is hydrolyzed by esterases in cells to the parent Calcein, a pH-
15 independent, cytosolic fluorescent marker, which remains inside of the cell. The time-dependent recovery of fluorescence in the presence of a given chelator provided a continuous measure for the capacity of the chelator to access the iron/CAL-containing compartment.

Calcein uptake and intracellular fluorescence were determined as follows:
20 K562 erythroleukemia cells were preloaded with calcein (CAL) by incubation with 0.25 mM of the fluorescent probe CAL-AM for 5 min at 37°C, washed and incubated in HBS medium containing anti-CAL antibodies in order to quench traces of extracellular-associated fluorescence. The suspensions were placed in 96-well plates (100 µl final volume) and analyzed as described above while maintaining the
25 system at 37°C. At the indicated time, the indicated chelator was added so as to reach a final 5 µM concentration.

The results are shown in **Figs. 2A-2D**. The values of half maximal time (sec) and fraction of fluorescence recovery were:

Fig. 2A: SIH: (125, 1) > HLA20 (175, 1) > HLA16 (225, 0.95) > HLM9 (200, 0.50), HLM8 (600, 0.4), L1 (ND)>> DFO (not shown)

Fig. 2B: HLA16 (220, 1) > HLA20 (390, 1) > M10 (1050) > VK-28 (1250,) >>, L1 & M9 (ND) >>>> DFO (not shown)

5 **Fig. 2C:** SIH: (100, 1) > VK-28 (1500, ?) >> M11, M12, M7 (ND)>>)>> DFO (not shown)

Fig. 2D shows relative permeabilities of the iron chelators HLA20, HLA16, HLM9, VK-28 in K562 cells (values are given relative to those obtained with SIH, for which 1.0 represents an apparent rate constant of 0.005 sec^{-1} . (equiv. to a $t_{1/2}$ of
10 ingress of 125 sec for a $5 \mu\text{M}$ chelator solution).

SIH= salicylaldehyde isonicotinoyl hydrazone.

Example 32. Neuroprotection of differentiated P19 cells

This experiment was carried out on P19 mouse embryonal carcinoma cells
15 differentiated to neuronal cells.

Differentiated P19 neuronal cells grown in 96-well culture plates were treated for 6 h with $50 \mu\text{M}$ 6-OHDA (6-hydroxydopamine) in full medium containing either $5 \mu\text{M}$ of the indicated chelator (HLM7, HLM8, HLM9, HLA16, HLA20, M7, VK-28, DFO) or $1 \mu\text{M}$ apomorphine (Apo). The cells were
20 subsequently washed and resuspended in fresh medium containing 5% Alamar blue, incubated for 4 h, and the fluorescence monitored at 450 nm exc 590 nm emission (Tecan Safire fluorescence plate reader). The results are shown in **Fig. 3**. Data are given as % protection, which is equivalent to the % activity relative to the system not treated with 6-OHDA.

25

Example 33 . Neuroprotection of PC12 cells against serum-deprivation induced apoptosis

PC12 cells were grown in serum-free medium alone or in serum-free medium with different concentration of the chelators VK-28, M32, HLA20 and Rasagiline. After 24 h incubation, the cells were subjected to MTT test.

The results are shown in **Figs. 4A-4B**. Cell viability was expressed as a percentage of cells cultured in medium supplemented with serum, which served as the control group and was designated as 100%. PC12 cells grown in serum-free medium had a cell viability of 38% (at 24 hr) and were used as a positive control.

Experimental data are shown as mean $\pm$ SD ($n = 6$).

As shown in Figs. 4A-4B, the chelators VK-28, HLA20 and M32 all protected against PC12 cell death after serum withdrawal. After 24 h incubation, the viability of PC12 cells grown in serum-free medium with 0.1 μ M VK-28, 0.1 μ M HLA20, or 0.1 μ M M32 was significantly different from that in serum-free medium without the chelators ($P < 0.01$). The number of survival cells was elevated to 80%, 65% and 59%, respectively, as compared with the serum-free control group (38%). At ten or hundred times the concentration of the chelators HLA20 (1 or 10 μ M) and M32 (1 or 10 μ M) there was no significant change in the protection against PC12 cell death induced by serum withdrawal. With concentration of 1 μ M, VK-28 also showed a good inhibitory activity against PC12 apoptosis induced by serum withdrawal. However, at the concentration of 10 μ M, the toxicity of VK28 became increasingly dominant. This concentration caused about 75% PC12 cell death in serum-free medium.

Example 34: Inhibitory effects on MAO activity in rat brain

Monoamine oxidase (MAO), an enzyme that plays a crucial role in the metabolic degradation of biogenic amines, exists in two functional forms: MAO-A and MAO-B. The two isoenzymes have different substrate and inhibitor specificities.

i. Preparation of brain MAO

Rats were decapitated and the brains were quickly taken into a weighted ice-cold sucrose buffer (0.32 M), and their weights were determined. All subsequent procedures were performed at 0–4 °C. The brains were homogenized in 0.25 M sucrose (one part tissue to 20 parts sucrose) in a Teflon glass homogenizer followed by the addition of sucrose buffer to a final concentration of 10% homogenate. The homogenates were centrifuged at 600 g for 15 min. The supernatant fraction was taken out and centrifuged at 4500g for 30 min, the pellet was diluted in 0.32 M sucrose buffer and kept frozen for later assaying of MAO. Protein concentration was determined with Bradford reagent at 595 nm, using bovine serum albumin as a standard.

ii. Determination of MAO inhibitory activity in vitro

The activity of MAO-A and MAO-B was determined by the adapted method of Tipton & Youdim (1983). The test compound was added to a suitable dilution of the enzyme preparation (70 µg protein for MAO-B and 150 µg MAO-A assay) in 0.05 M phosphate buffer (pH 7.4). The mixture was incubated together with 0.05 M deprenyl/selegiline, a specific inhibitor of MAO-B (for determination of MAO-A) or 0.05 M clorgylin, a specific inhibitor of MAO-A (for determination of MAO-B). Incubation was carried for 1 h at 37°C before addition of ¹⁴C-5-hydroxytryptamine binoxalate (100 M) for determination of MAO-A, or ¹⁴C-phenylethylamine 100 M for determination of MAO-B, and incubation continued for 30 min or 20 min, respectively. The reaction was stopped with 2 M ice-cold citric acid, and the metabolites were extracted and determined by liquid-scintillation counting in cpm units.

iii. Inhibition of MAO-A and MAO-B by the iron chelators

MAO-A and MAO-B activities were determined in rat brain homogenate *in vitro* following incubation with varying concentrations of the test compounds. The inhibitory activities of the tested compounds are shown in Figs. 5A-5D.

In one experiment, the *in vitro* inhibitory activity of HLA20, M32, VK-28, M30, M31, and propargylamine (P) was tested against rat brain MAO-B. The test compounds were added to buffer containing 10^{-7} M clorgylin and were incubated with the tissue homogenate for 60 min at 37°C before addition of ^{14} C- β -phenylethylamine. The results are shown in **Figs. 5A-5B**. MAO-B activity in presence of the test compound was expressed as a percentage of that in control samples. Mean values shown $\pm$ s.e.mean.

In another experiment, the *in vitro* inhibitory activity of HLA20, M32, VK-28, M30, M31, and propargylamine (P) was tested against rat brain MAO-A. The test compounds were added to buffer containing 10^{-7} M deprenyl and were incubated with the tissue homogenate for 60 min at 37°C before addition of ^{14} C-5-hydroxytryptamine. The results are shown in **Figs. 5C-5D**. MAO-A activity in presence of the test compound was expressed as a percentage of that in control samples. Mean values shown $\pm$ s.e.mean.

These experimental results showed that there were distinct differences in the inhibitory activities among the test compounds. While iron chelator M30 caused a significant inhibition of both MAO-A and MAO-B activities with the IC_{50} values less than 0.1 μ M, chelators M32 and M31 had almost no effect on MAO-A and poor inhibitory effect on MAO-B activity (17.2% and 14.2% inhibition at 100 μ M, respectively). VK-28 and HLA20 showed similar mild inhibitory activities on MAO-A (15.1% and 26.1% inhibition at 100 μ M, respectively), but on MAO-B activity HLA20 exhibited more potent inhibitory effect than that of VK-28 (42.0% inhibition for HLA20 and 13.3% for VK-28). Propargylamine (P) preferentially inhibited both MAO-A and MAO-B activities in a concentration-dependent manner, with the IC_{50} values 66.3 μ M and 10.1 μ M, respectively.

Example 35. Transport property of the chelators

Lipophilicity plays an important role in drug absorption and distribution. The logarithm of the *n*-octanol/water distribution coefficients (logD) is the most commonly used measure of the lipophilicity of a drug candidate. Here we used an *n*-octanol/water shake-flask procedure to determine logD. The results (Table 1) indicated that the distribution coefficients (logD) of the test chelators varied greatly with pH values and the compounds tested. In acidic and basic solution, all the test compounds have low log D values, which refer to a good hydrophilicity. This can be explained by the formation of oxinium chloride (in acid) and sodium oxinate (in base) derivatives. Table 1 shows the order of the lipophilicity of the chelators in water: HLM7 (2.19) > HLA16 (1.79) > HLA20 (1.57) > HLM9 (-1.70) > HLM8 (<-2). These data suggest that HLM9 and HLM8 may have a poor permeability through biological membranes due to their highly hydrophilicity; on the other hand, HLM7 HLA16, and HLA20, because of their lipid solubility, may be able to cross biological membranes.

Table 1 Distribution coefficients of the chelators at different pH values

Compounds	D ^a			LogD		
	in 0.01N HCl	in H ₂ O	in 0.01N NaOH	in 0.01N HCl	in H ₂ O	in 0.01N NaOH
HLA16	0.018	62.96	2.44	-1.74	1.79	0.39
HLM7	0.043	155.68	0.097	-1.37	2.19	-1.01
HLM8	0.0031	0.0049	0.020	< -2 ^c	< -2 ^c	-1.70
HLM9	0.038 ^b	0.018	0.0014	-1.42 ^b	-1.70	< -2 ^c
HLA20	0.025	37.02	0.70	-1.60	1.57	-0.16

a. Distribution ratios $D = C_{org}/C_{aq}$ for different compounds, where C_{org} and C_{aq} are concentrations of the measured compound in organic and in aqueous phase respectively. b. D was measured in phosphate buffer (pH = 5.64). c. These compounds were found to have Log D values below -2. Since such values are not considered reliable no exact values are given.

Example 36. Inhibition of lipid peroxidation in brain mitochondrial fraction

The radical scavenging/antioxidant properties of the novel chelators were determined by the lipid peroxidation assay. This system has been used to measure the ability of antioxidants to protect biological lipid from free radical damage. In the present work, formation of MDA in the mitochondria was induced with 50 μ M ascorbic acid and 5 μ M FeSO₄. As shown in Fig. 6, all the chelators tested inhibited lipid peroxidation. This inhibition was dose-dependent. The remarkable inhibitory effects were observed with all the chelators at 25 μ M, reducing radical damage by 90% to 97%. At compound concentration as low as 10 μ M these chelators significantly reduced radical formation (about 40% inhibition). This inhibition may be attributed to radical scavenging and iron chelating properties of the test compounds.

Example 37. Topical photoprotection

In order to determine the level of topical photoprotection provided by the iron chelators of the invention, guinea pigs are treated topically with the test compound, and are then exposed to varying doses of UV radiation to determine the sun protection factor (SPF). Hairless mice are treated topically with the test compound and then subjected to long-term exposure to a suberythral dose of UV radiation. The mice are evaluated for skin wrinkling and skin tumors.

In another experiment, guinea pigs are treated topically with the test compound, sunscreen, and a combination of the two and are then exposed to varying doses of UV radiation to determine the sun protection factor (SPF). Hairless mice are treated topically with the test compound, sunscreen, and a combination of the two and then subjected to long-term exposure to a suberythral dose of UV radiation. The mice are evaluated for skin wrinkling and skin tumors.

REFERENCES

- Andrews FJ, Morris CJ, Kondratowicz G, Blake DR. (1987) "Effect of iron chelation on inflammatory joint disease". *Ann Rheum Dis.* 46(4):327-33.
- Ben-Shachar, D, Eshel, G, Finberg, JP and Youdim, MB. (1991). "The iron
5 chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons." *J Neurochem*, 56:1441-1444.
- Bissett DL, McBride JF. (1996) "Synergistic topical photoprotection by a combination of the iron chelator 2-furildioxime and sunscreen". *J Am Acad Dermatol.* 35(4):546-9.
- 10 Breuer, W., Epsztejn, S., Millgram, P., Cabantchik, IZ. (1995) "Transport of iron and other transition metals into cells as revealed by a fluorescent probe". *Am J Physiol.* 268(6 Pt 1):C1354-61.
- Buss JL, Torti FM, Torti SV. (2003) "The role of iron chelation in cancer therapy". *Curr Med Chem* 10(12):1021-34.
- 15 Butterfield DA, Howard BJ, LaFontaine MA. (2001) "Brain oxidative stress in animal models of accelerated aging and the age-related neurodegenerative disorders, Alzheimer's disease and Huntington's disease". *Curr Med Chem.* 8(7):815-28.
- Crivori, P.; Cruciani, G.; Carrupt, P.A.; Testa, B. (2000) "Predicting Blood-
20 Brain Barrier Permeation from Three-Dimensional Molecular Structure". *J.Med.Chem.*, **43**: 2204-2216.
- Cuajungco, MP, Faget, KY, Huang, X, Tanzi, RE and Bush, AI. (2000) "Metal chelation as a potential therapy for Alzheimer's disease". *Ann.N.Y. Acad. Sci.* 920:292-304.

Flaherty JT, Zweier JL. (1991) "Role of oxygen radicals in myocardial reperfusion injury: experimental and clinical evidence". *Klin Wochenschr.* 69(21-23):1061-5.

5 Gassen, M and Youdim MB. (1999) "Free radical scavengers: chemical concepts and clinical relevance". *J Neural Transm Suppl.* 56:193-210.

Gassen, M., Gross, A. and Youdim, MB. (1998) "Apomorphine enantiomers protect cultured pheochromocytoma (PC12) cells from oxidative stress induced by H₂O₂ and 6-hydroxydopamine." *Movement Disorders* 13:242-248.

10 Gassen, M and Youdim MB. (1997) "The potential role of iron chelators in the treatment of Parkinson's disease and related neurological disorders." *Pharmacol Toxicol.* 80(4):159-66.

Gassen, M., Glinka, Y., Pinchasi, B., Youdim, MB (1996) "Apomorphine is a highly potent free radical scavenger in rat brain mitochondrial fraction". *Eur. J. Pharmacol.* 308(2): 219-25.

15 Gozes I, Perl O, Giladi E, Davidson A, Ashur-Fabian O, Rubinraut S, Fridkin M. (1999) "Mapping the active site in vasoactive intestinal peptide to a core of four amino acids: neuroprotective drug design." *Proc Natl Acad Sci U S A.* 96(7):4143-8.

20 Hershko C. (1994) "Control of disease by selective iron depletion: a novel therapeutic strategy utilizing iron chelators". *Eur J Biochem* 270(8): 1689.

Hershko C, Pinson A, Link G. (1996) "Prevention of anthracycline cardiotoxicity by iron chelation". *Acta Haematol.* 95(1):87-92.

Hewitt SD, Hider RC, Sarpong P, Morris CJ, Blake DR. (1989) "Investigation of the anti-inflammatory properties of hydroxypyridinones". *Annals of Rheum Diseases* 48:382-388.

Kitazawa M, Iwasaki K. (1999) "Reduction of ultraviolet light-induced oxidative stress by amino acid-based iron chelators". *Biochim Biophys Acta*. 27;1473(2-3):400-8.

Kontoghiorghes GJ. (2001) "Clinical use, therapeutic aspects and future potential of deferiprone in thalassaemia and other conditions of iron and other metal toxicity". *Drugs of Today* Vol. 37, pages 23-35.

10 Ostrakhovitch EA, Afanas'ev IB. (2001) "Oxidative stress in rheumatoid arthritis leukocytes: suppression by rutin and other antioxidants and chelators". *Biochem Pharmacol*. 62(6): 743-6.

Podda M, Grundmann-Kollmann M. (2001) "Low molecular weight antioxidants and their role in skin ageing". *Clin Exp Dermatol*. 26(7):578-82.

Polla AS, Polla LL, Polla BS. (2003) "Iron as the malignant spirit in successful ageing". *Ageing Res Rev* 2(1):25-37.

20 Roza AM, Slakey DP, Pieper GM, Van Ye TM, Moore-Hilton G, Komorowski RA, Johnson CP, Hedlund BE, Adams MB. (1994) "Hydroxyethyl starch deferoxamine, a novel iron chelator, delays diabetes in BB rats". *J Lab Clin Med*. 123(4):556-60.

Sawahara H, Goto S, Kinoshita N. (1991) "Double fluorescent labeling method used for a study on liposomes". *Chem Pharm Bull (Tokyo)* 39(1):227-9.

25 Sayre, LM, Perry, G, Atwood, CS and Smith, MA. (2000) "The role of metals in neurodegenerative diseases". *Cell. Mol. Biol*. 46:731-741.

van Asbeck BS, Georgiou NA, van der Bruggen T, Oudshoorn M, Nottet HS, Marx JJ. (2001) "Anti-HIV effect of iron chelators: different mechanisms involved". J Clin Virol 20(3):141-7.













5 Vile GF, Tyrrell RM. (1995) "UVA radiation-induced oxidative damage to lipids and proteins in vitro and in human skin fibroblasts is dependent on iron and singlet oxygen". Free Radic Biol Med 18(4):721-30.

Yogev-Falach M, Amit T, Bar-Am O, Youdim MB. (2003) "The importance of propargylamine moiety in the anti-Parkinson drug rasagiline and its derivatives for MAPK-dependent amyloid precursor protein processing." FASEB J. 2003 Oct 2
10 [Epub ahead of print].













Appendix I

code name	M6A	M7A	M8A
another name	StKKC(HQ-Pr)L	Fmoc-KKC(HQ-Pr)L	[L-Cys ⁵ (HQ-Pr)]GnRH
structure			
code name		M18A	M19A
another name		YGGC(HQ-Pr)L	YGGC(HQ-Pr)M
structure			
code name	M20A	M21A	M22A
another name	C(HQ-Pr)GGFL	C(HQ-Pr)GGFM	[D-Cys ⁵ (HQ-Pr)]GnRH
structure			
code name	M27A	M28A	
structure			


Appendix II

code name	M6	M7	M8
another name	StKKC(HQ)L	Fmoc-KKC(HQ)L	[L-Cys ⁵ (HQ)]GnRH
structure			
code name	M11	M12	M18
another name	D-HQ-CysOH	L-HQ-CysOH	YGGC(HQ)L
structure			
code name	M19	M20	M21
another name	YGGC(HQ)M	C(HQ)GGFL	C(HQ)GGFM
structure			
code name	M22	M27	M28
another name	[D-Cys ⁶ (HQ)]GnRH	[Cys ⁷ (HQ)]-Substance-P	[Cys ⁸ (HQ)]-Substance-P
structure			

Appendix III

code name	HLA16a	HLA20	M9a
another name			D-(HQ-Pr)-Ala
structure			
code name	M11a	M12a	M13a
another name	D-(HQ-Pr)-CysOH	L-(HQ-Pr)-CysOH	
structure			
code name	M15a	M17	M30
another name			
structure			
code name	M31	M33	M34
another name			
structure			

Appendix III (cont)

code name	M10a
another name	L-(HQ-Pr)-Ala
structure	

Appendix IV

code name	VK-28	HLA16	HLM7
another name		HQPCOOEt	
structure			
code name	HLM8	HLM9	M9
another name	HQAAla	HQAAlaEt	D-HQ-Ala
structure			
code name	M10	M11B	M12B
another name	L-HQ-Ala		
structure			
code name	M13	M15	M32
structure			













Appendix V

code name	M6B	M7B	M8B
structure			
code name	M18B	M19B	M20B
structure			
code name	M21B	M22B	M27B
structure			
code name	M28B	M35	M36







Appendix V (cont)

code name	M36a	M37	M38
structure			
code name	M39	M40	M41
structure			
code name	M42	M43	M44
structure			
code name	M45		M46
structure			

Appendix VI

code name	M9b	M11b	M12b
structure			
code name	M13b	M15b	HLA16b
structure			
code name	M17a	HLA20a	M30a
structure			
code name	M31a	M33a	M34b
structure			

Appendix VII

H1  <chem>N[C@@H]1CCN(CC1)C(=O)OCCNCC#C</chem>	H2  <chem>CC1=C(O)C(=O)N(C1)CCCl</chem>	H3  <chem>CC1=C(O)C(=O)N(C1)CSCC(N)C(=O)O</chem>
H4  <chem>CC(C)(C)OC(=O)CNC(=O)NCC#CC(=O)CCl</chem>	H5  <chem>CC(C)(C)OC1=CC=C2C(=C1)C(=CN2)CCN(CCC#C)C(=O)OC(C)(C)C</chem>	H6  <chem>CC#CCN(CBr)c1ccc2ncncc2c1O</chem>

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. A compound comprising an iron chelator function and a residue selected from the group consisting of a residue that imparts a neuroprotective function to the compound, a residue that imparts combined antiapoptotic and neuroprotective function to the compound, or both and pharmaceutically acceptable salts.

2. The compound according to claim 1 wherein: (i) the iron chelator function is provided by a residue selected from the group consisting of a 8-hydroxyquinoline residue, a hydroxamate residue, and a pyridinone residue; (ii) the residue imparting a neuroprotective function to the compound is selected from a neuroprotective peptide, a neuroprotective analog and a neuroprotective fragment thereof, or a L- or D-cysteine or L or D-alanine residue; and (iii) the residue imparting combined antiapoptotic and neuroprotective functions is a propargyl group.

3. The compound according to claim 1 or 2, which comprises: (a) a 8-hydroxy-5-quinolinyl residue, a 3-hydroxy-4-pyridinone residue, 1-hydroxypyridin-2-one or a hydroxamate residue as the iron-chelating function and a neuroprotective peptide selected from vasoactive intestinal peptide (VIP), gonadotropin-releasing hormone (GnRH), Substance P, enkephalin or analogs thereof or fragments thereof in which one amino acid residue is replaced by a L- or D-cysteine residue, as the neuroprotective function;

(b) the iron chelating function of (a) and a residue of L- or D-cysteine or L- or D-alanine as the neuroprotective function;

(c) the iron chelation function and the neuroprotective function of (a) or (b) and a propargyl group; or


(d) the iron chelation function of (a) and a propargyl group.

4. The compound according to claim 3, wherein said neuroprotective peptide analog is selected from the group consisting of the VIP fragment analogs of SEQ ID NO:2 that may bear a stearyl or a Fmoc group at the amino terminal, the GnRH analogs of SEQ ID NO:4 and SEQ ID NO:5, the Substance P analogs of SEQ ID

NO:7 and SEQ ID NO:8, and the enkephalin analogs of SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, and SEQ ID NO:14.

5. The compound according to claim 3(d) wherein said 8-hydroxy-5-quinolinyl is the 8-hydroxy-5-quinolinylmethylene radical, said 3-hydroxy-4-pyridinone is the N-ethylene-2-hydroxy-3-methyl-pyridin-4-one radical and said hydroxamate is a CONHOH-(CH₂)₂- radical that are linked to the propargyl group via -N- atom(s), or a linker selected from ethylenediamine, piperazine and 1,3,5-perhydrotriazine residue, or via the -NH- group of a L- or D-alanine or L- or D-cysteine residue or an ester thereof.

10 6. A compound of the formula I to IV or a pharmaceutically acceptable salt thereof:




wherein

20 R₁ is a residue of an analog of a neuroprotective peptide containing a cysteine residue that is linked to the C atom via the -S- atom of the L- or D-Cys residue, and wherein the amino terminal of the peptide is optionally substituted by a hydrophobic group such as Fmoc or stearyl;

R₂ is H or -NH-X;

R_3 is a group selected from the group consisting of



(ii) $-\text{CR}_5\text{R}_6\text{R}_7$; (iii) $-\text{N}(\text{CH}_3)-\text{X}$; (iv) $-\text{N}(\text{R}_8)-\text{CH}(\text{CH}_2\text{SH})\text{COOC}_2\text{H}_5$;

(v) $-\text{N}(\text{R}_8)-\text{CH}_2-\text{COOCH}_2\text{C}_6\text{H}_5$; and (vi) $-\text{S}-\text{CH}_2-\text{CH}(\text{COOH})-\text{NHR}_8'$;

R_4 is a group selected from the group consisting of (i) X ; (ii) COOC_2H_5 ;

(iii) $(\text{CH}_2)_2-\text{O}-\text{R}_8$; and (iv) $-\text{COO}-(\text{CH}_2)_2-\text{NH}-\text{R}_8$;

R_5 is H , C_1-C_4 lower alkyl, preferably CH_3 , or COOC_2H_5 ;

R_6 is H , COOH , COO^- or COOC_2H_5 ;

R_7 is selected from the group consisting of (i) $-\text{NH}-\text{R}_8$; (ii) $-\text{NH}_3^+$;




(iii) $-\text{NH}-\text{COCH}_3$, (iv) $-\text{NH}-\text{NH}-\text{R}_8$, and

(v) $-\text{NH}-\text{NH}-\text{CO}-\text{CH}(\text{CH}_2\text{OH})-\text{NH}-\text{R}_8$;

R_8 is H or X ; R_8' is H , X or Fmoc ;


R_9 is selected from the group consisting of (i) H ; (ii) $-\text{CO}-\text{CH}_2-\text{R}_1$;

(iii) $-\text{CH}_2-\text{COOCH}_2\text{C}_6\text{H}_5$; (iv) $-\text{CH}(\text{CH}_2\text{SH})\text{COOC}_2\text{H}_5$;



n is an integer from 1 to 6;

R_{11} is a group selected from the group consisting of

- (i) $-\text{S}-\text{CH}_2-\text{CH}(\text{COOH})-\text{NH}-\text{X}$;
(ii) $-\text{N}(\text{X})-\text{CH}_2\text{COO}-\text{CH}_2-\text{C}_6\text{H}_5$;
(iii) $-\text{N}(\text{CH}_3)-\text{X}$;
(iv) $-\text{N}(\text{X})-\text{CH}(\text{CH}_2\text{SH})\text{COOC}_2\text{H}_5$;
(v) $-\text{CH}_2-\text{NH}-\text{NH}-\text{CO}-\text{CH}(\text{CH}_2\text{OH})-\text{NH}-\text{X}$;
(vi) $-\text{C}(\text{CH}_3)(\text{COOH})-\text{NH}-\text{NH}-\text{X}$;
(vii) $-\text{CH}(\text{COOH})-\text{NH}-\text{X}$;
(viii) $-\text{CH}(\text{COOC}_2\text{H}_5)-\text{NH}-\text{X}$; and (ix) 


R_{12} is X , C_1-C_4 lower alkyl, preferably CH_3 , COOC_2H_5 or $-(\text{CH}_2)_2-\text{OH}$;

R_{13} is X , $-(\text{CH}_2)_2-\text{OX}-$, or $-\text{COO}-(\text{CH}_2)_2-\text{NH}-\text{X}$; and

X is a propargyl group,

but excluding the compound 5-[4-(2-hydroxyethyl)piperazin-1-ylmethyl]-8-hydroxyquinoline.

7. The compound of the formula I or a pharmaceutically acceptable salt thereof according to claim 6:




wherein

R_1 is an analog of a neuroprotective peptide selected from the group consisting of vasoactive intestinal peptide (VIP), gonadotropin-releasing hormone (GnRH), Substance P or enkephalin or a fragment thereof in which one amino acid

residue has been replaced by a L- or D-cysteine residue and R_2 is H or NH-propargyl.

8. The compound according to claim 7, wherein said analog is selected from the group consisting of the VIP fragment analog of SEQ ID NO:2 bearing a stearyl (identified herein as compound M6, Appendix II, and compound M6A, Appendix I) or a Fmoc group (compound M7, Appendix II and compound M7A, Appendix I) at the amino terminal, the residue of a GnRH analog of SEQ ID NO:4 (compound M8, Appendix II, and compound M8A, Appendix I) or SEQ ID NO:5 (compound M22, Appendix II, and compound M22A, Appendix I), the residue of a Substance P analog of SEQ ID NO:7 (compound M27, Appendix II, and compound M27A, Appendix I) or SEQ ID NO:8 (compound M28, Appendix II and compound M28A, Appendix I), and the residue of an enkephalin analog of SEQ ID NO:11 (compound M19, Appendix II, and compound M19A, Appendix I), SEQ ID NO:12 (compound M21, Appendix II, and compound M21A, Appendix I), SEQ ID NO:13 (compound M18, Appendix II, and compound M18A, Appendix I), and SEQ ID NO:14 (compound M20, Appendix II, and compound M20A, Appendix I).

9. The compound of the formula II or a pharmaceutically acceptable salt thereof according to claim 6:



wherein:

(a) R_3 is ---N--- (where the N is part of a piperidine ring) ---N---R_4 and R_4 is selected from:

(i) $-\text{COOC}_2\text{H}_5$, as represented by the compound herein designated HLA16 (Appendix IV);

(ii) a propargyl group, as represented by the compound herein designated HLA20 (Appendix III);

5 (iii) $-(\text{CH}_2)_2-\text{O}-\text{R}_8$, wherein R_8 is a propargyl group, as represented by the compound herein designated M17 (Appendix III); or

(iv) $-\text{COO}-(\text{CH}_2)_2-\text{NH}-\text{R}_8$, wherein R_8 is a propargyl group, as represented by the compound herein designated HLA16a (Appendix III); or


10 (b) R_3 is $-\text{S}-\text{CH}_2-\text{CH}(\text{COOH})-\text{NHR}_8'$ and R_8' is H, as represented by the compounds herein designated M11 and M12 (Appendix II), or R_8' is propargyl, as represented by the compounds herein designated M11a and M12a (Appendix III), or R_8' is Fmoc, as represented by the compounds herein designated M11B and M12B (Appendix IV); or

15 (c) R_3 is a group $-\text{CR}_5\text{R}_6\text{R}_7$, wherein R_5 is H, R_6 is COOH , R_7 is $-\text{NH}-\text{R}_8$, and R_8 is H, as represented by the compounds herein designated M9 and M10 (Appendix IV); or R_8 is propargyl, as represented by the compounds herein designated M9a and M10a (Appendix III); or R_5 is H, R_6 is COO^- and R_7 is $-\text{NH}_3^+$, as represented by the compound herein designated HLM8 (Appendix IV); or R_5 is H, R_6 is COOC_2H_5 and R_7 is $-\text{NH}_2$, as represented by the compound herein
20 designated HLM9 (Appendix IV); or R_5 and R_6 are both COOC_2H_5 , and R_7 is $-\text{NH}-\text{COCH}_3$, as represented by the compound herein designated HLM7 (Appendix IV); or R_5 is H, R_6 is COOC_2H_5 and R_7 is $-\text{NH}-\text{propargyl}$, as represented by the compound herein designated M31 (Appendix III); or

25 (d) R_3 is a group $-\text{NR}_8-\text{CH}(\text{CH}_2\text{SH})\text{COOC}_2\text{H}_5$, wherein R_8 is H, as represented by the compound herein designated M32 (Appendix IV), or R_8 is propargyl, as represented by the compound herein designated M33 (Appendix III); or

(e) R_3 is a group $-\text{N}(\text{CH}_3)-\text{propargyl}$, as represented by the compound herein designated M30 (Appendix III).


10. The compound of the formula III or a pharmaceutically acceptable salt thereof according to claim 6:



wherein R_9 is $-CO-CH_2-R_1$, wherein R_1 is the residue of an analog of a neuroprotective peptide or a fragment thereof containing a L- or D-Cys residue, selected from the group consisting of the residue of a VIP fragment analog of SEQ ID NO:2 bearing a stearyl (M6B, Appendix V) or a Fmoc group (M7B, Appendix V) at the amino terminal, the residue of a GnRH analog of SEQ ID NO:4 (M8B, Appendix V) or SEQ ID NO:5 (M22B, Appendix V), the residue of a Substance P analog of SEQ ID NO:7 (M27B, Appendix V) or SEQ ID NO:8 (M28B, Appendix V), and the residue of an enkephalin analog of SEQ ID NO:11 (M19B, Appendix V), SEQ ID NO:12 (M21B, Appendix V), SEQ ID NO:13 (M18B, Appendix V), and SEQ ID NO:14 (M20B, Appendix V).

11. The compound of formula III according to claim 10, as represented by the compounds herein designated M35, M36, M37, M38, M39, M40, M41, M42, M43, M44, M45 and M46 (Appendix V).

12. The compound of formula IV or a pharmaceutically acceptable salt thereof according to claim 6:



as represented by the compounds herein designated M9b, M11b, M12b, M13b, M15b, HLA16b, M17a, HLA20a, M30a, M31a, M33a, and M34b (Appendix VI).

5 13. The compound of formula I, II, III or IV according to any one of claims 6 to 12, as depicted in the Appendices I to VI herein, but excluding the compound designated VK-28 in Appendix IV.

10 14. A pharmaceutical composition comprising a compound according to any one of claims 1 to 13 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

15. A method for iron chelation therapy which comprises administering to an individual in need thereof an effective amount of a compound of any one of claims 1 to 13 or a pharmaceutical composition according to claim 14.

15 16. The method according to claim 15 is for treatment and/or prevention of a disease, disorder or condition associated with iron overload and oxidative stress, selected from:

20 (i) a neurodegenerative disease, condition or disorder, such as Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), multiple sclerosis, Friedreich's ataxia, Hallervorden-Spatz disease, epilepsy and neurotrauma;

(ii) a neoplastic disease or cancer, optionally in combination with one or more chemotherapeutic agents;

(iii) iron overload in hemochromatosis or thalassemia patients;

25 (iv) a cardiovascular diseases such as stroke or the damage associated with free radical generation in reperfusion injury;

(v) diabetes;

(vi) an inflammatory disorder such as a joint inflammatory disorder, particularly rheumatoid arthritis, inflammatory bowel disease (IBD) or psoriasis;

5 (vii) anthracycline cardiotoxicity in an individual undergoing treatment with anthracycline neoplastic drugs;

10 (viii) a viral, protozoal or yeast infection, wherein said viral infection is a retroviral infection, e.g, HIV-1, and the compound is administered to an AIDS patient, optionally in combination with antiviral agents, and said protozoal infection is malaria caused by Plasmodium falciparum, and said yeast infection is a Candida albicans infection;

(ix) skin ageing and/or skin damage associated with ageing;

15 (x) skin damage associated with exposure to sunlight and/or UV light; or retarding ageing and/or improving the ageing process in a healthy individual or an individual suffering from an age-related disease such as a neurodegenerative disease, disorder or condition.

17. Use of a compound according to any one of claims 1 to 13 and the compound 5-[4-(2-hydroxyethyl)piperazin-1-ylmethyl]-8-hydroxyquinoline herein identified as VK-28 (Appendix IV), for the preparation of a pharmaceutical composition for iron chelation therapy and neuroprotection.

20 18. The use according to claim 17, wherein said iron chelation therapy is for treatment and/or prevention of diseases, disorders and conditions associated with iron overload and oxidative stress, such as the diseases and disorders of claim 16.


25 19. Use of a compound according to any one of claims 1 to 13, and the compound herein identified as VK-28 (Appendix IV), for the preparation of a cosmetic composition for topical application for prevention and/or treatment of skin ageing and/or skin damage associated with ageing and/or exposure to sunlight and/or UV light.

20. Use of a compound according to any one of claims 1 to 13, and the compound herein identified as VK-28 (Appendix IV), ex-vivo for preservation of organs intended for transplantation such as heart, lung or kidney.


5 21. A method for iron chelation therapy, which comprises administering to an individual in need thereof an effective amount the compound herein identified as VK-28 (Appendix IV), for treatment and/or prevention of a disease, disorder or condition associated with iron overload and oxidative stress, excluding the prevention and/or treatment of a neurodegenerative disease, condition or disorder.

10 22. A compound according to claim 1 and as hereinbefore described with reference to Examples 1 to 29.

1/15

**Fig. 1A**

2/15

**Fig. 1B**

3/15




Fig. 1C

4/15




Fig. 2A

5/15




Fig. 2B

6/15






Fig. 2C


7/15

**Fig. 2D**


8/15

**Fig. 3**


9/15

**Fig. 4A**


10/15

**Fig. 4B**

11/15

**Fig. 5A**

12/15

**Fig. 5B**

13/15






Fig. 5C

14/15

**Fig. 5D**

15/15

**Fig. 6**

<110> TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD.
YEDA RESEARCH AND DEVELOPMENT CO. LTD.
YOUDIM, Moussa B. H.
WARSHAWSKY, Avraham
FRIDKIN, Matitiyahu
ZHENG, Hailin

<120> NEUROPROTECTIVE IRON CHELATORS AND PHARMACEUTICAL COMPOSITIONS
COMPRISING THEM

<130> TECH-003 PCT

<150> US 60/424,313
<151> 2002-11-07

<150> US 60/
<151> 2003-09-22

<160> 14

<170> PatentIn version 3.1

<210> 1
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide: a segment of vasoactive intestinal peptide
(VIP). Lys (position 1) is bound to Stearyl. Leu (position 4) is
amidated.

<400> 1

Lys Lys Tyr Leu
1

<210> 2
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide: a modification of peptide of SEQ ID NO: 1. Lys
(position 1) may be bound to stearyl or Fmoc. Leu (position 4)
is amidated.

<400> 2

Lys Lys Cys Leu
1

<210> 3
<211> 10
<212> PRT
<213> Human

<220>
<221> MOD_RES
<222> (1)..(10)
<223> Natural gonadotropin-releasing hormone (GnRH). Pro (position 1)
is 5-oxo-Pro. Gly (position 10) is amidated.

<400> 3

Pro His Trp Ser Tyr Gly Leu Arg Pro Gly
1 5 10

<210> 4

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide: a modification of the GnRH peptide of SEQ ID NO:3. Pro (position 1) is 5-oxo-Pro.Gly (position 10) is amidated

<400> 4

Pro His Trp Ser Cys Gly Leu Arg Pro Gly
1 5 10

<210> 5

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide: a modification of the GnRH peptide of SEQ ID NO: 3. Pro (position 1) is 5-oxo-Pro. Cys (position 6) is D-Cys. Gly (position 10) is amidated.

<400> 5

Pro His Trp Ser Tyr Cys Leu Arg Pro Gly
1 5 10

<210> 6

<211> 11

<212> PRT

<213> Human

<220>

<221> MOD_RES

<222> (11)..(11)

<223> Natural Substance P peptide. Met (position 11) is amidated.

<400> 6

Arg Pro Lys Pro Gln Gln Phe Phe Gly Leu Met
1 5 10

<210> 7

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide: a modification of Substance P peptide of SEQ ID NO: 6. Met (position 11) is amidated.

<400> 7

WO 2004/041151
Arg Pro Lys Pro Gln Gln Cys Phe Gly Leu Met
1 5 10

PCT/IL2003/000932

<210> 8
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide: a modification of Substance P peptide of SEQ
ID NO: 6. Met (position 11) is amidated.

<400> 8

Arg Pro Lys Pro Gln Gln Phe Cys Gly Leu Met
1 5 10

<210> 9
<211> 5
<212> PRT
<213> Human

<400> 9

Tyr Gly Gly Phe Met
1 5

<210> 10
<211> 5
<212> PRT
<213> Human

<400> 10

Tyr Gly Gly Phe Leu
1 5

<210> 11
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide: a modification of Met(5)-enkephalin peptide of
SEQ ID NO: 9.

<400> 11

Tyr Gly Gly Cys Met
1 5

<210> 12
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide: a modification of Met(5)-enkephalin peptide of
SEQ ID NO: 9.

<400> 12

Cys Gly Gly Phe Met
1 5

<210> 13
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide: a modification of Leu(5)-enkephalin peptide of
SEQ ID NO: 10.

<400> 13

Tyr Gly Gly Cys Leu
1 5

<210> 14
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide: a modification of Leu(5)-enkephalin peptide of
SEQ ID NO: 10.

<400> 14

Cys Gly Gly Phe Leu
1 5